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Although roll-out of combined anti-retroviral treatment (cART) has blunted HIV-AIDS onset, studies show 
increased development of cardio-metabolic complications in HIV-infected individuals. For this study we 
hypothesized that HIV-induced low-grade inflammation perturbs immune cell function/activation, thereby 
contributing to an increased risk for cardiovascular diseases (CVD) onset. Here we aimed to identify changes 
in monocyte and T cell subsets and determine its relationship to: (a) classical markers of HIV progression 
(CD4 count, viral load); (b) immune activation status; (c) endothelial dysfunction; and (d) traditional lipid 
profile and subclasses.  
Eighty participants were recruited from the Worcester Community Day Center (Worcester, Western Cape, 
South Africa): n=13 HIV-negative, n=67 HIV-positive. Recruits were divided as HIV-naïve and HIV-treated 
(on cART), and also groups based on CD4 count (control group, HIV-positive with CD4count > 500 
cells/µL, CD4 count from 200–500 cells/µL and CD4 count < 200 cells/µL). Clinical histories and a 
validated lifestyle questionnaire were completed. Fasted blood was collected and used to assess monocyte 
subpopulation phenotype (non-classical, intermediate, classical) by flow cytometry together with tissue 
factor (a marker for thrombus formation) and CD38 (a marker for immune activation) expression on 
monocyte and T cell subsets (CD4, CD8). Classical regulatory T cells (CD4+CD25++FOXP3+) with 
activation markers (glycoprotein A repetitions predominant [GARP] and special AT-rich sequence binding 
protein 1 [SATB-1]) were also evaluated together with an assessment of endothelial function (flow-mediated 
dilatation). C-reactive protein levels together with the traditional lipid profile were also evaluated. In 
addition, an assessment of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) subclasses was 
also completed.  
Our data revealed a robust increase in inflammation/immune activation and coagulation markers on CD8+ 
and CD4+ T cell populations, respectively (CD8+CD142+ [P = 0.01] and CD4+CD142+ [P = 0.0003]). 
Increased co-expression of inflammation and coagulation markers were also observed on both CD8+ and 
CD4+ T cells (CD8+142+CD38+ [P = 0.0001] and CD4+142+38+ [< 0.0001]). In addition, we found an 
expansion of both non-classical (P = 0.0001) and intermediate monocytes (P = 0.05) that were highly 
correlated with immune activation, coagulation and HIV disease progression markers. There was also an 
expansion of CD4+FOXP3+ regulatory T cells (P = 0.0005), together with higher levels of GARP (P = 0.001) 
and SATB-1 (P = 0.04) (especially in patients with relatively low CD4 counts). The lipid profile data 
revealed interesting changes, i.e. a significant decrease during early HIV-infection but with substantial 
increase after cART initiation. In addition, we also found significant changes in HDL and LDL subclasses.  
The most novel findings of this study are: a) the identification of a unique coagulation marker (CD142) 
expressed on CD8 and CD4 T cells and its relatively early expression in HIV-infected individuals (treatment 
naïve). CD142 is also co-expressed with immune activation and strongly correlates with disease progression 
markers; b) changes in lipid subclasses that significantly correlate to HIV immunological markers despite a 
decrease in terms of the traditional lipid profile expected. Such subclass changes may also be a driver for 
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CVD onset, although further research is needed to pursue this question; and c) upregulation of both anti-
inflammatory GARP and pro-inflammatory SATB-1 in regulatory T cells in HIV-treated individuals (with 
immune dysregulation) altering regulatory T cell function and also potentially contributing to CVD onset. 
Thus we propose that clinicians could be aware of immune activation and coagulation with HIV infection 
(even at relatively early stages of disease progression) as monitoring and control of these factors could result 
in improved healthcare and the long-term well-being for such patients. 




Hoewel die uitrol van gekombineerde anti-retrovirale behandeling (kARK) die aanvang van MIV-VIGS laat 
daal het, toon studies die verhoogde ontwikkeling van kardio-metaboliese komplikasies in MIV-
geïnfekteerde individue. In hierdie projek word daar vermoed dat MIV-geïnduseerde laegraadse inflammasie 
immuunsel funksie / aktivering ontwrig en sodoende bydra tot 'n verhoogde risiko vir kardiovaskulêre siektes 
(KVS).  
Die studie het die volgende doelwitte: identifiseer veranderinge in monosiet en regulerende T-sel subtipes en 
hul verhouding tot: (a) klassieke merkers van MIV vordering (CD4-telling, virale lading); (b) immuun 
aktivering status en; (c) endoteel wanfunksie. 
Tagtig deelnemers is gewerf (Worcester CDC [Wes-Kaap]): n=13 MIV-negatief, n=67 MIV-positief 
(gegroepeer as MIV-naïewe, MIV-behandeling op kARK), asook groepe op grond van CD4-telling (kontrole 
groep, MIV-positief met CD4-telling > 500 selle/μL, CD4-telling 200-500 selle/μL en CD4-telling < 200 
selle/μL) Kliniese geskiedenis is aangeteken en 'n gevestigde leefstyl vraelys is voltooi.  
Bloed monsters, geneem tydens ‘n tydeperk van vas, is ingesamel en gebruik om monosiet subpopulasie 
(nie-klassieke, intermediêre, klassieke) fenotipe deur vloeisitometrie te evalueer tesame met weefsel faktor 
(merker: trombus ontwikkeling) en CD38 (merker: immuun aktivering) uitdrukking op monosiet subtipes en 
CD8 T-selle. 
 Klassieke regulerende T-selle (CD4+CD25++Foxp3+) met aktivering merkers (GARP en SATB-1) is ook 
beoordeel tesame met endoteel funksie toets (vloei-bemiddelde ontsluiting). CRP met tradisionele 
lipiedprofiel is ook geëvalueer en verdere evaluering van HDL met LDL subklasse is uitgevoer. 
Die data het 'n beduidende toename in inflammasie / immuun aktivering (P <0.0001) en stolling merkers 
CD8+CD142+ (P = 0,01) getoon. 'n Hoë mede-uitdrukking van inflammasie en stolling merkers 
CD8+42+CD38+ is ook waargeneem (P = 0,0001).  
Die resultate het opregulering van beide nie-klassieke monosiete (P = 0,0001) en intermediêre monosiete (P 
= 0,05) getoon, en hierdie subtipes het hoogs gekorreleer met immuun aktivering en stolling en MIV siekte 
progressie merker. Daar was ook 'n uitbreiding van CD4+Foxp3+ T-selle (P = 0,0005), tesame met hoër 
vlakke van bykomende T-reg merkers GARP (P = 0,001) en SATB-1 (P = 0,04) (veral in pasiënte met 
relatiewe lae CD4 tellings). 'n Beduidende afname in lipiedprofiel vroeg na MIV-infeksie, met ‘n aansienlike 
toename na kARK inisiasie, saam met 'n beduidende verandering in HDL en LDL subklasse, is ook 
waargeneem. 
Die mees beduidende nuwe bevindinge van hierdie studie is: a) die identifisering van 'n unieke koagulasie 
merker (CD142) wat op CD8 T-selle uitgedruk word en sy relatiewe vroeë uitdrukking in MIV-geïnfekteerde 
individue (naïewe). Verder het ons gevind dat dit ‘n mede-uitdrukking met immuun aktivering deel en sterk 
ooreenstem met die siekte merkers; b) veranderinge in lipied subklasse wat beduidend korreleer met MIV 
immunologiese merkers ten spyte van 'n afname in terme van die verwagte tradisionele lipiedprofiel. Sulke 
Stellenbosch University  https://scholar.sun.ac.za
vi 
 
subklas veranderinge kan dalk ook die aanvang van KVS bevorder, alhoewel verdere navorsing benodig 
word om hierdie interessante idee aan te spreek; en c) opregulering van beide anti-inflammatoriese GARP en 
pro-inflammatoriese SATB-1 in Treg selle in MIV-behandelde individue (met immuun wanregulering) kan 
die balaans van Treg sel funksie ontwrig en ook potensiëel bydra tot die aanvang van KVS. 
 Ons stel voor dat dokters moet bewus wees van immuun aktivering en stolling met MIV-infeksie (selfs by 
relatiewe vroeë stadiums van die siekte) aangesien dit sal lei tot verbeterde gesondheidsorg en welsyn vir 
sulke pasiënte. 
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CHAPTER 1 INTRODUCTION 
1.1 BACKGROUND 
Previous studies demonstrated a robust association between human immunodeficiency virus (HIV) infection 
and the onset of cardiovascular diseases (CVD), especially coronary heart disease (Triant et al., 2012; 
Hansson et al., 2001). Despite this concern, the underlying mechanisms driving HIV-mediated CVD onset 
require additional investigations. However, immune activation and inflammation (the focus of this study) 
emerge as potential contributors to this process and require further evaluation (Baker et al., 2011; Hsue et al., 
2012; Beltran et al., 2015). How could this be a contributing factor in the era of combination antiretroviral 
therapy (cART)? Although most HIV-infected individuals on cART achieve viral suppression, this may not 
necessarily result in complete immunological recovery in such individuals (Prabhakar et al., 2011; Pinzone et 
al., 2012). For example, significant CD4 T cell depletion from gut mucosa (primarily chemokine receptor 5 
[CCR5+] memory T cells with activated phenotype) during the early stages of infection results in damage to 
the gut mucosal epithelium and subsequent microbial translocation. Moreover, ongoing microbial 
translocation is linked to systemic immune activation and permanent changes to host immune cells 
(Brenchley et al., 2006; Cassol et al., 2010). Microbial translocation can in turn induce persistent 
macrophage activation that is unrelated to the HIV viral load (VL) (Wallet et al., 2010). In addition, viral co-
infections (e.g. cytomegalovirus [CMV]) can contribute to the phenomenon of persistent immune activation. 
Moreover, increased T cell death caused by activation-induced cell death (AICD) increases turnover (thymic 
output) to replace dying cells as an attempt to maintain T cell homeostasis (Février et al., 2011). Another 
aspect of ongoing immune activation is the development of T cells with an “exhausted” phenotype.  
  
Such perturbations elicit effects on both adaptive and innate immune cells that subsequently lead to profound 
changes in immune signals, and production of cytokines and chemokines. Together such processes and 
related immune dysfunction can contribute to the onset of CVD, e.g. atherosclerosis. In light of this, the 
current study hypothesised that the onset of atherosclerosis in HIV-infected individuals occurs due to a) 
increased pro-inflammatory stimuli impacting on immune cell function, and b) failure of regulatory systems 
to control immune activation, or a combination of both. Here the aim was to describe changes in monocyte 
and T cell subsets in a local HIV-positive population and then ascertain how this relate to a) classical 
markers of HIV disease progression (CD4 count and VL), b) immune activation status and c) risk markers 
and functional assessments for CVD (Figure 1.1).  
  




Figure 1-1: The role of immune activation in triggering atherosclerosis. HAART: 
Highly Active Antiretroviral Therapy; AIDS: Acquired Immune Deficiency 
Syndrome; Treg: Regulatory T Cells 
 
 
The remainder of this thesis will cover the following: Chapter 2 consists of a review of current literature 
that focuses on the link between HIV and CVD onset – with emphasis on the role of immune activation. This 
chapter will culminate in the motivation, hypothesis, aims and objectives of the current study. Chapter 3 
covers a description of the materials and methods used to perform the research work, while data generated 
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CHAPTER 2 LITERATURE REVIEW 
2.1 HIV-POSITIVE PATIENTS AND THE LINK TO CVD 
The advent of HIV-mediated CVD has been shown in many studies, particularly an increased prevalence of 
coronary artery disease (Triant et al., 2012; Hansson et al., 2001). In support, the rate of myocardial 
infarction is twice as high for treated HIV-infected individuals versus non-infected counterparts (Triant et al., 
2012). Moreover, with successful combination antiretroviral treatment (cART) roll-out, HIV is increasingly 
managed as a chronic disease, meaning that treated individuals display increasing lifespans leading to an 
aging population. As a result complications such as pulmonary hypertension and sudden cardiac death (SCD) 
are becoming increasingly prevalent in HIV-positive individuals. For example, Tseng et al. (2012) 
demonstrated that SCD accounted for 86% of all cardiac-related deaths in this group of patients.  
Thus although cART prolongs the lives of HIV-infected individuals, the risk of developing non-acquired 
immune deficiency syndrome (AIDS) co-morbidities such as CVD remains high (Serrano-Villar et al., 
2016). CVD have therefore surfaced as a major cause of morbidity and mortality in HIV-infected individuals 
(Tseng et al., 2012) and contribute to 20% of deaths in this cohort (Zaaqoq et al., 2014). Increasing efforts 
are therefore being made to understand the underlying mechanisms driving this process. Studies completed 
thus far indicate that the onset of CVD in HIV-positive individuals is a complex process that involves 
multiple parameters that may include traditional risk factors, drug toxicity and persistent immune activation 
(Baker et al., 2011). Thus while the traditional risk factors and drug toxicity play a role in this process, 
immune activation emerges as a significant role player (Dixon et al., 2011; Kaplan et al., 2011) (refer Figure 
2.1). As the focus of this thesis is on the relatively understudied phenomenon of immune activation as a 
driver of CVD onset in HIV-positive patients, the nature of this link will be the major focus of this literature 
review.  
 




Figure 2-1: CVD in HIV-infected individuals. (a) For HIV-naïve patients (not on treatment) the role of 
HIV infection itself together with immune activation and coagulation are linked to increased CVD onset; 
(b) For HIV-treated individuals (long-term cART) the interaction between cART toxicity, traditional risk 
factors, altered lipid metabolism as well as immune activation and coagulation is shown. Together these 




2.2 THE HUMAN IMMUNODEFICIENCY VIRUS 
2.2.1 The Global HIV/Aids Pandemic 
Since the inception of the HIV/AIDS pandemic 30 years ago, it has become one of the biggest global health 
problems. For example, since 1981 a total of 78 million persons were infected with HIV, while 35 million 
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Figure 2-2: Global HIV prevalence in adults (15 – 49 years) 2015 by WHO region (World Health 
Organization, 2015) 
  
Current statistics reveal that there are 37 million individuals globally living with HIV/AIDS (World Health 
Organization, 2015), with 3 million under the age of 15 years. More than two thirds of all persons living 
with HIV are located in sub-Saharan Africa, equating to 26 million people. Here South Africa is saddled 
with the highest numbers with 7 million individuals identified as HIV-positive (Statistic SA/UNAIDS, 
2015) and 180, 000 South Africans dying of AIDS-related causes during 2015 (UNAIDS, Report on the 
Global AIDS Epidemic, Geneva: UNAIDS, 2015). Although cART roll-out is relatively successful (reaching 
17 million individuals) new infections continue to fuel this burden of disease. For example, during 2015 
there were 2 million newly-infected individuals, with 240, 000 under the age of 15 years (UNAIDS, 
Report on the Global AIDS Epidemic, Geneva: UNAIDS, 2015). Since 2000 there has been significant 
progress in terms of the universal goal to lower and ultimately controlling HIV infection, e.g. a 35% decrease 
in new infections since this time together with a 24% decline in AIDS-related diseases for individuals 
receiving cART (UNAIDS, 2015). However, as HIV-AIDS has evolved into a more chronically managed 
clinical condition there has been a parallel rise in non-AIDS related complications such CVD (Triant et al., 
2012; Hansson et al., 2001).  
2.2.2 HIV Structure 
The HIV belongs to genus lentivirus within the family Retroviridae. Retroviruses have a single-stranded 
ribonucleic acid (RNA) genome, with HIV possessing two copies. The life-cycle involves the process of 
reverse transcription, whereby RNA is converted to double-stranded copy DNA (cDNA) before integration 
into the host genome (Figure 2.3). Before replication can take place, viruses need to enter host cells and here 
HIV virions target CD4+ T cells (i.e. CD4+ T cell tropic) as this cell surface marker represents the viral 
receptor (Hu and Hughes. 2012). 




Figure 2-3: The structure of an HIV-1 virion. The diagram 
illustrates the lipid membrane, including gp120 and gp41, as well 
as the p17 matrix protein and the p24 core antigen. 
 
The HIV particle is spherical with a diameter measuring 120 nm and the intact virus structure (virion) 
consists of: 
 Viral envelope: the outer membrane coat of the virus that is composed of two phospholipid layers 
obtained from the host cell membrane when newly-formed virions bud from the cell. The envelope 
contains a virally-encoded glycoprotein (gp120) that is needed to attach to the host cell. In addition, 
gp41 is crucial for the fusion process between the virion and host cell. 
 Viral matrix: here the viral protein p17 surrounds the capsid and maintains the integrity of the virion 
particle; it is situated between the envelope and the core. 
 Viral core: it contains a viral capsid protein p24 that surrounds two single strands of HIV RNA and 
the enzymes needed for HIV replication (reverse transcriptase, protease and integrase). 
A The Genomic Structure of HIV 
The HIV genome contains nine genes that are located between two long terminal repeat regions (LTR); of 
these there are three (group antigen [gag], polymerase [pol] and envelope [env]) that encode structural 
proteins for new viral particles (Figure 2.4). The classical structural scheme of a retroviral genome usually is 
5' LTR-gag-pol-env-3' LTR. The nine genes comprise gag that in turn includes p17, p24 and p72; pol that 
includes reverse transcriptase p66, integrase p32 and protease p11, and env that includes gp120 and gp41. 
Additionally, tat and rev genes are regulatory proteins for gene regulation while vif, vpu, vpr and nef code for 
accessory proteins (Frankel and Young et al., 1998). 




Figure 2-4: The genomic structure of an HIV-1 virion. (Frankel and Young et al., 
1998). 
 
2.2.3 The HIV Life Cycle 
The life cycle starts when an HIV virion infects CD4-expressing cells, usually T helper cells or CD4+ 
monocytes and macrophages. Here gp120 binds to the CD4 receptor, with co-receptors CCR5 or C-X-C 
chemokine receptor type 4(CXCR4) also required in this process. After such binding the viral envelope fuses 
with the host membrane and the viral core enters the cytoplasm. This leads to the release of virion enzymes 
and viral genetic material (Fanales-Belasio et al., 2010). The reverse transcriptase enzyme subsequently 
converts the two RNA strands to cDNA (Figure 2.5). Thereafter, the enzyme integrase starts to facilitate the 
entry of viral DNA (provirus) into the host nucleus that is then transcribed into mRNA by the host cell’s 
enzymatic machinery. Such mRNA transcripts encode viral proteins and forms the basis for new progeny 
genomic RNA. The protease enzyme mediates the conversion of newly-translated polypeptides into 
functional proteins and newly assembled virions subsequently move to the cell surface (Goto et al., 1998). 
During the budding process, the virus may also incorporate different host proteins from the host membrane 
into its lipoprotein layer. This may include proteins such as human leucocyte antigen (HLA class I and II) or 
adhesion proteins such as intracellular adhesion molecule-1 (ICAM-1) that may facilitate adhesion to other 
target cells (AL-Jabri et al., 2003).  
 




Figure 2-5: The HIV life cycle.  Step #1: binding; Step #2: fusion; Step #3: reverse transcription; Step #4: 
integration; Step #5: replication; Step #6: assembly; and Step #7: budding (Goto et al., 1998); Figure 
copied from NIAID Source https://www.niaid.nih.gov. 
 
2.3 HIV/CVD: RELATIONSHIP WITH THE IMMUNE SYSTEM AND 
INFLAMMATORY RESPONSES 
HIV infection induces an immune response and this may result in a chronic stimulation due to the inability of 
the immune system to successfully deal with this stressor (i.e. the infecting virus). As HIV infection is linked 
to an immune response, the next sections will briefly review the nature of inflammation and then 
contextualize the role of HIV within this setting. 
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2.3.1 Immune Cells 
Immune cells are produced in the bone marrow, the generative tissue for all lymphoid and myeloid cells. 
Bone marrow provides a suitable environment for formation and differentiation of haematopoietic immune 
cells (Figure 2.6). 
 
 
Figure 2-6: Immune cells in the body. This includes the innate immune system (that 
arises from a common myeloid progenitor) and an adaptive immune system (that 
arises from a common lymphoid progenitor). 
 
2.3.2 Inflammation 
The Roman medical writer Cornelius Celsus write about the four basic signs of inflammation (redness, 
swelling, heat, and pain) around 2000 years ago (Medzhitov et al., 2010). Some 200 years later the Greek 
physician Galen put forward the notion that inflammation is a crucial response to injury. More recently, 
Rudolf Virchow added loss of function as a fifth cardinal sign, thereby indicating that inflammation 
constitutes a pathological condition (Medzhitov et al., 2010). 
The inflammatory process is initiated by infection or injury when specialized pattern recognition receptors 
(PRRs) such as toll like receptors (TLRs) recognize pathogen or damage-associated molecular patterns 
(PAMPs or DAMPs) (Land et al., 2015). TLRs (and other PRRs) stimulate the production of various 
mediators that include cytokines, chemokines and other bioactive substances. TLRs also activate adaptive 
immune cells that can initiate changes at various target tissues as a response to pathogens or injuries (Land et 
al., 2015). 
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A Immune activation and inflammation 
Inflammation is a broad term that explains the natural process arising from infection and/or injury and which 
involves the interaction between soluble factors and immune cells. When inflammatory cells recognize 
pathogens there is an initiation of pro-inflammatory cytokine and chemokine secretion (Tedgui and Mallat. 
2006). Inflammation is usually a transitory phenomenon with its signs apparent over a two to three-week 
period. Once pathogens are cleared then activation levels of the immune system reverts back to normal.  
During acute inflammation, numerous types of immune cells and plasma proteins are activated at the 
infection site. Such actions are initiated by a family of PRRs expressed on macrophage/monocyte cells and 
also expressed on natural killer (NK) cells and dendritic cells (DCs). PRRs expressed on phagocytes possess 
the ability to recognise pathogens. These cells are usually stimulated early during inflammation when 
macrophages and NK cells start producing pro-inflammatory cytokines (interleukin-1 [IL-1], IL-6, and tumor 
necrosis factor-alpha [TNF-α]) and chemokine receptors chemotactic ligand-2 (CCL2) and chemokine (C-X-
C motif) ligand 8 (CXCL8) (Duque and Descoteaux. 2014). Acquired immunity then follows – all these 
reactions can take place concurrently. Antigen-specific T cells can also amplify such an inflammatory 
response by cytokine production (Mogensen et al., 2009). CD4 T helper cells manage the overall immune 
response, while CD8 T killer cells or cytotoxic T cells have the primary task of killing pathogens, virus-
infected cells and malignant cells (Mogensen et al., 2009). Together such inflammatory mediators act on 
target tissues like blood vessels to cause vasodilatation, leakage of plasma, the migration of neutrophils 
together with the migration of tissue macrophages and mast cells to the infected site. Immune cells such as 
neutrophils, activated macrophages and NK cells can also kill and destroy infectious agents (Medzhitov et 
al., 2010). They also have the ability to terminate and eliminate the trigger once the damaged tissue is 
repaired - this is a highly-regulated resolution of inflammation. Here a regulatory process develops that 
switches mechanisms from a pro- to anti-inflammatory nature. Mediators possess anti-inflammatory and pro-
resolution properties (termed protectins and resolvins, respectively) that possess the ability to stimulate 
mucosal antimicrobial defense and clearance. This switch in turn recruits monocytes/macrophages (M2) 
(instead of neutrophils) and plays a role as an anti-inflammatory regulator that expresses IL-10 which is 
involved in tissue repair (Serhan et al., 2008); if the resolution phase is not achieved, chronic inflammation 
arises.  
2.3.3 The Role of HIV in Inflammation 
Under normal conditions the immune system is self-regulated, i.e. will turn itself off when pathogens are 
cleared. However, during HIV infection such inflammation can become chronic due to the inability of the 
immune system to clear the virus during the acute stage of infection (Paiardini and Müller-Trutwin. 2013). 
What prevents the immune system from completely eradicating the HIV in this instance? There are several 
reasons that can help explain this phenomenon. In the first instance, HIV infects some CD4 T helper cells 
and also other cells that express CD4 (e.g. monocytes, macrophages) and destroys a large number of CD4 T 
cells, especially memory cells (Février et al., 2011). The loss of a key immune regulatory cell type will 
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subsequently impact on other cells that make up the immune system. The invading virus can also establish 
latent reservoirs in memory cells so that it can be reactivated at a later stage to once again replicate. 
Secondly, there is the suggestion that the shift from Type 1 T helper (TH1) to Type 2 helper (TH2) cells, and 
also regulatory T cells (Treg cells) may contribute in this instance. However, this shift may be due to the loss 
of TH1 cells. Another option is that the immune system tries to rectify the pro-inflammatory milieu by up-
regulating “exhaustion” markers – such as programmed cell death protein markers (PD-1) and T cells 
immunoglobulin mucin domain-3 (Tim-3) – that in turn can render T cells non-functional. Finally, there may 
also be increased insensitivity of HIV to neutralized antibodies and cellular immunity as a result of its high 
mutation rate that allows it to escape immune surveillance and destructive systems (Miedema et al., 2013).  
Such factors may all contribute to continuous stimulation of the immune system and thus chronic 
inflammation can manifest in a systemic manner that now affects the entire body. This in turn can lead to the 
phenomenon of persistent immune activation that will occur even with the roll-out of cART. Such immune 
activation can be detected by CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T cells 
where elevations of such markers indicate persistent immune activation in HIV-infected individuals (Deeks 
et al., 2004). In support, research shows that with cART the co-expression of CD38 and HLA-DR decreases 
slightly but not to baseline levels measured in non-infected individuals (Al-Harthi et al., 2004). Together it is 
clear that HIV pathogenesis is driven by chronic inflammation that is strongly associated with infection in 
concert with robust increases of inflammatory markers such as IL-6, IL-10, TNF-α, interferon-gamma (IFN-
γ) and IFN-α (Stacy et al., 2009).  
2.3.4 HIV infection and CVD Link  
The HIV impacts on host immune responses in multiple ways including modulation of cytokine production 
and chemokine signaling networks and also as a driver of inflammation. The virus stimulates various cell 
types of the immune system to produce a range of inflammatory cytokines. The importance of HIV and viral 
components in driving immune activation/inflammation is clearly demonstrated by relatively lower 
inflammation and immune activation that accompany cART-mediated attenuation of HIV replication 
(Pinzone et al., 2012; Hunt et al., 2007). Moreover, a comparison between an HIV control group with a VL 
of less than 20 copies/ mL (i.e. below standard detection limit), and a low level viremia group (VL 20–200 
copies/ mL) showed that low level viremia is associated with higher levels of inflammation than controls 
(Reus et al., 2013).  
The risk of developing CVD in treatment-naïve patients is based on the potential impact of HIV infection as 
a driver of atherosclerosis. This can occur through mechanisms related to persistent immune activation and 
inflammation, accompanied by an increase in coagulation markers and lipid disorders (Baker et al., 2013). In 
support, the SMART (Strategies for Management of Antiretroviral Therapy) Study demonstrated the role of 
HIV replication and relatively high immune activation and an increased risk for CVD onset after cART was 
interrupted (Kuller et al., 2008). Huse et al. (2012) also established a robust association between elevated 
markers of immune activation and coronary atherosclerosis, supporting the important role of immune 
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activation in the onset and progression of atherosclerosis. Thus it emerges that continuous low-level viremia 
from HIV infection leads to persistent immune activation and chronic inflammation in HIV-infected persons. 
In addition, co-infection and microbial translocation across compromised epithelial gastrointestinal barriers 
(as a result of HIV infection) can fuel immune system activation and persistent chronic inflammation 
(Brenchley and Douek. 2008). In parallel with such an inflammatory response, HIV-infected individuals 
(cART-naïve and cART-treated) can thus develop atherosclerosis (Sandler and Douek. 2012) 
Long-term cART can also impact on heart function and the vasculature, thereby contributing to endothelial 
dysfunction, lipid disorders and an increased risk of cardiac complications (Cerrato et al., 2015). For 
example, the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study showed that HIV 
protease inhibitors (PI) are linked to an increased risk for myocardial infarction. This is a consequence of PI-
mediated effects on lipid metabolism, endothelial function and contributing to insulin resistance. cART is 
also associated with increased oxidative stress and mononuclear cell adhesion to the endothelium of vascular 
walls causing increased lipid accumulation and endothelial permeability (Dube et al., 2008; Reyskens et al., 
2013). 
Thus HIV infection can elicit direct effects on endothelial function (as discussed) while the production of 
relatively high levels of inflammatory cytokines enhance generalized inflammation and the formation of 
atheroma by macrophage cells.  
2.3.5 Adaptive Immune Activation and CVD Link 
Activation of adaptive immunity during HIV infection occurs relatively early during acute infection and 
upon initial exposure to the virus (McMichael et al. 2010). Here incoming HIV particles are taken up by DCs 
(professional antigen presenting cells [APCs]); that recognize PAMPs through their TLRs. DCs then break 
up the pathogens into protein fragments that are termed epitopes. Then the class II major histocompatibility 
complex (MHC-II) presents such epitopes to CD4 T cells, while class I MHC presents it to CD8 T cells. The 
T cell receptors (TCRs) on both CD4 and CD8 cells recognize the corresponding pathogen epitopes and 
eventually become activated (Gasper et al., 2014). The activated T cells then divide and proliferate to form 
an epitope-specific clonally expanded population. Activated T cells then start to secrete proteins 
(chemokines and cytokines), with respective subsets (e.g. effector versus Treg cells) each displaying a 
specific function. 
Persistent T cell activation during HIV infection leads to the exhaustion of T cells - manifesting as attenuated 
proliferative capacity (Hazenberg et al., 2000). This in turn results in the loss of cytokine production 
capacity, the expression of exhaustion phenotype markers (PD-1, Tim-3) and lowered expression of CD28 
co-stimulatory molecules. The increased number of CD8+CD28- T cells will lead to sub-clinical CVD that 
are associated with morbidity and mortality (Shahbaz et al., 2015; Kaplan et al., 2011). As T cells lose its 
ability to regenerate, senescence of the immune system develops. This is reflected by expression of 
premature aging markers, attenuated naïve CD4 and CD8 T cell numbers (due to decreased thymic output) 
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and a gradual depletion of total CD4 count that leads to a skewed CD4:CD8 ratio. Of note, lower CD4 counts 
can be indicative of an increased risk for atherosclerosis (Kaplan et al., 2011 Lichtenstein et al., 2010). Here 
data revealed a greater frequency of carotid plaques in individuals with CD4 counts of less than 200 cells/µL. 
There is also strong evidence that both CD4 depletion and loss of function are associated with atherosclerosis 
(Lichtenstein et al., 2010; Zaaqoq et al, 2015).  
The TH cell-mediated response also contributes to the development of atherosclerosis. In parallel, Treg cells 
inhibit the proliferation of effector T cells and the development of atherosclerosis. With CVD an imbalance 
exists between pathogenic TH and Treg cells that are associated with lesion development (Foks et al., 2015). 
Several in vitro and in vivo studies show that natural Treg cells can inhibit effector T cell proliferation, 
demonstrating its pathogenic role in atherosclerosis (Pastrana et al., 2013; Taleb et al., 2008). Induced Treg 
cells are generated in peripheral blood in the presence of transforming growth factor-beta (TGF-β) and IL-2. 
Treg cells mediate their suppressor function through the production of IL-10 and TGF-β. The disruption of 
TGF-β signaling as an anti-inflammatory cytokine in T cells accelerates atherosclerosis which in turn inhibits 
the proliferation and differentiation of T cells toward pathogenic TH cells (Mallat et al., 2009). There are 
further studies which show a protective role for IL-10 in atherosclerosis – this is achieved by inhibiting the 
production of inflammatory mediators, matrix metalloproteinases (MMPs), tissue factor (TF) production and 
also by exerting anti-apoptotic effects (Mallat et al., 2002).  
Thus Treg cells play an important role in the prevention of atherosclerosis and also to control inflammation 
during HIV infection. However, many studies show that Tregs play a role in inducing chronic infection by 
preventing the protective immune response of T and B cells, thus enabling chronic viremia and immune 
activation and inflammation (Chevalier et al., 2013). The elucidation of the crucial role of Tregs is therefore 
central to a better understanding of the underlying mechanisms driving the onset of atherosclerosis. 
A Cytotoxic T lymphocytes 
Cytotoxic T lymphocytes (CTLs) play a major role in controlling virus levels during a symptomatic period; 
CD8 T cells recognize the infected cell through an MHC-I dependent process and can also lyse such cells by 
perforin and granzymes secretion (Zhang et al., 2003). One of the characteristics of untreated HIV is the 
expansion of CD8 T cells. Such cells are mature and senescent and the reason for a decreased CD4/CD8 
ratio. The latter can predict morbidity and the eventual outcome(s) of HIV infection (Lu W et al., 2015; 
Serrano-Villar et al., 2014). CD8 T cells are detected in relatively low numbers during the early stages of the 
atherosclerotic process but become more dominant in plaque lesions during the latter stages (Ait-Oufella et 
al., 2014). CD8+ T cells may also possess a more direct pro-atherogenic function. For example, a relatively 
high number of activated circulating cells are directly linked to atherosclerotic plaques in treated HIV-
positive individuals. Increased CD8 T cells with HIV infection also express the fractalkine receptor 
(CX3CR1) and are enriched for protease-activated receptor-1 (PAR-1) (Mudd and Lederman. 2014; Hurley 
et al., 2012). 
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2.3.6 Innate Immune Activation and CVD Link 
The innate immune activation and response occur relatively early during infection and results in a 
significant, non-specific early response during the acute phase of infection. The mononuclear phagocyte 
system, which originates from myeloid progenitors in bone marrow and comprises monocytes, macrophages 
and DCs forms the foundation of innate immunity. There is strong evidence that innate immune activation 
plays an important role in HIV pathogenesis and that its components may contribute to the onset of 
atherosclerosis. Oxidized low-density lipoprotein (OX-LDL) activates adhesion molecules (selectin, 
immunoglobulin superfamily, integrin, and mucin-glycoprotein) which in turn recruit monocytes and 
macrophages (Chen et al., 2015). The early recruitment of monocytes/macrophages to atherosclerotic 
plaques is initiated as a defensive or adaptive response. Furthermore, OX-LDL activates target cells to 
produce monocyte chemo attractant protein (MCP-1) and vascular endothelial growth factor (VEGF) that can 
both contribute to plaque development. After activating adhesion molecules and monocyte recruitment to 
endothelial cells, OX-LDL also increases monocyte-platelet aggregation on endothelial cells that further 
contributes to plaque formation (Chen et al., 2015).  
 Blood monocytes and tissue macrophages can initiate the thrombotic pathway by TF (initiating factor of the 
extrinsic coagulation pathway) expression on their cell surfaces (Funderburg et al., 2010). In addition, 
changes in monocyte subsets (numbers and relative proportion of total monocytes) during different stages of 
HIV infection also play a crucial role in HIV pathogenesis (Zawada et al., 2012). Monocytes can be 
classified according to the relative expression of CD14 and CD16. Three different subpopulations have been 
identified, each with a distinct function. The non-classical (CD14+CD16++) and intermediate monocyte 
(CD14++CD16+) subsets are increased in HIV-infected patients and these subsets express relatively high 
levels of CCR5, CX3CR1 and CCR2 that are all associated with an increased risk for atherosclerosis, while 
classical monocytes are involved in phagocytosis and antimicrobial role (Yang et al., 2014).  
The differentiation of macrophages into M1 and M2 subtypes also plays an important role in the 
development of atherosclerosis. Here the pro-inflammatory M1 macrophages reflect the TH1 response and 
lead to the activation of endothelial and smooth muscle cells, while M2 macrophage cells possess a pro-
atherogenic role. The latter occurs via the expression of IL-4 and CD36 on macrophages that promote the 
uptake of OX-LDL and enhances foam cell formation (Moore and Tabas. 2011). 
Persistent activation of monocytes/macrophages in HIV infected-individuals is triggered by 
lipopolysaccharide (LPS);, while activated macrophages play an essential role in promoting systemic and 
chronic inflammation during HIV infection (Shalhoub et al., 2011; Mogensen et al., 2010). Monocytes are 
key pro-inflammatory cells, producing powerful cytokines such as IL-6 and TNF-ɑ. During the course of a 
normal immune response, immune cells possess the ability to eliminate the trigger (i.e. clear the pathogen) 
and terminate the response with the simultaneous restoration of damaged tissue – a process termed resolution 
of inflammation. At this point, there is a firmly established regulatory process at play, which changes 
mechanisms from a pro- to anti-inflammatory nature. This in turn employs monocytes/macrophages instead 
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of neutrophils as anti-inflammatory cells for tissue repair (Serhan et al., 2008). If the resolution phase is not 
achieved, chronic inflammation ensues and aberrant repair can occur that leads to fibrosis and the 
development of end-organ disease (Wynn et al., 2008). Fibrosis is a key feature of many chronic unresolved 
inflammatory diseases that include lymph node fibrosis with HIV infection and vascular fibrosis associated 
with atherosclerotic plaque formation. Recent work has also shown a correlation between the 
monocyte/macrophage marker, sCD163 and non-calcified coronary plaque formation lesions in both the 
general and the HIV-infected population, representing additional inflammatory activation driven by HIV 
(Burdo et al., 2011). 
As the immune system cannot completely eradicate HIV, activation of both adaptive and innate immunity 
can contribute to the pathogenesis of complications such as CVD, renal disease and cancer. This eventually 
results in CD4 depletion and the development of immunodeficiency in HIV-positive persons even though 
administered with cART. 
2.3.7 Immune activation and HIV pathogenesis 
There is currently strong evidence that immune activation is the major driver of HIV pathogenesis (Paiardini 
and Müller-Trutwin. 2013; Pandrea et al., 2008). Whether the development of immune deficiency 
complications like AIDS or non-immune deficiency complications such as CVD occurs (Hunt et al., 2007), 
the link between immune activation and HIV pathogenesis is quite clear from studies of different monkey 
species infected with simian immunodeficiency virus (SIV). Here the natural host or non-pathogenic species 
(e.g. African Green Monkey) did not develop immune activation and AIDS despite a relatively high viral 
load. By contrast, pathogenic species (e.g. Rhesus macaque) developed AIDS with a relatively high level of 
immune activation (Pandrea et al., 2008) (Table 2.1). 
 
 Table 2-1: HIV pathogenesis: a comparison between non-pathogenic and pathogenic species (Pandrea et al., 
2008: Miedema et al., 2013). 
Non-pathogenic species (e.g. African Green Monkey) Pathogenic species (e.g. Rhesus macaque) 
Stable viral replication High viral replication 
Normal level of immune activation and apoptosis High level of immune activation and apoptosis 
Restoration of CD4 T cells in peripheral blood and intestine No restoration of CD4 T cells 
Lower levels of CCR5 expressing CD4 T cells, with lack of 
disease progression 
Higher levels of CCR5 expressing CD4 T cells, 
with disease progression 
Preservation of immune cell subset function Abnormal immune cell subsets function 
Lack of microbial translocation, with absent of aberrant 
immune activation 
High levels of microbial translocation, with 
aberrant immune cell activation 
Establishment of early anti-inflammatory milieu No early anti-inflammatory role 
 
 
These comparative analyses show that major differences are reflected by how host immune cells respond to 
HIV (Christiaansen et al., 2015). For example, with non-pathogenic SIV infection immune activation is 
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dampened by increased IL-10 production, decreased T cell activation and attenuated apoptosis (Klatt et al., 
2012). In addition, monocytes become unresponsive to LPS stimulation and no longer secrete TNF-α, a 
powerful pro-inflammatory cytokine that impacts on the initiation of the immune response. Furthermore, 
there is an absence of microbial translocation in SIV natural hosts with a relatively low level of immune 
activation (Klatt et al., 2013; Brenchley et al., 2013). Thus, it is apparent that the nature of the early response 
of innate immune cells plays a key role in terms of the degree of HIV-mediated pathogenesis (Mogensen et 
al., 2010) 
2.3.8 Inflammation and Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease that is characterized by plaque formation that includes a 
number of co-factors such as OX-LDL, activated T cells and macrophages, cell death, smooth muscle and 
fibrosis (Tedgui et al., 2006). Persistent chronic inflammation and immune activation lead to increased 
utilization of antioxidants, resulting in oxidative stress that can be detected in several tissues of HIV-infected 
individuals (Wanjiku et al., 2013). Oxidative stress induces formation of OX-LDL with downstream effects 
such as the activation of monocytes and T lymphocytes, thereby increasing its ability to infiltrate vascular 
walls (Chen et al., 2015; Singh et al., 2002).  
Atherosclerosis is initiated by the infiltration of OX-LDL through arterial walls leading to increased 
expression of vascular cell adhesion and intracellular adhesion molecules, an early sign of an aberrant 
immune cell response (Hansson et al., 2001; Syed et al., 2013). Activated monocytes can also migrate from 
blood to the intima and sub-intima, where it can take up OX-LDL by scavenger receptors and resulting in 
monocytes forming early fatty plaques streaks (foam cells) (Woollard and Geissmann et al., 2010). Zidar et 
al. (2015) demonstrated that increased OX-LDL uptake by activated monocytes in HIV-infected patients is 
associated with higher levels of reactive oxygen species (ROS). DCs encounter atherosclerosis-related 
antigens with vascular changes and then migrate to the secondary lymphoid organ to present antigens and to 
promote antigen-specific pathogenic or Treg cell activation (Mallat et al., 2009). Activated T cells also 
produce mediators such as IFN-γ that can contribute to increased inflammation and atherosclerosis 
(Andersson et al., 2010) (Figure 2.7). 




Figure 2-7: The involvement of immune cells in the initiation of 
atherosclerosis. Infiltration of OX-LDL through the arterial wall activates 
both adhesion molecules and the recruitment of immune cells to the site of 
injury with downstream effects. 
 
Thus the variety of immune cells plays an important role to initiate atherosclerosis and continues to 
contribute to its subsequent progression (Libby and Hansson. 2015). This notion can be exploited within the 
clinical setting as studies show that the elevation of inflammatory markers such as C-reactive protein (CRP), 
IL-6 and D-dimer can help predict outcomes of patients burdened with acute coronary syndrome (Baker and 
Duprez. 2010; Funderburg et al., 2012). 
2.3.9 Viral and Immune System Interaction as a Driver of Atherosclerosis 
Although both the innate and adaptive immune responses are activated during HIV infection, this response is 
inadequate to eliminate/clear the invading virus. There are several reasons why this may occur, e.g. the 
ability of the virus to integrate into the host genome and establish a latent reservoir ensures that it can survive 
even a well-coordinated immune defense system. Moreover, the picture is complicated as cells that are 
expected to eliminate the virus can also play a damaging role by facilitating continued immune activation 
and progressive immune deficiency (Mogensen et al., 2010) (Figure 2.8). Thus in order to gain an improved 
understanding of mechanisms underlying CVD risk in HIV-affected individuals, there should be a focus on 



















Figure 2-8: The interaction between HIV and immune 
cells in the context of atherosclerosis. 
 
A The immune system’s response to HIV 
The viral protein trans-activator of transcription (Tat) directly affects the IFN-γ-mediated intracellular 
signaling pathway that usually increases antigen presentation capacity by stimulating the expression of 
MHC-II on antigen-presenting cells (Wu and KewalRamani. 2011). However, viral Tat decreases the antigen 
presentation capacity of macrophages and DCs by interfering with IFN-γ-mediated signaling and thereby 
limiting the overall immune response to invading viruses. IFN-γ is the main cytokine produced by TH1 and 
NK cells and it is main role is to stimulate cytotoxic T lymphocytes to eliminate the invading virus. IFN-γ 
also activates macrophages to enhance their eliminating ability, while an increased level at the time of 
infection suppresses the role of TH2 cells. 
There is a positive correlation between TNF-α elevation and HIV-1-induced viremia as the former is one of 
the most powerful pro-inflammatory cytokines that can elicit severe inflammatory-related damage (Norris et 
al., 2006). For example, TNF-α can induce IL-6 and IL-8 that leads to upregulation of viral replication. Both 
IL-6 and TNF-α, are also necessary during acute stage reactions, thereby contributing to fever and anorexia 
(processes characteristic of systemic inflammation). With HIV infection other modulators such as TGF-β and 
glycoprotein A repetitions predominant (GARP) play a role in the transfer of TH1 to Treg cells, and as the 
disease progresses this shift leads to an increasingly prominent role for TH2 and Treg cells (Christiaansen et 
al., 2015; Miller et al.,2014). However, the TH2 response is not enough to control HIV pathogenicity and 
these results in viral persistence and the development of chronic HIV-induced pathogenesis (Keynan et al., 
2008).  
The induction of anti-inflammatory cytokines such as IL-10 decreases the inflammatory response by the 
suppression of both inflammatory cytokine-mediated signalling and impaired DC maturation (due to 
inhibition of effector T cells) (Blanco et al., 2008). By contrast, IL-10 induction is crucial for supporting 
viral persistence and preventing viral clearance. For example, upregulation of IL-10 and PD-1 by monocytes 
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during HIV-1 infection leads to reversible CD4 T cell dysfunction and impaired viral clearance (Said et al., 
2010). Moreover, others found that the attenuation of IL-10 signalling induced viral clearance and resulted in 
the restoration of CD4 and CD8 T cell proliferation. This suggests that IL-10 may play a role in HIV-
mediated immune exhaustion (Yi et al., 2010). As HIV infection is associated with increased IL-10 levels, 
this shifts TH1 to TH2 and Treg cells (Christiaansen et al., 2015) (Figures 2.9 and 2.10). This subsequently 
leads to decreased activity of crucial immune cells responsible for viral clearance thereby causing persistent 
viral infection and chronic inflammation that eventually results in increased morbidity and mortality. 
Thus, although HIV promotes inflammation and immune activation which augments CTLs and helps with 
virus clearance, inflammation and immune activation also drives viral replication (Paiardini and Müller-
Trutwin. 2013). Conversely, IL-10 dampens inflammation and immune activation but also allows the 
invading virus to better replicate and perpetuate itself. It is important to note that a choice is required, i.e. 
either the virus is tolerated and reduced to relatively lower levels, or it should be effectively eliminated when 
it becomes active (as with an acute infection virus).  
 
 
Figure 2-9: Normal antiviral immune response. TH1 
activates CD8 to eradicate the virus. This occurs via 
powerful antibody production to neutralize the 
virus. In addition, interferon-gamma macrophages, 
DC and killer cells are all recruited to the site of 
infection (Christiaansen et al., 2015). 
 
Figure 2-10: HIV’s role in skewing immune cells. 
High IL-10 impairs TH1 and shifts the balance to 
TH2 and Treg cells. This in turn interferes with 
CD8 T cells and inhibits antibody production 
(Christiaansen et al., 2015). 
 
2.3.10 CD4 Depletion 
HIV attacks the immune system by targeting CD4 T cells, an integral constituent of the immune system. 
CD4 T cells coordinate the overall immune response to assist more broadly, e.g. B cells and CTLs. This can 
be mediated in the form of cytokine- and receptor-ligand-mediated downstream effects (Ait-Oufella et al., 
2014). CD4 T cell subsets consist of TH1 cells that assist and support CD8 T cells to kill infected cells and to 
activate macrophage intracellular killing (Février et al., 2011). TH2 cells support the production of 
antibodies by B cells and TH17 cells that are a subset involved in responses to extracellular bacteria. 
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Moreover, Treg cells are CD4+ but not a “helper” subset and can release immune suppressive cytokines to 
dampen the immune response (Ait-Oufella et al., 2014). 
Viral replication is sustained by chronic immune activation that leads to CD4 T cell depletion. Here 
persistent low-grade inflammation (even during the clinically asymptomatic latent stage and good control of 
VL) leads to progressive CD4 loss (Deeks et al., 2008). The strongest association between chronic immune 
activation and HIV/AIDS pathogenesis is provided by SIV infection studies where a relatively high level of 
viral replication (without immune activation) is not sufficient to produce SIV-mediated pathogenesis and 
progression to AIDS (Miedema et al., 2013). Such studies not only prove the role of immune activation in 
AIDS development, but also show that viral replication alone cannot induce disease progression – thus an 
important point to consider for the onset of CVD in this case. There are a number of causes for CD4 cell 
depletion that include direct effects of HIV viral replication and infection of CD4-expressing cells (Cummins 
et al., 2014). Of note, the number of CD4-infected cells is limited during early infection and its production 
relatively normal at this stage (Hazenberg et al., 2000). CD4 depletion in HIV patients is linked to persistent 
T cell activation and uninfected cells expressing CD4 can also be targeted for elimination but via activation-
induced cell death (AICD) (Février et al., 2011). 
2.3.11 Causes of Immune Activation 
A Microbial translocation  
Microbial translocation is a major contributor to immune activation and disease progression. This was first 
defined in 2006 when it was recognized that bioactive microbial products were significantly elevated in the 
plasma of HIV-infected individuals (Brenchley et al., 2006). LPS levels in such individuals correlated 
directly with the activation of both the adaptive and innate immune systems. During acute HIV infection 
gastrointestinal tract (GIT) damage occurs as a result of the depletion of gut-associated lymphocytes (Gori et 
al., 2010; Nazli et al., 2010). Here up to 60% of CD4 T cells within the intestinal mucosa are affected and 
display viral RNA expression (Brenchyley et al., 2008) Thus increased HIV replication together with CD4 T 
cell destruction also occurs in the gut mucosa and submucosa (as compared to other lymphoid tissues). Why 
should this response occur at this unusual location? The gut mucosa is a primary storage site for memory T 
cells (expressing CCR5 receptors) that possess a semi-activated status and are a preferred target for HIV 
replication (Veazey et al., 2000).  
The normal gut lining transports antigens associated with microbes and nutrients to immune cells located in 
clusters, i.e. Peyer’s patches (Jung et al., 2010). The majority of immune cells are located within such 
clusters and send an early warning to the immune system by identifying microbes to be eliminated. The main 
causes of microbial translocation are altered mucosal immunity that occurs due to elimination of a large 
proportion of CD4 TH cells, particularly TH17 and memory T cells (Février et al., 2011). Subsequently, 
there is inflammation-associated damage especially to gap junctions within the epithelium. This occurs as 
maintenance of GIT integrity is dependent on a functional mucosal immune system. However, when TH17 
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cells (usually responds to bacterial products) are significantly lowered in the GIT this can result in organ 
damage (Nazli et al., 2010). 
B Viremia 
The simultaneous decrease in CD4 T cells together with increased plasma viremia are hallmarks of an HIV 
primary infection. Although there is some normalization after the acute infection stage, this trend can resume 
with chronic infection (albeit at a more moderate pace). It is clear that HIV itself has a direct impact on 
immune activation. This effect initially increases during acute infection but decreases after initiating cART. 
Moreover, inflammatory and immune activation markers decrease within days of initiating therapy but can 
increase again (together with plasma viremia) as circumstances change, e.g. poor cART adherence (Sandler 
and Douek. 2012; Pinzone et al., 2012). 
The persistence of low-level viremia in HIV patients is a stimulus for immune activation and the most recent 
cART intensification trials show that the complete eradication of HIV is near impossible (Hatano et al., 
2011). Such persistent viremia also acts as an on-going stimulus for the immune system. (Klatt et al., 2013) 
demonstrated that T cell activation declines with lower levels of viral replication and that activation also 
further decreased during cART-mediated VL suppression. However, HIV-infected patients can still exhibit 
persistently abnormal T cell activation due to other factors such as co-infection and GIT leakage.  
C  Co-infection and immune activation 
HIV-positive individuals with chronic, active viral co-infection e.g. CMV, Hepatitis B and C virus (HBV & 
HCV) possess relatively higher plasma HIV VLs, lower CD4 cell counts and a faster progression to AIDS. 
Rempel et al. (2013) reported that persons co-infected by HIV/HCV displayed elevated monocyte activation 
compared to those only infected with HIV. Furthermore, HIV-positive women co-infected with HIV/HCV 
exhibited increased CD8 T cell activation and a high chance of progressing to AIDS, i.e. their risk of was 
three times higher versus women with HIV infection only (Kovacs et al. 2010). Co-infection with HIV/CMV 
also results in relatively higher levels of inflammatory markers and the onset of atherosclerosis (Naeger et 
al., 2010).  
2.3.12 Changes during the Acute and Chronic Stages of Infection 
A  Acute stage 
This phase of HIV infection starts immediately after infection and is characterized by viremia. The latter can 
be confirmed by laboratory tests that include assessments of HIV-RNA and p24 antigen detection (Tang et 
al., 2012). This phase usually lasts up to 6 months and ends when anti-HIV antibodies (AB) are detected in 
plasma. During acute infection, there is a transient loss of circulating CD4 cells (Overbaugh and Morris. 
2012). In parallel, there is a significant depletion of CD4 T cells (especially TH17 and effector memory TH 
cells) from the gastric mucosa due to disruption of lymphoid tissues and changes that occur in mucosal 
tissues (Février et al., 2011). There is also a dramatic expansion of CD8 T cells early-on during infection that 
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reflects the induction of antigen-specific CTL (Wherry and Ahmed. 2004). Such an increase is associated 
with decreased VL, suggesting that CD8T cells play a role in the early suppression of viral replication. 
Moreover, HIV-positive persons show an inversion of the normal CD4 to CD8 cell ratio, which is indicative 
of incomplete recovery to pre-infection CD4 T cell numbers. In support, up to half of peripheral CD8 T cells 
are activated in individuals with long-term HIV infection compared to values typically less than ten per cent 
in healthy HIV-negative individuals (Sandler and Douek et al. 2012).  
B Chronic stage  
The chronic HIV-infection stage starts after antibody formation (seroconversion) and is characterized by the 
progressive dysfunction of the immune system that culminates in its collapse. This is referred to as late stage 
infection or AIDS. However, HIV infection alone is not sufficient to lead to immune dysfunction. Instead a 
number of factors are responsible, i.e. HIV together with immune activation and inflammation are strongly 
linked to immune dysfunction and related morbidity and mortality (Kuller et al., 2008; Kaplan et al., 2011) 
(Figure 2.11). Chronic infection is characterized by the invading virus being trapped in lymphoid tissues by 
follicular DCs together with a gradual decline in CD4 T cell counts and low levels of HIV plasma viremia 
(Mogensen et al., 2010). Although latency may also occur with cART roll-out and thus reduce HIV plasma 
viremia to lower levels, residual viremia can contribute to immune activation. 
 
Figure 2-11:The different stages of HIV infection - including length of each respective stage and 
other parameters such as viral load, immune activation and CD4 T cell counts (Mogensen et al., 
2010). 
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2.3.13 T Cell Senescence 
The aging of immune cells and the immune system in general is referred to as immunosenescence. As T cells 
are the most important immune role player during HIV infection, its senescence is paramount within this 
context. Persistent immune activation in HIV-infected individuals can lead to T cell activation that can be 
measured by the expression of CD38 and HLA-DR on CD8 T cells. During a primary infection, there is also 
an upregulation of telomerase, a crucial enzyme involved in the maintenance of telomere length (Hearps et 
al., 2012). However, within the context of recurrent immune stimulation such upregulation is attenuated. 
Thus, memory T cells exhibit short telomere lengths that lead to early or premature aging (Deeks et al., 
2011). Senescence occurs when the functional ability of immune cells are impacted by the permanent 
exhaustion of T cells. The increasing turnover of new T cells then leads to premature aging of all the immune 
system cells and organs, with an accumulation of aging markers on T cells (CD28- and CD57+) (Moro-Garcia 
et al., 2012). Furthermore, peripheral blood monocytes from young HIV-positive individuals show changes 
in phenotype, function, and telomere length that closely resemble those detected in elderly controls aged 
approximately 30 years older (Deeks et al., 2011; Hearps et al., 2012). However, such immune-related 
changes are not fully restored by cART. 
2.4 MONOCYTE CELLS 
2.4.1 Monocyte Subpopulations 
Monocytes are the most dynamic within the mononuclear phagocyte system and display a great deal of 
plasticity (Figure 2.12). Monocytes develop in the bone marrow (from common myeloid progenitor cells) 
and form a network of agranulocytic myeloid cells (Bell and Bhandoola et al. 2008). Such cells are 
responsive to macrophage colony-stimulating factor (M-CSF) that can alter their phenotype and function 
(Das et al., 2015). Circulating monocytes make up 5–10% of total leukocytes and circulate for up to three 
days before migrating to specific tissues where they function as precursor cells to macrophages and in some 
cases as for DCs (Yang et al., 2014). Focusing on morphology, monocyte nuclei can display different forms, 
i.e. kidney-shaped, oval, or lobulated and can also exhibit varying nucleus-to-cytoplasm ratios. The 
discovery of monocyte subpopulations has provided a significant advance in the understanding of the crucial 
role such cells play in terms of chronic inflammation, e.g. as occurs with HIV infection. 




Figure 2-12: Range of appearances of typical monocytes. (a) kidney shape nucleus 
with gray-blue cytoplasm; (b). Lobed nucleus with gray-blue cytoplasm and fine 
granulation. (Theml et al. 2004). 
 
 
Monocytes are key role players of the innate immune system. Both macrophages and DCs are derived from 
monocytes and are important antigen presenting cells, playing a central role in HIV pathogenesis (Coleman 
et al., 2009). Monocytes also possess the ability to respond to different environmental stimuli (e.g. cytokines) 
and are the main responders to microbial LPS (Funderburg et al., 2010). Thus monocytes serve as a crucial 
link between GIT translocation and immune activation during HIV-1 infection. Monocytes are also 
responsible for pro-inflammatory pathways that produce cytokines to initiate local and systemic 
inflammation (Yang et al., 2014; Tedgui and Mallat. 2006). In support, monocytes from HIV-infected 
persons (with virological suppression) produce high levels of intracellular pro-inflammatory cytokines such 
as IL-6 and TNF-α compared to uninfected controls (Scully et al., 2016). Of note, the intermediate monocyte 
subpopulation (CD14++ CD16+) independently predicts CVD events and this may be explained by relatively 
high levels of pro-inflammatory cytokines secreted with the expansion of this subset (2012, Rogacev et al). 
2.4.2  HIV Infection and Monocyte Subpopulations  
Monocytes are usually differentiated according to cell surface expression of phenotypic markers, cytokine 
production and gene expression profiles (Gren et al., 2015; Wong et al., 2011). They are differentiated into 
classical monocytes (CD14+CD16-) that make up 80–90% of total circulating monocytes and CD16+ 
expressing monocytes (CD14+CD16+) that constitute the remaining, circulating monocytes (Yang et al., 
2014). The CD14+CD16+ monocyte population is further divided into intermediate (CD14++CD16+) and non-
classical monocytes (CD14+CD16++). During HIV infection monocytes show activated phenotypes which 
increase the expression of the CD14+CD16+ population (Funderburg et al., 2012). The 
CD14+CD16+monocyte subset is preferentially susceptible to HIV-1 infection as it expresses relatively high 
CCR5 levels (Ellery et al., 2007). The identification of such subpopulations during HIV infection is 
necessary to better understand monocyte function. For example, expansion of both intermediate and non-
classical monocyte subsets during HIV infection is proposed to play an important role in HIV-mediated 
a b
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pathogenesis, especially CVD onset and progression (Funderburg et al., 2012). The significance of CD16+ 
monocytes in atherosclerosis is highlighted by its pro-inflammatory capacity and increased ability to produce 
cytokines (IL-6), matrix metalloproteinase (MMPs), expressing CCL2, as well as their potential role to 
activate endothelial cells.  
A Classical monocyte (CD14++CD16-)  
The ‘’classical’’ terminology is employed in this instance as their phenotype matches the original description 
of a monocyte (Ziegler-Heitbrock et al., 2015) and is described as CD14++ CD16- due to bright CD14 
staining. Their main function is to facilitate phagocytosis that is also linked to ROS generation (Yang et al., 
2014). Classical monocytes also produce cytokines such as TNFα and IL-1β, while expressing a high level of 
CCR2 as homing markers. In addition, they also secrete IL-10, the anti-inflammatory and 
immunosuppressive cytokine. These monocytes also play a crucial role during the onset of acute myocardial 
infarctions and are involved in the early resolution of inflammation (Fang et al., 2015; Yang et al., 2014). By 
contrast, CD16+ monocytes are involved in the latter stages of inflammation and secrete relatively low levels 
of IL-10 (Yang et al., 2014). 
B Intermediate monocyte (CD14++CD16+) 
Despite its naming, the characteristics of intermediate monocytes do not simply fall midway between 
classical and non-classical monocytes. Instead, it is a specialized subpopulation with the ability to secrete 
significant amounts of inflammatory cytokines, thus possessing robust pro-inflammatory potential (Zawada 
et al., 2012). This subpopulation also expresses CCR2 at relatively low levels compared to classical 
monocytes, while expressing CCR5 as the main HIV receptor (Tacke et al., 2007). During infection 
intermediate monocytes migrate to the site of infection and invade tissues via CCR2/CCL2 (Yang et al., 
2014). This subset also increases during HIV infection and is an independent predictor for CVD events 
(Rogacev et al., 2012). 
C Non-classical monocyte (CD14+CD16++)  
The CD16+ monocyte population increases significantly with infections, even if of a localized nature. There 
is indeed a correlation between CD16 expression, TGF-β and elevated TNF-α serum levels (Ziegler-
Heitbrock et al., 2015). CD14+CD16++ monocytes are also considered an inflammatory monocyte subset in 
humans that is highly correlated with atherosclerosis and CVD. Non-classical monocytes express the 
chemokine receptor CX3CR1 at relatively high levels and also protect vessel walls against CX3CR1/CCL3 
invasion in response to triggering stimuli. Non-classical monocytes with the Ly6C- phenotype are classified 
as anti-inflammatory in nature as they and play an important role in patrolling the vascular endothelium 
(Yang et al., 2014). 
Some studies show that the CD14+CD16++ population can generate low pro-inflammatory stimuli (producing 
TNF-α and IL-6) as well producing relatively high levels of anti-inflammatory cytokines (Thomas et al., 
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2015). The CD16+ population is the preferential target for HIV infection as it expresses a relatively high 
level of CCR5 receptors. Furthermore, there is an association between the CD16+ population and increased 
TLR-4 levels (Crowe et al., 2010). A recent study demonstrated that both non-classical and intermediate 
monocytes correlated with viremia, T cell activation and IL-6 (Funderburg et al., 2012). In addition, they 
showed that non-classical monocytes generally displayed the highest TF expression levels among monocyte 
subsets, except for intermediate monocytes during HIV infection. Thus, the role of each monocyte subset 
during HIV-1 infection is a crucial factor to consider especially within the context of inflammation; 
coagulation and the development of CVD (refer Table 2.2).  
Table 2-2: Comparison of the three monocyte cell subpopulations. (Yang et al., 2014; Funderburg et al., 2012 
and 2010; Wong et al., 2011; Woollard and Geissmann et al., 2010; Ziegler-Heitbrock et al., 2015 and 2007). 
HUMAN 
MONOCYTE 
CLASSICAL INTERMEDIATE NON–CLASSICAL 
Surface markers CD14++CD16- CD14++CD16+ CD14+CD16++ 
Percentage 
(Normal range) 















Linked to CVD & chronic inflammatory 
disease & HIV 




Ly6C+ Ly6C+ Ly6C- 
 High CD62L expression    
Response to LPS 
High IL-10 & low TNFα 
levels 
IL-1β and TNF-α 
Low IL-10 & high TNF-α 
levels 
Gene signature  
Links to T cell activation and antigen 
presentation 
Correlates with T cell 
activation 
Viral load (HIV) 
Decrease with HIV-1 
infection 
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2.4.3 The Role of LPS in Monocyte Activation 
LPS is a gram-negative bacterial product that is linked to immune activation with HIV infection (Brenchley 
et al., 2006). It directly activates monocytes and macrophages and is recognized as a potent activator of 
especially macrophages. Such activation leads to increased TNFα secretion - the earliest and most potent 
pro-inflammatory cytokine. LPS stimulates monocytes/macrophages via the TLR4 that is associated with the 
CD14 molecule (Mogensen et al., 2009; Tedgui and Mallat. 2006). TNF-α displays contrasting roles in non-
pathogenic versus pathogenic SIV infection, i.e. for the former immune activation is dampened by rendering 
monocytes insensitive to LPS and thereby decreasing TNF-α secretion while increasing IL-10 production 
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(Klatt et al., 2012). IL-10 can in turn inhibit LPS–induced human monocyte TF expression (Lindmark et al., 
1998).  
2.4.4 Expression of Tissue Factor on the Surface of Monocytes 
Tissue factor (a thromboplastin) is a 47-kDa glycoprotein that is expressed on the cell surface of monocytes 
and platelets. Tissue factor is an important cellular coagulation marker and is responsible for initiating 
extrinsic clotting pathways (Ferreira et al., 2010). It normally circulates in plasma as an inactive protein until 
serine protease activates other coagulation pathway factors. Moreover, in vivo biological activity of 
monocyte TF is linked to plasma D-dimer levels.  
With hemostasis there is a balance between the formation and dissolution of thrombi. It can be divided into 
two stages, i.e. the primary one that comprises the platelet and vascular response and a secondary one that 
includes coagulation factors (Levi et al., 2003). Platelets, vessels and coagulation factors can together stop 
bleeding and allow for vessel repair by the formation of a stable fibrin platelet plug at the site of injury. In 
addition, physiological anti-coagulants such as anti-thrombin III (AT-III) and activated protein C oppose 
thrombosis. Thus clot formation is balanced by plasmin-mediated fibrinolysis that results in the formation of 
fibrin degradation products (FDPs) such as D-dimer (Levi et al., 2003).  
During HIV infection there is a strong correlation between plasma LPS and immune activation, with the 
former contributing to immunodeficiency that can occur with chronic HIV infection (Brenchley et al., 2006). 
Moreover, LPS can also increase pro-coagulant TF on circulating blood monocytes, e.g. Funderburg et al. 
(2012) demonstrated a significant proportion of monocytes expressing TF in HIV-infected blood samples 
versus matched controls. These data indicate an important role for LPS in terms of monocyte TF induction 
that in turn can contribute to clotting and ultimately CVD onset in HIV–infected persons (Funderburg et al., 
2010; Funderburg and Lederman. 2014). This can be further compounded by monocyte TF expression 
preventing fibrinolysis and rendering clots resistant to heparin (Semerao et al. 2009).  
The pivotal role of inflammation in the development of thrombus formation has been the subject of many 
studies, supporting a correlation between inflammation and pro-thrombotic factors (Levi et al., 2003). For 
example, the SMART Study was the first to show a strong association between inflammation and 
coagulation, and CVD morbidity and mortality in HIV-infected individuals (Kuller et al., 2008). Others also 
demonstrated increased TF expression with HIV infection and that this correlated with viremia and T cell 
activation. This was the case especially for the activation of monocyte subsets where - for acute coronary 
syndrome (ACS) patients - TF expression is robustly linked to non-classical monocyte subsets in HIV 
positive patients (2012, Funderburg et al) (Figure 2.13). 




Figure 2-13: The role of TF in the initiation of the extrinsic coagulation 
pathway. TF binds to factor VIIa and this activates Factor X. This then 
forms a prothrombinase complex together with activated Factor V to 
convert prothrombin (Factor II) to thrombin (Factor IIa). Thrombin can 
then lead to conversion of fibrinogen to fibrin (Levi et al., 2003). 
 
2.4.5 D-dimer 
D-dimer is an FDP that is formed when clots are broken down by plasmin actions. It helps to prevent clot 
formation and is an important step in the hemostasis process (Ruttmann et al., 2006). Such formation of D-
dimer can be exploited as a biomarker to predict CVD events and mortality. For example, the SMART Study 
found that D-dimer (and IL-6) are crucial biomarkers for all-cause and CVD-related mortality in especially 
HIV-infected persons (Kuller et al., 2008). D-dimer has also been correlated with TF levels, reflecting 
fibrinolysis and clot formation in HIV–infected persons with immune activation (Funderburg et al., 2010). 
2.5 REGULATORY T CELLS 
2.5.1  Introduction 
Due to their suppressive function, CD4+CD25+FOXP3+ Treg cells play an important role in self-tolerance 
and maintaining immune homeostasis. Here a healthy immune system should maintain a balance between 
maximizing recognition, the clearance of infectious agents and reducing immune-mediated pathology. Treg 
cells are a subset of CD4 T lymphocytes and are responsible for this balance and also plays a major role in 
controlling immune activation and HIV pathogenesis (Chevalier and Weiss. 2013) (Figure 2.14). 




Figure 2-14: The balance between effector T cells and Treg cells. 
 
2.5.2 Regulatory T Cell Phenotype  
Tregs normally comprise less than 10% of circulating CD4 T cells and are further characterized by the 
expression of an interleukin-2 receptor-alpha (IL-2Rα) chain (CD25) (Furtado et al. 2002). Moreover, 
Sakaguchi et al. (2007) demonstrated that cell tolerance is maintained by active T cells that express the IL-
2Rα chain. Treg cells also express relatively low levels of IL-7Rα chains (CD127) (Klein et al., 2010; 
Seddiki et al., 2006). The latter is a useful marker as it is expressed on the cell surface, thereby eliminating 
the requirement for intracellular fork head box P3 (FoxP3) protein staining when used in combination with 
CD4 and CD25. FOXP3 is a master regulator of Treg function and development (Fontenot et al., 2003) and 
binds numerous gene promoters to ensure increased suppressive activity and inhibition of effector T cells. 
Here target genes include special AT-rich sequence binding protein (SATB-1) and GARP (Beyer et al., 2011; 
Probs-Kepper and Buer. 2010). SATB-1 is a genome organizer that regulates chromatin structure and gene 
expression. In line with the Treg suppression function its expression should be lowered in regulatory T cells 
and highly expressed in conventional T cells (Beyer et al., 2011). By contrast, GARP is a transmembrane 
protein that is selectively expressed by activated regulatory T cells but not by conventional CD4 T cells 
(Wang et al., 2009). Thus both GARP and FOXP3 are up-regulated in activated Treg cells, with GARP also 
acting as a receptor for latent TGF-β (Stockis et al., 2009). This determines its role in suppression function. 
In addition, it may play a role in the shift of TH1 to Treg cells during HIV infection (Miller et al., 2014).  
However, no single expression marker (including FOXP3) has thus far been identified as a specific marker 
for Treg cells as they also express on effector T cells (Wang et al., 2009). This lack of specificity makes the 
identification of Treg cells quite difficult, especially in cases of immune activation. Although the expression 
of GARP as a unique marker for activated regulatory T cells is a step in the right direction, the relative lack 
of its expression in resting inactivated Treg cells is a limitation for Treg cell identification. 
2.5.3 Role of Tregs in HIV Infection 
Persistence of immune activation is a hallmark of HIV infection (even with long-term cART) and is 
associated with CD4 depletion and disease progression (Valverde-Villegas et al., 2015). As CD4 T cells 
perform a central role in the immune system, a decrease in its count and/or function leads to immune 
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dysregulation and defects in cell mediated–immunity (CMI). A key issue is to understand how the immune 
system deals with immune activation without suppressing an HIV-specific immune response. Here Treg cells 
are major role players during immune activation and mediating a response to HIV infection. Although there 
is robust evidence that Treg cells elicit beneficial effects by limiting immune activation, they can also trigger 
detrimental outcomes by suppressing the viral immune response (Keynan et al., 2008). Treg cells express 
CCR5 (in addition to CD4) that are main receptors for HIV to target (Chevalier and Wiess. 2013). After TCR 
activation, naïve CD45RA Treg cells display increased expression of HIV co-receptors (CCR5, CXCR4) 
indicating a susceptibility to HIV infection (Oswald-Richter et al., 2004). Previous studies reported increased 
Treg cell frequency (possibly reflecting overall loss of total CD4 TH cells) with HIV infection together with 
a decrease in CD4+ Treg cells (Bi X et al., 2009). The higher Treg cell frequency may be helpful during 
immune activation as this likely reflects increased activity and function.  
There is a lack of consensus regarding specific phenotypic markers that define Treg cells during HIV 
infection. Here Treg cell identification may be complicated as CD25+ Treg and FOXP3+ may be up-regulated 
in conventional CD4 T cells as a result of immune activation (Chevalier and Wiess. 2013). In this instance 
GARP can be used as a marker to distinguish CD25+ Treg cells from conventional T cells. This is due to the 
fact that GARP is more specific to activated Treg cells and is also not expressed in conventional T 
lymphocytes (Gauthy et al., 2013). Studies have shown that an increased Treg cell frequency during chronic 
infection is associated with immune activation of Tregs in circulation (Bi X et al., 2009). Others 
demonstrated that there is an association between immune activation with CD4 depletion and increased 
production of Treg cells in the thymus of HIV-infected individuals (Bandrea et al., 2010). Furthermore, 
Epple et al. (2011) showed that mucosal (but not peripheral) FOXP3+ Treg cells are robustly increased 
during untreated HIV infection and that this normalizes after cART. The number of Treg cells also strongly 
correlate with both CD4+ and CD8+ T cell activation, suggesting that Treg cells are major contributors to 
immune activation observed during chronic HIV infection (Eggena et al., 2005).  
2.5.4 Regulatory T Cell Function 
The suppressive function of Tregs is mediated by IL-10 and TGF-β. Downstream, induced regulatory T 
(iTreg) cells are stimulated by IL-10 (termed Tr1 cells) and Th3 cells stimulated by TGF-β (Wan and Flavell. 
2007). Moreover, Tregs can also mediate suppression by cell-to-cell contact and here IL-35 is needed for 
suppression of contact of DCs with macrophages (Vignali et al. 2009). Treg-mediated suppression can also 
be triggered by cytolysis via granzyme A, while Tregs can also target DC maturation and function. CTLA-4 
expressed on Tregs can down-regulate co-stimulatory molecules (CD80 and CD86) that usually maintain 
immaturity and decrease antigen-presenting cells while simultaneously blocking the activation of FOXP3 T 
cells (Oderup et al., 2006). 
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2.5.5 Regulatory T Cell Role in Atherosclerosis  
The role of Treg cells as a protective mechanism in atherosclerosis is currently an issue of interest, stemming 
from their role as an anti-inflammatory subset responsible for damping the pathogenic immune response. The 
involvement of T cells in atherosclerosis is established on the theory that an imbalance between pathogenic T 
cells (TH1 and TH2) and Tregs leads to the development and progression of atherosclerosis (Mallat et al., 
2003). The role of CD4+CD25++FOXP3+ Treg cells in maintaining immune homeostasis and inhibiting the 
pathogenic immune response is facilitated by its suppressive activity. This occurs via the secretion of anti-
inflammatory cytokines (TGF-β and IL-10) that inhibit pathogenic T cell function (Mallat et al., 2003). TGF-
β plays an important role not only in inducing Tregs from naïve CD4+ CD25- cells and generating Th3, but 
also by mediating protective effects in the context of atherosclerosis (Mallat and Tedgui. 2002). Robertson et 
al. (2003) demonstrated that TGF-β deficiency leads to an acceleration of atherosclerosis and further showed 
that it can inhibit the proliferation and differentiation of T cells into pro-atherogenic TH1 and TH2 cells 
(Mallat and Tedgui. 2002). Greater IL-10 deficiency also increases the infiltration of inflammatory cells into 
the endothelium, causing activated T cells to increase the secretion of pro-inflammatory cytokines (Zhang 
and An. 2007). Thus IL-10 plays a crucial role in the prevention of atherosclerosis (Mallat et al., 1999). In 
addition, Treg cells can limit OX-LDL uptake and foam cell formation through the inhibition of M2 
macrophages that usually elicit a pro-atherogenic effect by increasing IL-4 and CD36 expression (Figure 
2.15). The latter can promote OX-LDL uptake as well as the formation of foam cells (Tse et al., 2013; 
Pastrana et al., 2012).  
 
Figure 2-15: The role of Treg cells in atherosclerosis. through anti-
inflammatory cytokines (IL-10, TGF-β, IL-35) and cell-to-cell contact. (1) 
Tregs inhibit OX-LDL uptake and prevent foam cell formation; (2) Tregs also 
inhibit proliferation to effector T cells (TH1 and TH2); and (3) Monocyte 
differentiation into anti-inflammatory M1 and proatherogenic M2 (Tse et al., 
2013). 
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2.5.6 Regulatory T cell Types and Development 
Although all immune cells develop in the bone marrow, T cell maturation and differentiation occur in the 
thymus. In addition, natural Treg (nTreg) cells (subset of CD4+CD25+) develop in the thymus and migrate to 
peripheral blood where they are responsible for immune homeostasis (Lin et al., 2016) (Figure 2.16) (Table 
2.2). 
 
Figure 2-16: The development of natural Treg (nTreg) and adaptive Treg (iTreg) 
cells. 
 
Another type of Treg cell is the adaptive or induced Treg cell (iTreg) that is a non-regulatory CD4+ T cell 
that acquires CD25 (IL-2Rα) in circulation (Pastrana et al., 2012). TGF-β has a major role in the 
differentiation and expression of iTreg from naïve CD4. As anti-inflammatory cytokines, TGF-β and IL-2 
enhance the expression of FOXP3 (nuclear transcription factor) and CD25 (α chain of IL-2 receptor) on 
Tregs (Wan and Flavell. (2007). 
 
Table 2-3: Comparison between natural Treg and adaptive Treg cells (Lin, X. et al., 2013). 
NATURAL Treg CELLS ADAPTIVE (INDUCED) Treg CELLS 
Induction in thymus Induction in periphery 
Not based on antigen-stimulation Based on antigen-stimulation 
IL-2 dependent IL-2 dependent 
High CD25 expression Variable CD25 expression 
Cytokine-independent regarding suppressor function 
(cell-to-cell contact) 
Cytokine-dependent in terms of suppressor function (IL-
10 and TGF-β) 
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2.5.7  The Role of GARP in HIV Infection 
GARP is found on the surface of activated Treg cells, megakaryocytes and platelets where it acts as a 
receptor for TGF-β (Stockis et al., 2009). It is mostly expressed on activated natural Treg cells and not on 
induced Treg (iTreg) cells (in presence of TGF-β) (Wang et al., 2009). GARP expression on CD4+CD25+ 
Treg cells indicates the activation of FOXP3 Treg and this may explain its role as a suppressor. The 
involvement of GARP in Treg cell function is based on induction during TCR stimulation; Treg function is 
upregulated and controlled by FOXP3. Upon TCR stimulation, human effector CD4+CD25- (T helper) can 
upregulate FOXP3 while ectopic GARP expression in antigen-specific TH cells also occurs (Wang et al., 
2009). GARP is induced relatively early after TCR stimulation on CD4+CD25++ Treg cells (Probst-Kepper 
and Buer, 2010) and its interaction with TGF-β on the cell surface (as a receptor) provides further support for 
GARP’s regulatory role in the immune response. Here TGF-β has a major role in maintaining and inducing 
FOXP3, which in turn is necessary for suppressive activity during HIV infection (Wang et al., 2009). 
An important aspect to consider is how the immune system interacts with immune activation without 
suppressing the HIV-specific immune response; Treg cells are major contributors to this response. Thus 
GARP-mediated regulation of Treg cells is important in this instance. GARP is upregulated upon TCR 
stimulation and together with FOXP3 and TGF-β may help explain the phenomenon of chronic infection and 
the vicious cycle of immune activation. Here CD4+CD25+ may be induced by a direct viral infection or by 
chronic antigenic stimulation. Such activation leads to increased suppressive mechanisms and inhibition of 
the protective immune response mediated by T and B cells. This leads to chronic viremia and persistent 
immune activation (Paiardini and Muller. 2013; Keynan et al., 2008).  
 
Figure 2-17: FIV infection : role of GARP and TGF- β in the transfer of 
TH1 to induced-Tregs (Miller et al., 2014).  
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Miller et al. (2014) demonstrated that GARP together with TGF-β can convert TH1 cells to Treg cells in an 
animal model of feline immunodeficiency virus (FIV) infection (Figure 2.15). This can explain the 
maintained Treg cell number and function during HIV infection, even with depletion of CD4. It also sheds 
light on the beneficial role of Treg cells in terms of a suppressor-type function. This can also help explain the 
immune dysfunction of CD4 T cells that effectively limits the functioning of the antiviral CD4 T cell 
response. Others found that soluble GARP protein (sGARP) efficiently repressed the proliferation of naïve 
CD4+ T cells into effector T cells and that it was involved in the induction of Treg cells (Hahn et al., 2013). 
This work also showed the potent anti-inflammatory role of sGARP that prevents T cell-mediated 
destruction of graft-versus-host disease. 
2.5.8 The Role of SATB1 as Activated Markers for Regulatory T Cells 
SATB-1 is  800 amino acids long and contains three DNA-binding domains. It has the ability to bind matrix 
attachment regions (MARs) that control gene expression in maturing T cells. SATB-1 was identified as a 
nuclear protein that organizes the chromatin network and regulates expression of several genes and a key 
modulator in the development and differentiation of effector T cells. In particular, TH2 cell (by regulation of 
GATA-3) promotes and induces TH2 cytokine IL-4 secretion (Gottimukkala et al., 2012). Furthermore, 
SATB-1 is strongly upregulated and expressed in T effector cells (Thabet et al., 2012). There is an inverse 
expression pattern between FOXP3 and SATB-1 in maintaining Treg identity and function (Gottimukkala et 
al., 2012). Beyer et al. (2011) showed that SATB-1 repression in Tregs is necessary for suppressive activity 
and the inhibition of effector T cell differentiation. This means that FOXP3 negatively regulates SATB-1. By 
contrast, lentivirus can upregulate SATB-1 in Treg cells thereby blunting the ability of Treg cells to suppress 
the activation of effector T cells. Such SATB-1 overexpression skews its regulatory function towards the 
effector program and numerous pro-inflammatory genes are thus activated thereby increasing IL-4 and IFN- 
production (Thabet et al., 2012). 
2.6 ANTIRETROVIRAL THERAPY IN THE HIV INFECTED-POPULATION 
Globally more than 35 million individuals are infected with HIV, with 7 million currently in South Africa 
(World Health Organization. 2015). However, cART has been successfully rolled out over the last decade 
with 17 million (50%) of the global infected population now receiving such treatment (UNAIDS, Report on 
the Global AIDS Epidemic, Geneva: UNAIDS, 2015). The introduction of cART has created significant 
changes by decreasing mortality among HIV-infected patients, prolonging life expectancy, suppressing HIV-
1 replication, restoring immune function and reducing transmission. There are currently six cART classes 
that can be employed with each respective one targeting a particular process in the viral cycle: 
1. Nucleoside reverse transcriptase inhibitors (NRTIs) 
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
3. Protease inhibitors (PIs) 
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4. Integrase inhibitors (IIs)  
5. Fusion inhibitors (FIs) 
6. Chemokine receptor antagonists (CRAs) 
In the South African context, cART is usually initiated when CD4 counts are less than 350 cell/mL (Mberi et 
al., 2015) although in some cases it is initiated within one week of HIV diagnosis. The latter group can 
include pregnant women, individuals displaying CD4 counts of less than 200 cells/mL, patients exhibiting 
Stage 4 of HIV disease progression (WHO classification) and individuals suffering from co-morbidities such 
as tuberculosis (Arg et al., 2016). 
For first line treatment the following regimen is usually employed: TDF (Tenofovir) + FTC (Emtricitabine) 
or 3TC (Lamivudine) + EFV (Efavirenz). If a patient does not respond to such treatment and VL remain 
relatively high (HIV RNA > 1, 000 copies) then the treatment is escalated to second line therapy, i.e. AZT 
(Zidovudine) + 3TC (Lamivudine) + LPV/r (Lopinavir/ Ritonavir). For third line treatment, the following 
regimen can be used: Raltegravir/ Darunavir/Etravirine (Arg et al., 2016). Recently, US clinics have begun to 
initiate cART when CD4 cell numbers fall below 500 cells/mL, while in middle- and low-income countries 
the counts were raised from 200 to 350 cell/mL (Fox et al., 2010). This should increase the number of HIV-
positive individuals receiving treatment and improve the immunological state as CD4 T cell recovery is a 
slow process that requires years and also depends on CD4 T cell number prior to cART initiation (Wilson 
and Sereti. 2013).  
Although the role of ART in suppressing disease onset in HIV-infected patients is a cornerstone of 
therapeutic strategies, complete immune recovery is needed to prevent immune activation and to restore 
immune function and thus limit the onset of non-AIDS-related co-morbidities such as CVD.  
Treatment Strategies  
The primary focus was initially to suppress HIV replication and to also manage drug toxicity and side-
effects. However, the current emphasis is to improve the general health of the HIV-infected population and 
also how best to extend life spans to match that of non-infected individuals. The focus has therefore shifted 
to the management of immune activation/inflammation and is based on three parameters, namely: a) 
reducing T cell activation, b) decreasing cytokine production and c) improving the underlying risk factor 
profile. Here the various cART combinations are most effective to reduce T cell activation and to also 
decrease immune activation markers (Rajasuriar et al., 2013). Some researchers suggested that cART 
initiation during the early stages of infection could limit viral reservoirs and decrease immune activation to 
normal levels (Sellers et al., 2014). However, others found that cART initiation during the acute stages of 
HIV infection failed to prevent persistent immune activation (Vinkoor et al., 2013). These results suggest 
that the early pathogenesis of HIV disease leaves more permanent, detrimental effects on overall immune 
function. 




As a result of such associated pathologies, anti-inflammatory agents and statins have also been employed as 
co-treatments, with the latter successful as it lowered harmful circulating lipid levels and decreasing CVD 
risk (Funderburg et al., 2014). Thus, it is clear that pharmacologic approaches such as cART cannot lead to 
the total eradication of this debilitating disease and/or cure individuals burdened with HIV infection. Thus 
efforts to develop novel therapeutic interventions to help combat HIV and associated co-morbidities should 
be continually pursued. For example, Younan et al. (2013) demonstrated that hematopoietic stem cell (HSC) 
transplantation may be a prospective alternative to conventional cART as treated animals demonstrated 
increased CD4 counts, a higher CD4/CD8 ratio and also improved CD4 T cell function. Such preclinical, 
pilot studies offer early hope that HIV-positive individuals will eventually receive improved therapies that 
should enhance their overall well-being and also blunt the onset of various co-morbidities such as CVD.  
2.7 RESEARCH QUESTION, MOTIVATION, AIMS AND OBJECTIVE OF THE STUDY 
Antiretroviral treatment prolongs and improves the quality of life of HIV-infected individuals by viral 
suppression and by decreasing HIV/AIDS complications. However, despite its efficacy full-scale 
immunological recovery is not achieved and low grade inflammation and immune activation persist and 
induce changes in immune cell function and phenotype. Such changes can in turn lead to an increased risk 
for CVD onset. Although some studies explored the phenomenon of on-going inflammation and immune 
activation with chronic HIV infection, simultaneous evaluation of changes to monocytes, CD8 T cells (CTL) 
and Treg cells and their relationship to CVD risk markers has not been previously performed. This will also 
be the first time – as far as we are aware – that such a study has been pursued within the South African 
context.  
The hypothesis of this study is therefore that HIV-1 infection induces several changes in the phenotype 
and function of immune cells, particularly in the case of monocytes, CD8 T cells, CD4 T cells and Treg 
cells, and those such changes pre-dispose infected individuals to the future development of atherosclerosis 
and CVD.  
The current project set out to answer the following research questions: 
1. Does HIV infection affect monocyte subset expression and changes in phenotype? 
2. Does HIV infection affect FOXP3 cells? In addition, what is the relationship between activation 
markers (GARP, SATB-1, and FOXP3) and disease progression? 
3. What is the correlation between immune activation and coagulation markers in T cells? 
4. What is the correlation between immune markers and metabolic profile?  
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The aims of this study were to assess: a) both coagulation and immune activation marker expression on 
monocytes and T cells (CD4 and CD8), b) expression of novel activation markers (SATB-1, GARP) on 
Tregs with chronic HIV infection and c) the relationship of immune activation markers to CVD risk.  
 
To achieve these aims, the following objectives were set: 
1. Assess monocyte subpopulation expression in both treatment-naïve and HIV-treated individuals - 
classic versus intermediate versus non-classic monocytes  
2. Evaluate markers for TF (CD142) and CD38 expression on the different monocyte subsets 
3. Determine CD38 and CD142 markers on CD8 and CD4 T cells 
4. Evaluate and compare the frequency of (CD4+FOXP3+, GARP and SATB-1) in CD25+ and CD25- 
cells and their relationship with other markers 
5. Correlate the above-mentioned immune markers with: a) well-known CVD risk markers (CRP, lipid 
profile) and b) markers of disease progression (CD4 and VL).
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CHAPTER 3 METHODOLOGY 
3.1 STUDY POPULATION AND DESIGN 
This thesis forms part of a larger longitudinal investigation, namely the Cape Winelands HAART to HEART 
Study that is set within the Cape Winelands region of the Western Cape (South Africa). This particular thesis 
is a cross-sectional study that investigated the association between immune activation and the onset of 
cardiac diseases in HIV patients on cART. Ethical approval was obtained from the Human Research Ethics 
Committee of Stellenbosch University and the Department of Health (Western Cape Government, South 
Africa) reference number RP090/2013. Prior to the study, all participants were informed about various 
procedures and the consent form was signed by all study subjects included. After completion of informed 
consent, blood samples (fasted) were obtained from participants together with the completion of various 
evaluations (detailed later in this section). The inclusion criteria were HIV-positive and HIV-negative 
participants 18-55 years, while the HIV/tuberculosis infection patients were excluded from the study. The 
subject recruits were divided into three groups: HIV-negative subjects (N= 13), HIV-positive cART naïve 
(N= 26), and HIV-positive on cART (N= 41) (Figure 3.1). 
 
Figure 3-1: Layout of research methodology. Summary of study recruits and various assessments 
completed: flow mediated dilatation (FMD) for endothelial function assessment, analysis of blood 
metabolite profile and the assessment of immune activation 
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3.2 CLINICAL VISITATIONS  
The study was conducted at Worcester Community Day Care Center (CDC) located within the Worcester 
Hospital (Western Cape, South Africa) that is a public referral facility that forms part of the metro and 
district health services. This facility also provides primary health care services and is responsible for 
treatment/ management of HIV-positive patients in the region. 
3.2.1 Clinical History and Patient Characterization: 
All HIV-positive and HIV-negative participants were recruited from the same communities (Worcester 
region, South Africa) to ensure that they shared similar CVD risk and socio-economic factors; the main 
history and characterization profile of participants were: 
 Age 
 Ethno-racial composition (Mixed Ancestry [‘’Colored’’], Caucasoid, Black) 
 Duration of disease since HIV diagnosis 
 History of cART - including duration, first or second line and regularity of treatment 
 Viral load 
 CD4 count  
 Blood pressure  
 CVD history (including family history) 
 Record of any other drugs taken  
 Information regarding smoking and diabetes mellitus  
 Regularity of follow-ups 
3.2.2 Blood Collection 
Whole blood was collected by a research nurse and 5 tubes (20 mL) were collected from each patient. For 
CD4 counts, lipid profile and CRP evaluations, blood samples were sent to the nearby Worcester National 
Health Laboratory Service (NHLS, South Africa) laboratory within 30 minutes after collection. In addition, 1 
mL of blood was collected into an EDTA tube and placed in a 15-mL polypropylene tube containing BD 
FACS lysing solution (BD Biosciences, San Jose CA) (1:9; lysing solution: distilled water) for the later 
evaluation of two flow cytometric panels (refer section 3.6.1.1).  
Of the fresh whole blood samples collected, 1x EDTA-containing and 1x red-top (clotted blood) tubes were 
immediately centrifuged at 500–1000 g for 10 minutes (Biocom Biotech Centrifuge, Centurion South 
Africa). Plasma and serum were isolated and samples were subsequently stored at - 80°C until thawed for 
various analyses such as viral load (VL) assessments and lipoprotein sub-class assessments.  
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3.3 CD4 COUNT 
TruCOUNT tubes (BD Biosciences, San Jose CA) together with MultiTESTTM CD3 FITC/ CD8 PE/ CD45 
PerCP/ CD4 APC Reagent (BD Biosciences, San Jose CA) were used to perform CD4 counts. MultiTEST 
CD3-FITC/ CD8-PE/ CD45-PerCP/ CD4-APC reagent was added to the TruCOUNT tube followed by 
addition of 50 μL EDTA blood and gentle mixing. The samples were then incubated for 15 minutes at room 
temperature (in the dark); whereafter FACS lysing solution was added to the tube. This was followed by 15 
minutes incubation at room temperature (in the dark), after which the cells were analyzed on a Becton 
Dickinson FACS Calibur four-color flow cytometer with designated software (BD Biosciences, San Jose 
CA). This is the standard CD4 count methodology employed by the Worcester NHLS (South Africa) 
laboratory and testing was done within 30 minutes after collection. 
3.4 VIRAL LOAD (HIV-1 QUANTITATIVE ASSAY) 
The evaluation of VL is an important assessment of HIV status and disease progression and here  1 mL of 
frozen plasma (previously collected) was decanted into a 1.7 mL Axygen micro centrifuge tube (Axygen Inc, 
Union City CA) and the sample tested using the NucliSensEasyQ® HIV-1 v1.2 Viral Load Test (BioMerieux 
Inc., Boxtel, Netherlands). It is a quantitative test based on nucleic acid sequence based-technology with a 
combination of real-time molecular beacons and has a detection range of 350 to 106 copies/ml. These tests 
were completed at a SANAS-accredited laboratory based within the Division of Medical Virology, Faculty 
of Medicine and Health Sciences (Stellenbosch University, South Africa).  
3.5 FLOW-MEDIATED DILATATION  
Endothelial dysfunction represents an early event in atherosclerosis progression and FMD is a useful non-
invasive test that can be employed in this instance. It is based on the ability of the endothelium to release 
nitric oxide (NO) in response to a stress stimulus (Solages et al., 2006). Here the brachial arterial diameter 
can be measured by ultrasound (high-resolution camera). This test initially evaluates the baseline brachial 
artery diameter (at rest) whereafter the maximum diameter is taken after 5 minutes of ischemia (pressure cuff 
placed around the forearm inflated to suprasystolic pressure for 5 minutes) once the blood pressure has been 
deflated (Figure 3.2). The subsequent vasodilation can be imaged and quantitated as an index of vasomotor 
function (Cornetti et al., 2002; Jarrete et al., 2016). The percent FMD reflects the percentage change in 
diameter and is an indicator of NO-mediated vasodilatation and endothelial function. Such procedures were 
performed (in parallel) at the Worcester CDC by one of our collaborators from the Division of Medical 
Physiology (Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa). 




Figure 3-2: The ultrasound equipment used for FMD evaluation 
 
3.6 CRP LEVELS: 
CRP levels were measured by the immunoturbidmetric method, with relatively high levels defined as > 10 
mg/L (Lau et al., 2006). Assays are based on the reaction between a soluble analyte and the corresponding 
antigen or antibody bound to polystyrene particles. For CRP quantification, particles consisting of a 
polystyrene core and a hydrophilic shell were used in order to covalently link anti-CRP antibodies. A dilute 
solution of test sample was mixed with latex particles coated with mouse monoclonal anti-CRP antibodies. 
CRP in the test sample will form an antigen-antibody complex with latex particles. Light scattering 
(measured by a nephelometric procedure after 6 min) is proportional to analyte concentration in the sample. 
An automatic blank subtraction was performed and CRP concentrations were calculated by using a 
calibration curve.  
3.7 LIPID TESTS: 
3.7.1 Traditional lipid tests 
A Total cholesterol test: 
Cholesterol is measured enzymatically in serum or plasma in a sequence of coupled reactions that hydrolyze 
cholesteryl esters and oxidize the 3΄-OH group of cholesterol (Hopkins. 2004). H2O2 is one of the reaction 
by-products and levels were quantified by a peroxidase-catalyzed reaction that produces a color. Absorbance 
was measured at 500 nm with color intensity being proportional to cholesterol levels. 
B TG test: 
Serum/plasma samples are exposed to a sequence of coupled reactions that result in triglycerides being 
hydrolyzed to produce glycerol (Hopkins. 2004; Fawwad et al., 2016). Glycerol is then oxidized using 
glycerol oxidase and a reaction by-product (H2O2) is measured as described above for cholesterol.  
C  HDL test:  
HDL is measured directly in serum where the apoB-containing lipoproteins in specimens are reacted with a 
blocking reagent (Hopkins. 2004). This renders them non-reactive with the enzymatic cholesterol reagent 
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(under assay conditions). ApoB-containing lipoproteins are thus effectively excluded from the assay and 
only HDL-chol is detected. How measured though?  
D LDL test: 
Most of the circulating cholesterol is found in three major lipoprotein fractions: very low-density 
lipoproteins (VLDL), LDL and HDL.  
[Total chol] = [VLDL-C] + [LDL-C] + [HDL-C]  
LDL-cholesterol is calculated from the measured values of total cholesterol, triglycerides and HDL-
cholesterol according to the relationship:  
[LDL-C] = [Total C] - [HDL-C] - [TG]/5, where [TG]/5 is an estimate of VLDL-cholesterol (Fawwad et al., 
2016). Values are expressed in mg/dL. Desirable levels of LDL-chol are below 130 mg/dL (converted to 
mmol/L by dividing values by 38.67) for adults and 110 mg/dL (converted to mmol/L by dividing values by 
38.67) for children.  
3.7.2 Lipoprint LDL System (lipoprotein sub-fractions)  
 
Fasting blood sample was obtained from study recruits in the morning. Total cholesterol and triglycerides in 
serum were analyzed using the enzymatic CHOD-PAP method. This is an electrophoretic method that allows 
for the separation of lipoproteins on polyacrylamide gels by using the Lipoprint LDL System (Quantimetrix, 
Redondo Beach CA) (Dutheil et al., 2014). This method enables the analysis of 12 lipoprotein sub-fractions, 
i.e. VLDL, intermediate-density lipoprotein (IDL) 1-3, LDL 1-7 and HDL. 
 
Stellenbosch University  https://scholar.sun.ac.za
43 
 
3.8 FLOW CYTOMETRY  
We performed these studies at the CAF Fluorescent Imaging Unit at Stellenbosch University. Here we used 
the BD FACS Aria I cell sorter (BD FACS Aria I, BD Biosciences, and San Jose CA) and employed the 
following strategy (Figure 3.3): 
 
 
Figure 3-3: Flow diagram of flow cytometry protocol. This is a 
broad road map of the strategy employed and will be explained 
in detail for the rest of this chapter. 
 
3.8.1 Optimization of Flow Cytometry Set-up 
A Panel design and gating strategy for flow cytometry work 
Multicolor flow cytometry is a powerful tool to detect and analyze multiple parameters at the cellular level. 
However, quality of the results depends on proper panel design and optimization of the instrument set up and 
here we employed the following panels (Table 3.1): 
Panel #1:  immune activation and coagulation markers on monocyte and lymphocyte T cells: 
CD3, CD8, CD38, CD142, CD14, CD16. 
 
Panel #2:  regulatory T cell markers: 
CD3, CD4, CD25, FOXP3, GARP, SATB-1.  
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Table 3-1: Antibody panels employed for flow cytometric analyses 
MARKERS 
Immune activation Monocyte Regulatory T cell 
CD3 APC-H7 CD3 APC-H7 CD3 APC-H7 
CD38 PE CD16 PE-CY7 CD4 FITC 
CD8 BV 421 CD14 PE CF 594 CD25 PE-CY7 
CD142 APC (HTF) CD142 APC (HTF) FOXP3 HU V450 
 CD38 PE GARP PE 
  SATB-1 ALEXA fluor 647 
 
 
Gating strategy for CD8 activation markers:  
One hundred thousand events were collected for each tube and cells were gated according to lymphocyte 
population. The side scatter (SSC) was plotted against forward scatter (FSC) to identify and differentiate 
lymphocytes. T cells were extracted from lymphocytes by plotting CD3 APC-H7 Vs SSCA, while the 
doublets were excluded using forward scatter-height (FSC-H) versus forward scatter-area (FSC-A). We then 
identified the CD3+CD8+ cells and determined the expression of CD38 and CD142 on CD8+ T cells (refer 
Figure 3.4 for flow cytometry gating strategy).  
 
 
Figure 3-4: Flow cytometry-gating strategy to determine expression of CD38 and 
CD142 on CD8+ T cells. (a) SSC versus FSC to identify lymphocytes; b) Dot plot shows 
SSC versus CD3 APC-H7 to identify T lymphocytes; c) CD3 singlets dot plot - FSC-
height versus FSC-area; d) CD8 BV421 versus CD3 APC-CY7; and e) Expression of 
CD38 andCD142 on CD8 + T cells. 
 




The identification of monocyte sub-populations was based on the expression of CD14 and CD16 markers. 
Furthermore, fluorescent minus one (FMO) for CD16 was used to differentiate between CD16+ positive and 
CD16- negative populations. The antibodies employed to stain for the monocyte panel included: APC-H7 
mouse anti-human CD3, BV412 mouse anti-human CD8 and PE-CY 7 mouse anti-human CD16 –refer 
Figure 3.4 for flow cytometry gating strategy.  
Gating strategy for monocyte panel 
We began with CD14 versus SSC to identify (separate) individual monocyte populations. The single cell 
monocyte (singlets) was generated using FSC-H and FSC-A. This was followed by CD14+CD3- versus SSC 
to ensure that the CD3+ population was excluded from the monocyte population. Lastly, we performed 
CD16+ versus SSC (Figure 3.5). 
 
Figure 3-5: The gating strategy used to acquire monocyte subsets. (a) 
SSC versus CD14; (b) Monocyte singlet for CD14, FSC-H versus FSC-A; 
(c) Gate for CD14+ and CD3- (SSC) versus CD3 APC-CY7 to exclude 
CD3 positive cells from monocyte subsets; (d) CD16 PE-CY7 vs SSC  
Treg cells 
The identification of Treg cells was based on the expression of classical Treg CD3+CD4+CD25++FOXP3+ 
and the identification of activated markers (GARP, SATB-1) on Treg cells. For this panel, the gating strategy 
was based on the expression of CD4+ FOXP3+ cells and CD4+ CD25 variability (CD25–, CD25+ and 
CD25++). We assessed both intra- and extracellular markers for Treg cell evaluation. Extracellular markers 
included APC-H7 mouse anti-human CD3, FITC mouse anti-human CD4, PE CY7 anti-human CD25 and 
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PE mouse anti-human GARP. For intracellular marker assessment, additional steps were required as detailed 
in section 3.6.2. 
Gating strategy for Treg cells 
We started with SSC versus FCS to gate the lymphocyte population, then CD3 single cell (singlet) using 
FCS-H versus FCS-A, followed by CD3APC-CY7 versus FCS and CD4 FITC versus FCS. For Treg 
identification and differentiation, CD4+FOXP3+ (V450) was evaluated versus CD25 PE-CY7 variable 
(CD25++, CD25+ and in CD25-) (Figure 3.6). 
 
 
Figure 3-6: Representative flow cytometry dot plots demonstrating Treg cells gating. 
(a) SSC versus FSC to gate lymphocytes; (b) FCS-H versus FCS-A for CD3 singlets; 
(c) CD3 versus FSC; (d) CD4 versus FSC; (e) CD4+ FOXP3+ versus CD4+ CD25 
variable (CD4+CD25-, CD4+CD25+, CD4+CD25++) was used to identify and 
differentiate Treg cells.  
 
B Antibody titration 
Titrations were done to determine optimal volumes that generate a bright enough signal to allow for precise 
measurement of antibody flouresence. Furthermore, this also minimizes non-specific binding and also 
ensures that the most cost-effective approach is employed. The first titration experiment was performed with 
the highest recommended antibody volume (manufacturer instructions), whereafter it was titrated downwards 
(doubling dilution). For example, for CD25 PE-CY7 we started with the recommended 5 µL volume in tube 
#1 that was followed by 2.5 µL, 1.25 µL and 0.625 µL, respectively, for the next set of tubes. During 
titrations, various factors may influence this procedure, e.g. antibody concentration, time of incubation, 
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temperature and the number of cells. Thus to ensure accurate results all titrations should be performed under 
similar conditions, see (table 3.2) for titrated antibody volumes, manufacturer information. 
Titration of CD8 activation markers (CD3+, CD8+, CD38+)  
Titrations were started after washing of cells. Here four tubes were prepared with different antibody 
concentrations, e.g. for CD3 APC-H7 we started with the recommended volume of 5 µL /test in tube #1, 
followed by 2.5 µL, 1.25 µL and 0.625 µL, respectively, for the next set of tubes. A similar procedure was 
adopted for CD8 BV421 titration. However, for CD38 PE the titration started with 20 µL in the first tube, 
followed by 10 µL, 5 µL and 2.5 µL, respectively, in the next set of tubes. Subsequently, 100 µL of cells 
(after thawing and washing steps) were added to each respective tube. Samples were then incubated for 30 
minutes at room temperature (in the dark), where after 2 mL of PBS was added to each sample. Samples 
were then centrifuged at 500 g for 5 minutes (Lab Centrifuge, Biocom Biotech, Centurion, South Africa) 
where after the supernatant was decanted and the pellet re-suspended in 300–400 µL PBS. Samples were 
thereafter stored at 4°C and analysed by flow cytometry within 24 hours. 
Titration of monocyte activation markers  
Four tubes were labelled with different volumes, i.e. 5 µL, 2.5 µL, 1.25 µL and 0.625 µL. For CD3 APC-H7, 
CD14 PE-CF594, CD16 PE-CY7 and CD142 APC each antibody titration started with 5 µL (as 
recommended) and then titrated downwards, i.e. 2.5 µL, 1.25 µL and 0.625 µL, respectively. After cells were 
thawed and centrifuged, 100 µL aliquots were added to the respective tubes (with antibody dilutions) and 
incubated for 30 minutes in the dark at room temperature. Subsequently, 2 mL PBS was added and samples 
centrifuged at 500 g for 5 minutes (Lab Centrifuge, Biocom Biotech, and Centurion, South Africa). The 
supernatant was then removed and the pellet re-suspended in 0.3 mL PBS. Samples were stored at 4°C and 
analysed by flow cytometry within 24 hours. 
Titration of regulatory T cell activation markers 
For this panel titrations were done for surface and intracellular markers. Here four tubes were labelled with 
different volumes, e.g. for CD25 PE-CY7 we started with the recommended volume (5 µL) followed by 
downward titration as before.  
After the staining, incubation and washing of such samples, data were acquired using the BD FACS Aria 
(BD Biosciences, San Jose CA) and post-acquisition analysis was performed using FACS Diva software (BD 
Biosciences, San Jose CA). Thus we generated a histogram for each antibody titration (Figure 3.7). Here 
both negative and positive populations were identified for each antibody. For example, peaks on the right 
side of the histogram represent the positive population. Population statistics of the histogram were generated 
and the values were exported to excel sheets (for each antibody) and used for a standard curve. Additionally, 
the staining index (SI) value for each titration was calculated using the equation 3-1 (Telford et al., 2009): 







)                     (3-1) 
The equation used to calculate the staining index and to generate the titration curve. MFI= mean 




Figure 3-7: Staining index and different antibody concentrations for antibody titration. (a) four dilutions 
(TM1 - 5 µL; TM2 – 2.5 µL; TM3 – 1.25 µL; and TM4 - 0.625 µL) to obtain optimal concentration for 
TF (CD142). a) Staining for CD142+ using different dilutions; and (b) Brightness of signal. Optimal 
concentrations were determined according to relatively high SI values with a value that was roughly less 
than half the recommended concentration. Thus the titration provides an intense signal to be detected 
with a relatively low antibody concentration. TM: Tube Monocyte (label for the different sample tubes). 
 
 
Table 3-2: Titrated antibody volumes, manufacturer information and isotypes employed. 
Antibodies Manufacture  Volume (µL) Isotype (clone) 
CD8 BV 421 BD Biosciences, San Jose CA 2 µL Ms IgG1, κ (RPA-T8) 
CD142 APC (HTF) Bio Legend Inc. , San Diego CA 2 µL Ms IgG1, κ (NY2) 
CD14 PE CF 594 BD Biosciences, San Jose CA 4 µL Ms (BALB/c) IgG2b,κ(MϕP9) 
CD4 FITC BD Biosciences, San Jose CA 8 µL Ms IgG1, κ (RPA-T4) 
CD3 APC-H7 BD Biosciences, San Jose CA 3 µL Ms (BALB/c) IgG1, κ (leu-4) 
CD16 PE-CY7 BD Biosciences, San Jose CA 3 µL Ms IgG1, κ (3G8) 
FOXP3 HU V450 BD Biosciences, San Jose CA 3 µL Ms IgG1 (259D/C7) 
SATB-1 ALEXA fluor 647 BD Biosciences, San Jose CA 3 µL Ms IgG1 (14/SATB1) 
GARP PE BD Biosciences, San Jose CA 3 µL Ms IgG2, κ (7B11) 
CD25 PE-CY7 BD Biosciences, San Jose CA 2 µL N/A 
CD38 PE BD Biosciences, San Jose CA 5 µL N/A 
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C Flow cytometry color compensation 
Multiple staining flow cytometry has the advantage of identifying and characterizing very low cell 
frequencies in the periphery. However, a major problem with this method is the overlap between fluorescent 
dyes. Thus where emission spectra of flourchromes may overlap, compensation is made to limit spill-over of 
fluorescent signals from one detector channel to another. Some fluorochromes can also be excited by more 
than one laser and thereby contribute to spillover. The main goal of compensation is therefore to eliminate 
spillover, especially when considering the technical limitation of tandem dyes, which are susceptible to 
damage upon exposure to light or high temperatures.  
  
Procedures: 
BD Comp beads (BD Biosciences, San Jose CA) were vortexed before usage. Falcon tubes (BD 
Biosciences, San Jose CA) were labeled for each respective fluorochrome antibody and 100 µL of 
staining buffer added per sample. BD comp beads for negative and positive controls were then 
vortexed. One full drop (60 L) of BD comp beads (negative control) and one full drop (60 L) 
of BD comp beads (positive; anti-mouse Igκ) were added to each respective tube. This was followed 
by a vortexing step. Subsequently, the titrated antibody volume was added to labeled tubes, 
followed by vortexing and incubation for 30 minutes in the dark at room temperature. Thereafter we 
added 0.5 mL staining buffer to each tube. This procedure was completed to ensure that the 
instrument is indeed functioning optimally – thus a control step for the instrument (Figure 3.8).  
 




Figure 3-8: Instrumental set up by comp beads compensation. Compensation controls 
must consist of a negative and a positive population for each single color.  




D Fluorescence minus one (FMO) 
The gating control was an additional parameter required for optimization. Fluorescence minus one 
technology was performed in order to differentiate between positive and negative events. This procedure 
involves the addition of all fluorescent reagents to a cell sample except for one. It is an important procedure 
especially for antibody markers where positive signals are expressed at relatively low levels, e.g. GARP and 
SATB-1. It is also necessary to differentiate between positive and negative populations, e.g. for CD16 where 
11 antibody colors were employed in an experiment.  
Procedure: 
Eleven FMO tubes were prepared, i.e. each tube with all antibodies except the antibody that the 
respective tube was labeled with. After the appropriate antibodies were added to the respective tubes, 
100 μL of FACS-lysing blood was added and tubes gently mixed and incubated for 30 minutes in the 
dark at room temperature. The staining protocol used during the antibody titration experiment was 
detailed earlier and was followed for cellular surface and intracellular markers; a) Treg panels; b) 
activation markers; and c) monocyte panels (Addendum A Figures). 
3.8.2 Routine Cell Separation and Cell Staining 
We usually completed 10 blood samples at a time and employed stained as indicated (Table 3.3). 
Table 3-3: Composition of three flow cytometric panels used and placement of the 11 antibodies into the 
relevant panels 
Immune activation markers Monocyte population markers Regulatory T cell markers 
CD3 APC-H7 CD3 APC-H7 CD3 APC-H7 
CD38 PE CD16 PE-CY7 CD4 FITC 
CD8 BV 421 CD14 PE CF 594 CD25 PE-CY7 
CD142 APC (HTF) CD142 APC (HTF) FOXP3 HU V450 
 CD38 PE GARP PE 
  SATB-1 ALEXA fluor 647 
 
 
Where: APC: Allophycoyanin; PE:Phycoerythrin; FITC:Fluorescein isothiocyanate; APC-
H7:Allophycocyanin-Hilite®7; PE-Cy7:Phycoerythrin-cyanine 7; BV421:Brilliant violet 421; 
SATB-1 Alexa Fluor 647: Special AT-rich sequence-binding protein 1; GARP: Glycoprotein A 
repetition predominant; FOXP3 HU V450: Fork head boxp3 human Violet 450. 
 
Equipment  
a. 15 mL polypropylene tube (BD Biosciences, San Jose CA) 
b. 12 × 75 mm polyester Falcon tube (BD Biosciences, San Jose CA) 
c. Vortex mixer  
d. Centrifuge (Lab Centrifuge, Biocom Biotech, Centurion, South Africa). 
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e. Flow cytometry (BD FACS Aria, BD Biosciences, San Jose CA) 
Reagents: 
i. PBS phosphate buffer solution 
ii. BD FACS-lysing solution (1 from fix-lysing: 10 water) (BD Biosciences, San Jose CA) 
iii. FOXP3 buffer set (BD Biosciences, San Jose CA) 
iv. Wash buffer (PBS with 0.5% BSA and 0.1% sodium azide).  
Preparation of Antibody Staining Mixture 
Antibody panels consisted of both cellular surface and intracellular markers. For monocyte and activation 
panels the antibody staining mixture was prepared for surface staining for 10 samples. For Treg cells the 
surface and intracellular staining protocol was prepared for 10 samples (refer Tables 3.4, 3.5 and 3.6).  
 
Table 3-4: Monocyte staining mix panel for 10 samples. 
AB µL/test ×12 (total/10 patients) 
CD3 APC-H7 3 µL 36 µL 
CD8 BV421 2 µL 24 µL 
CD38 PE 5 µL 60 µL 
CD14 PECF594 4 µL 48 µL 
CD16 PE-CY7 3 µL 36 µL 
CD142 APC (HTF) 2 µL 24 µL 
Buffer (PBS) 1 µL 12 µL 





Table 3-5: Treg surface staining mix for 10 samples. 
AB µL/test (Total /10 patient )×12 
CD3 APC-H7 3 µL 36 µL 
CD4 FITC 8 µL 96 µL 
CD25 PE-CY7 2 µL 24 µL 
GARP PE 3 µL 36 µL 
Buffer (PBS) 4 µL 48 µL 





Table 3-6: Treg Intracellular staining mix for 10 samples. 
AB 
µL/test Total for 10 patient ×12 
SATB- Alexa fluor 6471 3 µL 36 µL 
FOXP3 HV450  3 µL 36 µL 
Buffer (PBS) 4 µL 48 µL 
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A Cell preparation  
1 mL of blood from EDTA tube was collected in BD FACS lysing solution in a 15-mL polypropylene tube 
(BD Biosciences, San Jose CA). After mixing, the sample was allowed to stand for 10 minutes and then 
stored at - 80°C until the time of staining. The frozen sample was thawed at 37°C and then centrifuged at 
400–500 g for 10 minutes (Lab Centrifuge, Biocom Biotech, Centurion, South Africa). The supernatant was 
then decanted and cells twice washed with PBS. We then added 100 µL of cells to two Falcon tubes (BD 
Biosciences, San Jose CA), respectively. Here tube #1 was prepared for a monocyte and CD8 T cell 
activation markers panel, while tube #2 was prepared for a Treg markers panel. The appropriate amount of 
surface staining reagents was then added to the respective tubes. 
B Flow cytometry routine panel and acquisition  
Monocyte panel with immune activation 
Monocytes and T cells were identified by size and granularity. Monocytes were distinguished by expression 
of CD14 and CD16, while T-lymphocytes were identified by CD3 and CD8. Cell surface molecule 
expression was studied by staining cells with the following flourochrome-labeled antibodies: APC-H7 mouse 
anti-human CD3, BV412 mouse anti-human CD8, PE-CY 7 mouse anti-human CD16, PE-CF594 mouse 
anti-human CD14, APC anti- human CD142 (TF) and PE anti-CD38 (refer Figure 3.5. for gating strategy). 
Immune activation was measured using anti-CD38 PE, anti-CD3 APC-H7, anti-CD8 BV412 and TF CD142 
(refer Figure 3.4). 
After thawing frozen samples at 37°C, it was centrifuged at 500 g for 10 minutes (Lab Centrifuge, Biocom 
Biotech, Centurion, South Africa). The supernatant was thereafter decanted and the pellet re-suspended in 2 
mL PBS. Cells were thereafter washed (2x) and then placed in a Falcon tube (BD Biosciences, San Jose CA). 
The appropriate antibody panel (titrated) was then added to the respective tubes (CD3, CD14, CD16, CD142, 
CD8, and CD38). This was followed by 30 minutes incubation at room temperature, whereafter cells were 
washed with 2 mL PBS. Samples were then centrifuged at 500 g for 5 minutes (Lab Centrifuge, Biocom 
Biotech, Centurion, South Africa), re-suspended in 0.3 mL PBS and stored at 4°C until flow cytometric 
analysis was performed within 24 hours. 
Regulatory T cell panel  
Here identification is based on expression of classical Treg markers (CD4+CD25+FOXP3+) and the 
identification of activated markers (GARP, SATB-1). This panel contains both extracellular surface and 
intracellular markers for antibody staining. We started with extracellular staining steps (as described before) 
with APC-H7 mouse anti-human CD3, FITC mouse anti-human CD4, PE CY7 anti-human CD25 and PE 
mouse anti-human GARP.  
Stellenbosch University  https://scholar.sun.ac.za
54 
 
Intracellular markers antibody staining- panel 2 
We included a permeabilization step for intracellular antibody staining (V450 mouse anti-human FOXP3 and 
Alexa Fluor 647 mouse anti SATB-1), where after standard staining procedures were followed as for the 
extracellular experiments (for CD3, CD4, GARP and CD25). For the permeabilization step (for intracellular 
staining of SATB-1 and FOXP3) the FOXP3 buffer set was employed (Human FOXP3 buffer set, BD 
Biosciences, San Jose CA). Here cells were re-suspended in wash buffer and then 0.5 mL of Buffer C 
(Human FOXP3 buffer set, BD Biosciences, San Jose CA) was added to each tube. After vortexing the 
samples were incubated for 30 minutes at room temp in the dark (some antibodies photosensitive), thereafter 
cells were washed with 2 mL of PBS, followed by centrifugation at 500 g for 5 minutes (Lab Centrifuge, 
Biocom Biotech, Centurion, South Africa). The wash buffer was then removed and the pellet washed for a 
second time. Subsequently, titrated concentrations of both FOXP3 and SATB-1 were added to the cells 
together with diluted PBS. With some gentle shaking this allowed for the re-suspension of the pellet. It was 
thereafter incubated for 30 minutes in the dark (room temperature). After incubation, the cells were washed 
and re-suspended in 0.3 mL wash buffer and analysed by flow cytometry within 24 hours. 
3.9  SAMPLE ACQUISITION AND DATA ANALYSIS  
The samples were acquired using the BD FACS Aria flow cytometer (BD Biosciences, San Jose CA) and 
analysed using FACS Diva software (BD Biosciences, San Jose CA). One hundred thousand events were 
collected per sample tube and expression for each marker determined based on total gated events. Data were 
exported from the FACS Diva software (BD Biosciences, San Jose CA) to an Excel spreadsheet to allow for 
further analyses. 
3.10 STATISTICAL ANALYSIS  
The percentage data were exported to an Excel spreadsheet and statistical analysis performed using Graph 
Pad Prism (Version 5, Graph Pad Software, San Diego CA). Here all data were derived from the parent 
percentage, except GARP and SATB-1 (from grandparent percentage). One-way ANOVA analyses were 
performed and comparisons made between four study groups distinguished by CD4 count (control, CD4 
count > 500, CD4 count 200-500, and CD4 count < 200). In addition, we also compared data for control 
versus naïve versus HIV-treated groups. Correlations between the variables were also performed using the 
Spearman’s correlation. All statistical analyses were performed under supervision of a qualified statistician – 
Prof. Daan Nel (Department of Statistical Sciences, Stellenbosch University). The statistical significance of 
results was determined by the respective P value obtained: if P ≤ 0.05, the result is significant; for P value 
between 0.05 and 0.005, the result is highly significant; and for P < 0.005 the result is extremely significant. 
Data are reported as mean percentage ± SD (standard deviation). 
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CHAPTER 4 RESULTS 
All the data presented in this chapter show the mean percentage of markers ± standard deviation (SD). One 
way-ANOVA was performed on expression markers to compare different study groups, while student t-test 
analyses were also performed to compare between two specific groups. 
The Spearman correlation test was performed and such correlations are presented with linear regression XY 
data, together with significant coefficient r- and p-values. In this instance, all data are presented with 
standard error of the mean (SEM). 
4.1 PATIENT DEMOGRAPHICS  
A total of 80 participants were recruited for this study. This comprised a control group of 13 HIV-negative 
persons and 67 HIV-positive individuals (N=21 on first line treatment and N=20 on second line treatment); 
the age range the participants varied from 18 to 55, with a mean age of 38 years. Here 64% (N=51) were 
females while males comprised the rest (Table 4.1). An evaluation of HIV-positive individuals using the 
WHO staging classification showed that 65% can be categorized into stage 1 (N=44), 11% into stage 2 
(N=7), 15% (N=10) into stage 3 and 9% into stage 4 (N=6). Data collected from patient histories revealed 
that 51% of the HIV-positive participants (N=34) exhibited a family history of CVD while 59% were 
smokers (N=47). 






HIV treated 1st 
line 




Number of donor 13 26 21 20  





































































66 ± 40 
63 
104±45 <0.01 
Time cART (month) 
mean ± SD 
Median 
N/A N/A 
49 ± 31 
48 
78 ± 45 
68 
0.03 
Smoking (number cigarettes per week: 
mean ± SD 
Median 
0.6 ± 0.5 
1 
0.8 ± 0.3 
1 
0.5 ± 0.5 
1 





N/A - not applicable; N/S - not significant; DBP - diastolic blood pressure; SBP - systolic blood pressure; HR - 
heart rate; CD4 nadir - the lowest CD4 count; HIV/DX - time of HIV diagnosis; Time/cART - time since starting 
cART. 
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4.2 CD4 COUNT  
HIV-positive participants were randomly selected and displayed CD4 counts ranging from 3–1, 800 cells/µL. 
For the HIV-naïve group the mean CD4 count was 548 ± 333 (median = 503 cells/µL), while for the HIV-
treated group the mean CD4 count was 354 ± 280 (median = 300 cells/µL) (P = 0.006). When sub-dividing 
the HIV-positive patients into groups based on CD4 count, mean CD4 counts of the HIV-positive groups 
with CD4 > 500, CD4 count (200–500) and CD4 count < 200 were 756 ± 219, 349 ± 73 and 127± 76 
cells/µL, respectively (Figure 4.1). 
 
 
Figure 4-1: Summary of CD4 counts. (a) Expression of the percentage CD3+CD4+ between control and 
HIV positive individuals with varying CD4 counts (P=0.0001); (b) Comparison of CD4 counts between 
naïve and HIV-treated patients receiving cART (548 ± 333 vs. 354 ± 280; P=0.006); (c) HIV-positive 
subgroups constituted on the basis of CD4 counts (P<0.0001) (data presented as mean ± SEM). 
 
Correlation analyses between CD4 counts and various immunological markers revealed that CD4 is 
negatively correlated with several of these markers (Table 4.2). 
 
Table 4-2: Correlation between CD4 counts and various immunological markers 
CD4 count versus; R-value p-value 
CD8+CD38+ (%) -0.34 0.005 
CD8+CD142+ (%) -0.29 0.02 
CD8+142+38+ (%) -0.37 0.001 
CD4+FOXP3+ (%) -0.52 0.0001 
CD25++FOXP3+SATB-1+ (%) -0.03 0.7 
CD25++GARP+ (%) -0.44 0.0001 
VL (C/mL) -0.45 0.001 
 
 
4.3 VIRAL LOAD  
The mean VL of the HIV-positive group was 53, 532 copies/mL (median = 5, 675 copies/mL). For the three 
groups, i.e. CD4 count > 500, CD4 count (200-500) and CD4 count < 200, mean VL were 11.440 ± 31.5; 
a cb
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329 ± 431 and 527.300 ± 756 copies/mL, respectively (Figure 4.2). Moreover, the Spearman correlation 
performed between VL and CD4 counts showed a negative relationship (r = - 0.45; p-value = 0.001).  
 
 
Figure 4-2: Assessment of VL in HIV-positive individuals. (a) Naïve vs. HIV-treated; (b) HIV-positive 
groups with varying CD4 counts (data presented as mean ± SEM). 
 
 
4.4 CYTOTOXIC T LYMPHOCYTES  
Cytotoxic T lymphocytes (CD8 T cells) are expanded and activated during HIV infection and thus express 
markers that allow for the identification of immune activation. Analysis of total lymphocytes (as percentage 
of total leukocytes) in the study groups revealed that it was 24 ± 6% for the control group versus 31 ± 9%, 22 
± 9%, and 15 ± 8% for groups with CD4 count > 500, 200–500 and < 200, respectively (Figure 4.3).  
Cytotoxic T lymphocytes (CD8 T cells) are expanded and activated during HIV infection and thus express 
markers that allow for the identification of immune activation. Analysis of total lymphocyte percentages (of 
total leukocytes) in the study groups showed that the mean percentage of total lymphocytes in the control 
group was 24 ± 6 versus 31 ± 9, 22 ± 9, and 15 ± 8 for groups with CD4 count > 500, 200–500 and < 200, 
respectively (Figure 4.3)  
ba




Figure 4-3: Percent lymphocytes with HIV infection. (a) Controls vs. HIV-positive individuals; (b) 
Controls vs. naïve vs. HIV-treated persons; and (c) Varying CD4 counts (data presented as mean ± SEM). 
 
4.4.1 Immune Activation Status – CD8+CD38+  
As CD38 expression on CD8+ T lymphocytes is a robust marker of systemic immune activation (Paiardini et 
al., 2013), the degree of immune activation for different HIV stages was evaluated. Our data show that this 
was significantly higher in all HIV-positive groups compared to controls (Figure 4.4). Further analysis 
demonstrated that there was increasing immune activation with lower CD4 counts, with incremental changes 
in the sub-groups not being statistically different. For the control group the number of CD8+ T cells 
expressing CD38 was 4.2 ± 2.8% compared to 26.8± 18.2% for the group with a CD 4 count > 500 cell/µL. 
For the group with a CD4 count between 200 and 500 this amounted to 36.5 ± 22.0% compared to the last 
group (CD4 count < 200) where the value was 46.7 ± 28.0% (p=0.0001).  
 
 
Figure 4-4: Immune activation (CD8+CD38+) in study groups. (a) Controls vs. HIV-positive individuals; (b) 
Control vs. naïve vs. HIV-treated; and (c) Controls vs. HIV-positive individuals with varying CD4 counts (data 
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4.4.2 Immune Activation Markers on CD3+CD4+ T cells 
The degree of immune activation expressed on CD3+CD8- (CD4) between the control and HIV-positive 
groups revealed strong positive results. Here the value for the control group was 33 ± 11% versus 63 ± 16% 
for the HIV-positive group and 59 ± 12% for the naïve group. Further analyses based on CD 4 count showed 
a progressive increase with lower CD4 counts, i.e. 54 ± 11% for CD4 > 500, 61 ± 13% for the group with a 
CD4 count between 200 and 500 and 73 ± 14% for the group with CD4 counts<200) (P<0.0001). 
 
Figure 4-5: Immune activation (CD3+CD8-CD38+) in study groups. (a) Controls vs. HIV-positive individuals 
(P < 0.0001); (b) Control vs. naïve vs. HIV-treated; and (c) Controls vs. HIV-positive individuals with varying 
CD4 counts (data presented as mean ± SEM). *** 
 
4.4.3 Coagulation Markers (CD142) on CD8 T Cells 
CD142 is an important marker related to the extrinsic coagulation pathway and is usually expressed on the 
surface of monocytes and platelets (Ferreira et al. 2010). Current literature indicates that a positive link 
between inflammation and coagulation exists. It is therefore very useful to evaluate CD142 on CD8+ T cells. 
Here the data show that the highest CD142 levels were detected in the HIV-positive patients with relatively 








Figure 4-6: Expression of CD142 on CD8 T lymphocytes. (a) Control vs. HIV-positive persons; (b) Controls 
vs. naïve vs. HIV-treated individuals (P = 0.1); and (c) Comparisons with varying CD4 counts in HIV-
positive individuals (P = 0.01) (data presented as mean ± SEM). 
  
 
4.4.4 Coagulation Markers on CD3+CD8- T cell (CD4) 
Expression of coagulation markers on CD3+CD8- T cell (CD4) showed significance when comparing the 
control versus the HIV-treated group, i.e. CD142 expression on CD3+CD8- T cells (CD4) was 9 ± 6% for 
controls compared to 28 ± 25% for the naïve group (Figure 4.7). We also found a progressive increase in 
CD142 expression with lower CD4 counts.  
 
Figure 4-7: Expression of CD142 on CD3+CD8- (CD4) T lymphocytes. (a) Control vs. HIV-positive persons 
(P=0.02); (b) Controls vs. naïve vs. HIV-treated individuals; and (c) Comparisons with varying CD4 counts in 
HIV-positive individuals (P=0.0003) (data presented as mean ± SEM). 
 
4.4.5 Co-expression of CD38 and CD142 on CD8 T Cells 
For the current study, we combined the expression of an immune activation marker (CD38) with a 
coagulation marker (CD142) on CD8 T cells – for the first time as far as we are aware. These data show that 
such co-expression is extremely significant between controls and HIV-positive persons (P=0.0005) and also 








Figure 4-8: Immune activation and coagulation assessment in CD8 T cells. (a) Representative flow 
cytometry dot plot showing co-expression of CD38 and CD142 on CD8 T cells in an HIV-negative control 
sample; (b) Representative flow cytometry dot plot demonstrating co-eexpression of CD38 and CD142 on 
CD8 T cells in an HIV-positive sample with a relatively low CD4 count (CD4 count = 3 cells/µL); (c) 
Controls vs. HIV-positive; (d) Controls vs. naïve vs. HIV-treated patients (Controls vs. naïve P=0.002; 
Controls vs. HIV-treated P<0.002); and (e) CD38 and CD142 expression on CD8 T cells with varying CD4 
counts (data presented as mean ± SEM).  ** P=0.0001.  
 
4.4.6 Co-expression of CD38 and CD142 on CD4 T Cells  
Co-expression of immune activation and coagulation markers on CD3+CD8- (CD4) T cells revealed 
significant results, i.e. 2.5 ± 1% for controls versus 20 ± 20% for the HIV-treated group (P=0.002) (Figure 
4.9). For the group with the lowest CD4 count (<200) this was even higher, i.e. 31 ± 20% when compared 










Figure 4-9: Co-expression of CD142 and CD38 on CD3+CD8- (CD4) T lymphocytes. (a) Control vs. HIV-positive 
persons (P=0.002); (b) Controls vs. naïve vs. HIV-treated individuals (P=0.008); and (c) Comparisons with 
varying CD4 counts in HIV-positive individuals (P<0.0001) (data presented as mean ± SEM). 
 
4.4.7 The Correlation between CD4 Counts and CD8+CD142+ 
A correlation between CD4 counts and TF (CD142) expressed on CD8 T cells was performed and showed a 
significant negative correlation (Spearman correlation r =- 0.29; p-value = 0.02) (Figure 4.10).  
 
Figure 4-10: Negative correlation between CD4 count and CD142 expression on CD8 T cells 
 
 
4.4.8 Correlation between Viral Load and Immune Activation and Coagulation Markers 
Spearman correlations were also completed for VL versus CD8+CD142+ or CD8+CD38+ and here a positive 
correlation was found in both instances (Figure 4.11). Correlations were performed a comparison between 
immune activation and coagulation markers expressed on CD8 T cells and their relationship to disease 
a b ca b c
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progression markers (CD4 and VL), monocyte subsets and activated markers of regulatory T cell (Table 4.3). 
Hence, increased immune activation and coagulation was positively correlated with all of these markers.  
 
Figure 4-11: . Correlation and linear regression for VL and immune activation and coagulation. (a) VL 
and immune activation marker (CD38 on CD8 T cells) (r=0.27, P=0.04); and (b) VL and CD8+CD142+ 
(r = 0.26, P= 0.04). 
 
 
Table 4-3. The correlation between immune activation and coagulation markers and other markers 
Variable CD8
+/142+ CD8+/38+ CD8+/142+/38+ 
CD4 count (cell/µL) r = - 0.29 & P = 0.02 r = - 0.34 & P = 0.005 r = 0.37 & P = 0.004 
VL (C/mL) r = 0.26 & P = 0.04 r = 0.27 & P = 0.04 r = 0.30 & P = 0.03 
CD14+CD16++ (%) r = 0.31 & P =0.001 r = 0.51 & P = 0.001 r = 0.38 & P = 0.001 
CD14+CD16+ (%) r = 0.22 & P = 0.05 N/S N/S 
GARP (%) r = 0.49 & P = 0.001 r = 0.43 & P = 0.001 r = 0.55 & P = 0.0001 
SATB-1 (%) r = 0.31 & P = 0.008 r = 0.39 & P = 0.001 r = 0.43 & P = 0.001 
CRP (mg/L) r = 0.25 & P = 0.03 N/S N/S 
 
 
N/S - not significant, CRP – C-reactive protein; VL - viral load; CD14+CD16++ - non-classical 
monocytes; CD14+CD16+ - intermediate monocytes; GARP - glycoprotein A repetition 
predominant; SATB-1 - special AT-rich sequence-binding protein-1. 
 
ba
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4.5 MONOCYTE SUBSETS  
Monocytes can be identified by the expression of CD14 and form part of the total leukocyte population. It 
can be subdivided into three subpopulations distinguished by particular combinations of CD14 and CD16 
expression on their surface (refer below).  
4.5.1 Classical Monocyte Subset (CD14+CD16-)  
Classical monocytes decrease during HIV infection and there is corresponding expansion of the intermediate 
and non-classical monocyte subsets in proportion to the total monocytes; this preferential expansion is 
significant in chronic HIV infection with low CD4 counts. As predicted, our data revealed a decrease in 
classical monocytes with HIV infection, especially for individuals with relatively low CD4 counts (Figure 
4.12).  
 
Figure 4-12: Analysis of classical monocyte subset as a percentage of total CD14+ monocyte events.  (a) 
Controls vs. HIV-positive group; (b) Controls vs. naïve vs. HIV-treated (P=0.02); (c) Classical monocyte 
subset expression with varying CD4 counts (P=0.08) (data presented as mean ± SEM). 
 
4.5.2 Intermediate Monocyte Subset (CD14+CD16+) 
These data showed an increased number of CD14+CD16+ cells in the HIV-positive treated group versus the 
cART naïve and control groups (Figure 4.13). There was also a significant increase in CD14+CD16+ in the 
low CD4 count group versus controls. 
 
a b c




Figure 4-13: Evaluation of the intermediate monocyte subpopulation with HIV infection. (a) Controls vs. 
HIV-positive (4 ± 2.7% vs 10 ± 15%; P-value not significant); (b) Controls vs. naïve vs. HIV-treated 
patients (p=0.05); and (c) Intermediate monocyte expression between Controls and HIV-positive patients 
with varying CD4 count groups (P = 0.05) (data presented as SEM). 
 
4.5.3 Non-classical Monocyte Subset (CD14+CD16++) 
The expression of non-classical monocytes showed extremely significant results between the control and 
HIV-positive groups (P=0.0001). The percentage CD14+CD16++ monocytes showed an increase for groups 
displaying a relatively low CD4 count (P=0.0001) (Figure 4.14). 
 
 
Figure 4-14: Expression of non-classical monocytes with HIV infection. (a) Control group vs. HIV-
positive group; (b) Control vs. naïve vs HIV-treated (0.06 ± 0.1% vs. 0.5 ± 0.6% vs. 1 ± 1.1%; P<0.0001); 
and (c) Non-classical monocytes with varying CD4 counts(data presented as mean ± SEM). ** P=0.001; 
*** P=0.0001.  
 
A Comparative analysis: expression of monocyte subsets in HIV-negative controls versus HIV-
positive individuals (with relatively low CD4 counts) 
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The expression of monocyte subsets in control group show the normal range of percentage, classical 




Figure 4-15: Images of the three monocyte subsets in an HIV-negative (control) sample. Panels A, B and 




Expression of monocyte subsets in individuals with low CD4 counts 
The expressions of monocyte subsets show expansion of these subsets in intermediate and non-classical 
monocyte subsets.  
 
 
Figure 4-16: Images of three monocyte subsets in HIV-positive individuals with relatively low CD4 counts 
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4.5.4 Monocyte Subsets and CD38 Expression  
No significant differences were found for CD38 expression on monocyte subsets, except for the comparison 
of control versus HIV-positive group in classical monocyte (P=0.01) (Figure 4.17)  
 
 
Figure 4-17: CD38 expression on the surface of monocyte subsets. (a) Comparison between 
controls and the HIV-positive group for three monocyte subsets (non-classical, intermediate and 
classical monocyte) showed limited changes except for expression on classical monocytes (80 ± 11% 
vs. 88 ± 12%; p=0.01); (b) Comparison between controls and HIV-positive persons with varying 
CD4 counts.  
 
4.5.5 Monocyte Subsets and Expression of TF (CD142+)  
These results did not show any significant differences, except for TF expression on non-classical monocytes 
(Figure 4.18). 
 




Figure 4-18: TF expression on monocyte subsets. (a) Controls vs. HIV-positive for three monocyte 
subsets (classical, intermediate and non-classical monocyte); and b) Control vs. varying CD4 counts for 
the three monocyte subsets. Data presented as mean ± SEM. 
 
4.5.6 Correlations 
A Monocyte subsets and TF expression on CD8 T cell 
 CD14+CD16++ monocyte subset  
A correlation analysis was performed between the CD14+CD16++ monocyte subset and coagulation markers 
(CD8+CD142+) and also with coagulation plus immune activation (CD8+CD38+CD142+). There was a 
positive correlation between the CD14+CD16++ monocyte subset and CD8+CD142+ (r=0.31; P=0.01) and also 
with CD8+CD142+CD38+ (r=0.38; P=0.001) as shown in Figure 4.19.  




Figure 4-19: Correlation between non-classical monocyte subset and coagulation  (a) CD8+CD142+ (r=0.31; 
P=0.01); and (b) with CD8+CD38+CD142+ (r=0.38; P=0.001). 
 
CD14+CD16+monocyte subset 
A correlation analysis was next performed between the CD14+CD16+ monocyte subset and CD8+CD142+ 
markers on CD8 T cells and here results showed a positive correlation (r=0.22; P =0.05) (Figure 4.20). 
 
 
Figure 4-20: Correlation between the intermediate monocyte subset and a 
coagulation marker expressed on CD8 T cells (r .22; P=0.05). 
 
 
CD14+CD16- monocyte subset 
The classical monocyte subset (CD14+CD16-) showed a negative correlation with CD8+CD142+ (r = - 0.24; 








Figure 4-21: Correlation between classical monocytes and a coagulation 
marker. Linear regression analysis shows a negative correlation between the 
classical monocyte subset and the coagulation marker (r = - 0.24; P=0.03). 
 
 
B Monocyte subsets and immune activation 
CD14+CD16++ 
Correlation of non-classical monocytes with an immune activation marker (CD8+CD38+) was also performed 
and this showed an extremely significant positive correlation (Figure 4.22). Of note, there were no 
significant correlations with the other monocyte subsets – refer Table 4.4.  
 
 
Figure 4-22: Correlation between non-classical monocytes and 
immune activation marker. Shows a positive correlation (r=0.51; 
P=0.0001). 
 
C CD4 count and monocyte subsets 
CD14+CD16++ 
The correlation performed between CD14+CD16++ and CD4 counts showed a significant negative correlation 
(r = - 0.40 and P=0.001) (Figure 4.23). 





Figure 4-23: A negative relationship between non-classical monocytes and CD4 
count. (r = - 0.40, P=0.001). 
 
 CD14+CD16+ 
A correlation was also performed between CD14+CD16+ and CD4 counts and showed a significant negative 
relationship (Figure 4.24).  
 




CD14+CD16- subset  
Figure 4.25 shows a significant positive correlation between classical monocytes and CD4 counts. Comparison 
between immune activation and coagulation marker is viewd in Table 4-4.    
 




Figure 4-25: Positive correlation between classical monocytes and CD4 counts. 
(r=0.30; P=0.01). 
 
Table 4-4: comparison between immune activation and coagulation marker  
Variable 1 CD14+CD16- CD14+CD16+ CD14+CD16++ 
Monocyte subsets Classical monocytes Intermediate monocytes Non-classical monocytes 
CD8+CD38+ (%) N/S N/S r = 0.51, P = 0.001 
CD8+CD38+CD142+ (%) N/S N/S r = 0.38, P = 0.001 
CD8+CD142+ (%) r = - 0.24, P = 0.03 r = 0.22, P = 0.05 r = 0.31, P = 0.01 
CD4+FOXP3+ (%) N/S N/S r = 0.23, P = 0.04 
CD25++SATB-1+ (%) r = - 0.28, P = 0.01 r = 0.27, P = 0.02 r = 0.32, P = 0.001 
CD25++GARP+ (%) r = -0.46, P = 0.001 r = 0.41, P = 0.001 r = 0.42, P = 0.001 
CD25- GARP+ (%) r = - 0.31, P = 0.01 r = 0.25, P = 0.03 r = 0.43, P = 0.001 
CD4 count (cells/µL) r = 0.30, P = 0.01 r = - 0.27, P = 0.03 r = - 0.40, P = 0.001 
VL (C/mL)  N/S N/S 
CRP (mg/L) N/S N/S r = 0.23, P = 0.05 
 
 
VL - viral load; CD4+FOXP3+- regulatory T cell; CD25++GARP+- glycoprotein A repetition predominant; 
CD25++SATB-1- special AT-rich sequence-binding protein-1 in regulatory T cells; CD8+CD38+- immune 
activation marker; CD8+CD142+- coagulation marker; CD8+CD38+CD142+- co-expression of inflammation 
and coagulation marker; CRP- C-reactive protein. 
.
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4.6 REGULATORY T CELL SUBSETS 
Tregs are a subset of CD4 T cells that normally make up less than 10 per cent of this group of cells 
4.6.1 Regulatory T Cells (CD4+FOXP3+) 
An increase in CD4+FOXP3+ expression in Treg cells with HIV infection is a key feature associated with 
such disease progression. Here the findings show that HIV-infected individuals possess a greater percentage 
of CD4+ T cells that express FOXP3, especially with relatively lower CD4 counts (Figure 4.26). Here the 
percentage CD4+FOXP3+ cells in the control group was 6.8 ± 1.7% compared to 16± 16% and 19.7 ± 19% 
for CD4 counts (200-500 cells/L) and CD4 counts less than 200 cells/L. CD4+FOXP3+ Treg cells were 
also correlated with various immunological markers (Table 4.5), where it showed a positive correlation with 
immunological and coagulation markers while displaying a negative relationship with CD4 count.  
 
 
Figure 4-26: CD4+FOXP3+ expression in HIV-positive individuals. (a) Comparison between controls 
vs.the HIV-positive group; (b) Comparison between controls vs. naïve vs. HIV-treated; (c) Comparison 
with varying CD4 counts. Data presented as mean ± SEM. *** P 0.0005, * P = 0.01. 
 
 
Table 4-5: Correlation of CD4+FOXP3+ with various immunological markers 
CD4+FOXP3+ vs r-value p-value 
CD8+CD38+ (%) 0.34 0.001 
CD8+CD142+ (%) 0.17 0.13 
CD8+142+38+ (%) 0.20 0.08 
CD25++SATB-1+ (%) 0.47 0.0001 
CD25++GARP+ (%) 0.42 0.0009 
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4.6.2 Regulatory Markers in Cytotoxic T Cells (CD3+CD4-FOXP3+)  
We also evaluated the expression of FOXP3 on CD8 T cells and the results revealed a significant increase in 
FOXP3 expression in the HIV-positive group with relatively low CD4 counts (Figure 4-27) (P=0.005). 
 
 
Figure 4-27: CD8+FOXP3+ expression in HIV-positive individuals. (a) Comparison between control and 
HIV-positive groups; (b) Comparison between control vs. naïve vs. HIV-treated groups; (c) Comparison 
with varying CD4 counts (P=0.005). 
 
CD4+CD25++FOXP3+ subset 
As shown in Figure 4.28, a significant rise in the expansion of FOXP3 in CD4+CD25++ cells, particularly 
with relatively low CD4 counts; such upregulation is linked to disease progression (Bi, X. et al., 2009).  
As shown in Figure 4.24, a significant rise in the expansion of FOXP3 in CD4+CD25++ cells, particularly 
with relatively low CD4 counts; such upregulation is linked to disease progression (Bi, X. et al., 2009).  
 
 
Figure 4-28: FOXP3 expression on CD4+CD25++ cells.  (a) Comparison between control and HIV-positive 
groups; (b) Comparison between control vs. naïve vs. HIV-treated groups; and (c) Comparison of the 
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4.6.3 Activated Markers Special AT-rich Sequence-Binding Protein-1 (SATB-1) 
A CD4+CD25++SATB-1 
These data revealed increased SATB-1 expression in CD4+CD25++ cells with the lowest relative CD4 counts 
(Figure 4.29).  
 
 
Figure 4-29: The expression of SATB-1 in CD25++ cells with HIV infection. (a) Control vs. HIV-positive 
groups; (b) Controls vs. naïve vs. HIV-treated groups; and (c) SATB-1 expression with varying CD4 
counts (data presented as mean ± SEM). 
 
B CD4+CD25- FOXP3+SATB-1 
A comparison of SATB-1 expression on CD25- FOXP3+ cells showed an upregulation in HIV-infected 
groups versus controls, i.e. from 10 ± 18% to 23 ± 22% (Figure 4.30). There was also increased SATB-1 
expression for the group with the lowest CD4 counts (<200).  
 
 
Figure 4-30: SATB-1 expression in CD25-FOXP3+ cells.  (a) Control vs. HIV-positive group (P=0.008); (b) 
Control vs. naïve (P=0.002) vs. HIV-treated groups; (c) SATB-1 levels in HIV-positive individuals with 
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C CD3+CD4-FOXP3+SATB1+ (CD8+FOXP3+SATB-1+) 
SATB-1 expression on CD8 T cells showed no significant differences between study groups (Figure 4.31). 
 
 
Figure 4-31: SATB-1 expression on CD8 T cells  (CD8+FOXP3+). (a) Control vs. HIV-positive group; (b) Control 
vs. naïve vs. HIV-treated groups; (c) SATB-1 levels in HIV-positive individuals with varying CD4 counts. 
 
4.6.4 Activated Markers Glycoprotein a Repetitions Predominant (GARP)  
A CD4+CD25++GARP subset 
Our data showed increased GARP+ cells with chronic infection (Figure 4.31).  
 
Figure 4-32: Expression of CD25++GARP+ for different groups. (a) Control vs. HIV-positive group; (b) 
Control vs. naïve vs. HIV-treated groups; (c) GARP expression with varying CD4 counts. , GARP 
increase between CD4 > 500 and CD4 200-500 (* P<0.04), and highly significant when comparing CD4 > 




The expression of GARP on CD25- cells was robustly increased with all HIV infection groups, with a 
relatively low CD4 count (P=0.003) (Figure 4.33). The mean percentage of the control group was 0.2 ± 0.1 
a b c
a b c
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versus 0.5 ± 0.5, 3.2 ± 6, and 4.5 ± 6 for the groups with CD4 counts > 500, 200–500 and < 200, 
respectively. The GARP expression in CD25- controls was 0.2 ± 0.1% compared to 2.5 ± 5% in the HIV-
positive group (P=0.003). 
 
 
Figure 4-33: Expression of GARP in CD4+CD25- cells.  {a) Control vs. HIV-positive individuals (P=0.003); 
(b) Control vs. naïve vs. HIV-treated groups (P=0.004); (c) Control group and HIV-positive with varying 
CD4 counts (data presented as mean ± SEM). ** P=0.003.  
 
C CD3+CD4-FOXP3+GARP (CD8+FOXP3+GARP) 
GARP expression in CD8+ T cells revealed no significant results (Figure 4.34). 
 
 
Figure 4-34: GARP expression in CD8+FOXP3+ T cells.  (a) Control vs. HIV-positive individuals; (b) Control 
vs. naïve vs. HIV-treated groups; (c) Control group and HIV-positive individuals with varying CD4 count (P 
not significant). 
 
4.6.5 Correlation between Treg Markers and Various Immunological Markers  
To better understand the role of Treg cells during the different HIV stages, correlations with other 
immunologic markers were completed as detailed below: 
a b cb
a b ca b c
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A Correlations between monocyte and Treg subsets  
i CD14+CD16++ and CD4+CD25++FOXP3+SATB-1 
The Spearman analysis showed a positive correlation between non-classical monocytes and SATB-1 
expressed on CD25++ FOXP3+ cells (r=0.32; P=0.001) (Figure 4.35).  
 
 
Figure 4-35: Correlation between non-classic monocyte and SATB-1. Linear 
regression analysis showing a significant positive relationship between 
CD25++FOXP3+SATB-1+ and CD14+CD16++. 
 
ii CD14+CD16+ and CD4+CD25++FOXP3+SATB-1 
The correlation of intermediate monocytes and activated marker SATB-1 expressed on CD25++FOXP3+ also 
showed a positive correlation (r=0.27; P=0.02) (Figure 4.36). 
 
Figure 4-36: Correlation between intermediate monocytes and SATB-1.  
Linear regression showing a positive correlation between CD14+CD16+ and 
CD25++FOXP3+ SATB-1. 
 
iii CD14+CD16- and CD25++FOXP3+SATB-1 
However, the findings show that the classical monocyte subset correlated negatively with the 
CD25++FOXP3+ SATB-1 subset (r = - 0.28; P=0.01) (Figure 4.37). 





Figure 4-37: Negative correlation between CD25++FOXP3+SATB-1 and 
CD14+CD16- cells. 
 
iv Correlation between CD14+CD16++and CD25++GARP+ 
The correlation between non-classical monocytes and the activation marker GARP produced a positive 
correlation (r=0.42; P=0.001) (Figure 4.38).  
 
 
Figure 4-38: The correlation between non-classic monocytes and 
CD25++GARP. Linear regression showing a positive relationship between non-
classical monocytes and GARP expression on CD25++. 
 
v Correlation of CD14+CD16++ and CD4+CD25-GARP 
The correlation between non-classical monocytes and GARP (CD4+CD25-GARP) also generated a positive 
correlation (r=0.43; P=0.001) (Figure 4.39).  
 




Figure 4-39: The correlation between non-classic monocytes and CD25-
GARP. Linear regression with significant positive correlation between CD25-
GARP+ and CD14+CD16++ (r=0.43; P=0.001). 
 
vi Correlation between CD14+CD16+ subset and GARP expression 
Correlations were performed between CD14+CD16+ and GARP expressed on CD25++ and CD25- cells 
(Figure 4.40). The results showed a positive correlation between CD14+CD16+ and CD25++GARP+ (r=0.41; 
P=0.001) and also between CD14+CD16+ and CD25-GARP+ (r=0.25; P=0.03).  
 
 
Figure 4-40: The correlation between intermediate monocytes and GARP expression. Positive linear regression 
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vii Correlation between classical monocytes and GARP  
Spearman correlations between classical monocytes (CD14+CD16-) and GARP expression were also 
performed on CD25++ CD4+ and CD25- CD4+ cells, respectively (Figure 4.41). Here data revealed a negative 
relationship between CD14+CD16- and CD25++GARP (r = - 0.46; P=0.001) and also with CD25-GARP (r = - 
0.31; P=0.01) (table 4.6). 
 
 




Table 4-6: Comparison between Treg subset (SATB-1, GARP and FOXP3) correlationsand HIV infection 
Variable SATB-1 GARP FOXP3 
VL (C/mL) N/S r = 0.40 & P = 0.001 N/A 
CD4 (cell/µL) N/S r = - 0.44 & P =0.0002 r = -0.52 & P = 0.00006 
CD8+38+ (%) r = 0.39 &, P = 0.001 r = 0.43 & P = 0.001 r = 0.34 & P = 0.001 
CD8+142+ (%) r = 0.31 & P = 0. 008 r = 049 & P = 0.001 N/S 
CD8+142+38+ (%) r = 0.43 & P = 0.001 r = 0.55 & P =0.0001 r = 0.20 P = 0.08 
CD14+CD16++ (%) r = 0.41 & P = 0.001 r = 0.42 & P = 0.001 r = 0.23 & P = 0.04 
CD14+CD16+ (%) r = 0.27 & P = 0.02 r = 0.41 & P = 0.001 N/S 




VL - viral load; CD8/38 - immune activation markers; CD8/142 - coagulation marker; CD8/38/142 - 
immune activation and coagulation markers; CD14+CD16++ - non-classical monocytes; CD14+CD16+- 
intermediate monocytes; CD14+CD16- - classical monocytes; FOXP3 - fork head boxp3.  
 
a ba
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4.7 C-REACTIVE PROTIEN COMPARISONS  
As CRP is robust marker linked to acute myocardial infarction in HIV pathogenesis (Triant et al., 2009), we 
also evaluated its levels in the different groups. Here we found a significant increase in CRP levels in the 
group with a relatively low CD4 count, i.e. 3.3 mg/L and 23 mg/L for the control and the group with a CD4 
count < 200, respectively (Figure 4.42).  
 
Figure 4-42: Evaluation of CRP levels in study cohort. (a) Controls vs. HIV-positive group;   (b) Control 
vs. naïve vs. HIV-treated groups; (c) Comparison of CRP levels with varying CD4 counts (data presented 
as mean ± SEM). * P=0.01. 
 
4.8 FLOW MEDIATED DILATATION  
FMD is defined as the percentage change in diameter and is employed an indicator of nitric oxide (NO)-
mediated vasodilatation (endothelial function). There are no standard cut-off a value available in the 
literature, but generally an FMD of 6% or higher is regarded as a normal value.   Our data revealed that FMD 
percentages between study groups were not significant (Figure 4.43). The results did, however, show a slight 
improvement in endothelial function in the HIV-positive group versus controls.   In addition, there was a 
small improvement in the HIV-positive group with a CD4 count > 500 versus controls (not statistically 
significant). The mean FMD percentage in the control group was 4.7 ± 3 compared to 7.3 ± 4 for the HIV-
positive group (refer Addendum B for complete data set). 
 
a b ca b c




Figure 4-43: FMD (%) with HIV infection. (a) Control vs. HIV-positive patients; (b) Control vs. naïve vs. 
HIV-treated groups; (c) Control and HIV-positive groups with varying CD4 counts. 
 
4.9 TRADITIONAL LIPID PROFILE 
Plasma levels of a traditional lipid panel (total cholesterol, triglycerides, LDL and HDL) were determined 
using standard methods.  
4.9.1 Total Cholesterol  
Evaluation of total cholesterol (TC) in the study groups showed a significant decrease with HIV infection 
(P=0.005) (Figure 4.44). Further comparisons demonstrated a decrease in TC levels for individuals with a 
CD4 count < 200 versus the control group (P=0.02).  
 
 
Figure 4-44: Evaluation of TC in study groups.  (a) Control vs HIV-positive patients (P = 0.005); (b) 
Control vs. naïve vs. HIV-positive treated groups (5 ± 0.9 mmol/L vs. 4.1 ± 1 mmom/L vs. 4.2 ± 0.8 




a b ca b c
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4.9.2 Triglyceride Levels 
The results revealed a decrease in TG levels for the HIV-positive group versus controls (P=0.001) (Figure 
4.45). Further analyses showed highly significant results between the controls and the groups with varying 
CD4 counts (200-500) and CD4 counts < 200 (Figure 4.45).  
 
Figure 4-45: Assessment of TG levels with HIV infection. Controls  vs. HIV-positive group (P=0.001); 
(b) Control vs. naïve vs. HIV-treated groups (P=0.004); (c) Comparisons with varying CD4 counts (data 
presented as mean ± SEM). ** P=0.003 and * P=0.01. 
 
4.9.3 High-density lipoprotein Levels 




Figure 4-46: Evaluation of HDL levels with HIV infection. (a) Controls vs. HIV-positive group(P=0.2); (b) 
Control vs. naïve vs. HIV-treated groups (P=0.08); (c) Comparison of HDL levels for HIV-positive 




a b ca b c
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4.9.4 Low-density lipoprotein levels 
 
 
Figure 4-47: Evaluation of LDL levels with HIV infection. (a) Controls vs. HIV-positive group (P=0.09); 
(b) Control vs. naïve vs. HIV-treated groups (P=0.2); (c) Comparison of LDL levels for HIV-positive 
individuals with varying CD4 counts 
 
However, more detailed analyses revealed that LDL and total cholesterol levels were decreased in 
individuals not on treatment yet and also for those receiving second line treatment (Tables 4.7 and 4.8). 
Table 4-7: Summary of lipid data 
 
 Table 4-8: Summary of the lipid data 
 
* p<0.05 vs. control; ** p<0.005 vs. control  
 
 
Correlations were next performed between the traditional lipid biomarkers (HDL and LDL) and various 
immunological markers. However, no significant correlations were found in this instance (Tables 4.8 and 
4.9).  
 
a b ca b c
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Table 4-9: Correlation between HDL and  immune markers. 
 
HDL vs  r- value p-value 
CD14+CD16++ -0.10 0.39 
CD14+CD16+ 0.17 0.15 
CD14+CD16- -0.13 0.27 




Table 4-10: Correlation between LDL and immune markers 
LDL vs r-value p-value 
CD14+CD16++ -0.13 0.25 
CD14+CD16+ 0.14 0.22 
CD14+CD16- -0.15 0.18 
CD8+CD142+ -0.09 0.46 
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4.10 EVALUATION OF HDL AND LDL SUBCLASSES  
4.10.1 HDL Subclasses 
To gain additional insight into lipid profiles an electrophoretic method was employed (Lipoprint LDL 
System, Quantimetrix, Redondo Beach CA) that allows for the analysis of 12 lipoprotein sub-fractions, i.e. 
VLDL, IDL 1-3, LDL 1-7 and HDL. Here there was an increase in the large HDL subclass for all HIV-
infected individuals together with decreased small HDL subclasses (Figures 4.48 and 4.49).  
 
Figure 4-48: .Distribution of HDL subclasses in control and HIV individuals. Results represent means ± 
SEM. # p=0.05 and * p<0.05 compared to controls. 
 
Figure 4-49: Representative HDL subclasses scan results 
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C -0.10 -0.27 -0.08 0.25 0.28 -0.49* 0.51* 0.35 -- -- -0.42 -0.47* 
1st line-T 0.00 0.13 0.14 0.32 -0.17 -0.35 0.67** -0.41 -0.47* 0.20 -0.09 -0.18 
2nd line-T -0.06 -0.36 -0.39 -0.10 -0.11 -0.21 0.40 -0.26 -0.31 -0.43 -0.60* -0.64** 





C 0.42 0.14 -0.19 -0.03 0.26 0.24 0.05 0.14 -- -- -0.22 -0.12 
1st line-T -0.11 0.14 -0.13 -0.31 0.12 0.30 -0.50* 0.26 0.64** -0.18 0.23 0.25 
2nd line-T 0.17 0.50* 0.38 -0.01 0.24 0.29 -0.36 0.38 0.18 0.41 0.46* 0.49* 






C -0.14 0.16 0.17 -0.20 -0.40 0.30 -0.48* -0.39 -- -- 0.50* 0.48* 
1st line-T 0.12 -0.35 -0.08 -0.13 0.11 0.18 -0.44 0.30 0.00 -0.13 -0.13 -0.01 
2nd line-T -0.06 0.05 0.19 0.14 -0.08 0.03 -0.23 0.01 0.28 0.23 0.45* 0.47* 
N 0.44 0.17 0.04 -0.10 0.13 0.49 -0.25 0.23 -0.18 -0.23 0.04 0.18 
 
 
V – variable; L-HDL - large- HDL subclass; I-HDL - intermediate-HDL subclass; S-HDL - small-HDL 
subclass; C - control; 1st line-T - first line therapy; 2nd line-T - second line therapy; N - naïve; WC - waist 
circumference; BMI - body mass index; CD4-N = CD4nadir; CD4-C - current CD4 count; SBP - systolic 
blood pressure; DBP - diastolic blood pressure; HR - heart rate; TC - total cholesterol; TG - triglyceride; 
HDL-C - high density lipoprotein-cholesterol; LDL-C - low density lipoprotein –cholesterol; P < 0.05, * P < 
0.005**. 
 
These correlations show that the large HDL subclass is generally associated with beneficial risk factor 
profiles, i.e. with increased HDL-C levels and decreased TG levels together with lowered BMI and waist 
circumference. The intermediate and small HDL subclasses in HIV-positive individuals were associated with 
more harmful risk profiles, i.e. with lowered HDL-C levels, increased BMI and waist circumference, greater 
CD4 nadir counts and higher systolic blood pressures (Table 4.11). Additional analyses were performed and 
showed a significant positive correlation between I-HDL and immune activation markers in naïve patients 
(r=0.54; P=0.02).  I-HDL also correlated positively with classical monocytes (r=0.54; P=0.02) and negatively 
with intermediate monocytes (r = - 054; P=0.02) as illustrated in Table 4.12. 
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C .0167 -.2507 -.0076 -.1487 .1483 -.4016 .2913 -.1576 .1098 
N .1033 -.3294 .1239 .0643 -.0939 -.1199 .0698 .2140 -.1305 






C .1618 -.7753 .2629 .3754 -.3731 -.2828 -.0709 .1883 -.2071 
N .0740 .5403 -.1147 -.5308 .5486 .3842 .1570 .0599 .2709 






C -.1126 .6828 -.1544 -.1050 .1039 .5113 -.2001 .0183 .0359 
N -.1876 -.0822 -.0421 .4048 -.3843 -.1829 -.2183 -.3136 -.0835 
T -.0597 -.1474 -.0906 .0299 -.0302 .0726 -.1181 -.0010 -.2250 
 
 
L-HDL - large high density lipoprotein; I-LDL - intermediate high density lipoprotein; S-HDL - small high 
density lipoprotein; C - control; N - naïve; T - treated; CD8+CD38+ - immune activation marker; CD8+CD142+ - 
coagulation marker; CD14+CD16++ - non-classical monocytes; CD14+CD16+ - intermediate monocytes; 
CD8+CD142+CD38+ - co-expression of immune activation and coagulation markers on CD8 T cells; 
CD4+FOXP3+ - regulatory T cell; CD25++SATB-1 - activation markers for Treg cells; CD25++GARP - 
activation markers of Treg cells.  
 
4.10.2 LDL Subclasses Evaluation 
 
Figure 4-50:  Distribution of LDL subclasses in control and HIV-infected individuals. Results are 
presented as mean ± SEM. #P = 0.05, *P < 0.05 compared to controls. 
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For the LDL subclass analysis, the results show limited changes except for significantly higher IDL-C levels 
in the HIV-positive groups, with this specifically manifesting in the naïve and second line treatment groups 
(Figures 4.50 and 4.51). More correlations were performed by comparing the different LDL subclasses with 
various parameters (refer Table 4.13). Focusing on the IDL subclass, these data show a significant positive 
correlation with total cholesterol and LDL for the control group. For the HIV-positive groups there was also 
a positive correlation with LDL and a concomitant negative correlation with HDL.  
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Correlations between LDL subclasses and immunological markers revealed that IDL-C in HIV-positive 
individuals correlated positively with immune activation (r=0.45; P=0.009) and Treg markers (r=0.35; 
P=0.04). In addition, IDL-B in HIV-infected patients correlated positively with Treg markers (r=0.45; 
P=0.009). However, the correlation in naïve patients showed a positive result between the IDL-A and 
immune activation (r=0.48; P=0.04) and highly significant results with CD8+CD38+CD142+ (r=0.76; 
P=0.001) (refer Table 4.14). 
 















































































































































C -.0148 -.0635 -.0114 .1066 -.1070 .4216 -.0432 .6498 -.3595 
N -.0270 .1594 .0076 -.0943 .0845 .1434 -.0923 .0742 .1182 





C -.2231 -.2626 -.2134 -.2154 .2173 -.2358 .4762 -.1476 .0133 
N .2472 .1616 -.0632 -.1342 .1431 .1672 .0304 .0317 -.1359 





C .1276 -.0948 .1001 .1471 -.1461 .1651 .1583 .3647 -.2224 
N .0385 .0205 -.1163 -.1390 .1318 .1840 -.0569 -.1262 -.0452 





C .4892 .2238 .4096 .3220 -.3215 .2372 -.1322 -.0931 .2445 
N .1618 .4826 -.0862 -.2610 .2488 .7632 -.2358 .0183 -.1016 






C .0179 .0034 -.0200 -.0535 .0556 -.3792 .2025 -.6769 .3142 
N .2847 .4575 .4010 .3715 -.3440 .0306 .3864 .2812 .2924 
T -.0969 -.1462 -.0071 .1817 -.1917 .0178 -.3077 -.1455 -.1519 
 
 
V = variable; C = control; N = HIV-naïve; T = HIV-treated 
IDL – intermediate-density lipoprotein; VLDL - very low-density lipoprotein; C - control; N - naïve; 
T - treated; V - variable; CD8+CD38+ - immune activation marker; CD8+CD142+ - coagulation 
markers; CD14+CD16++ - non-classical monocyte; CD14+CD16+ - intermediate monocyte; 
CD8+CD142+CD38+ - co-expression of immune activation and coagulation on CD8 T cell; 
CD4+FOXP3+ - regulatory T cell; CD25++SATB-1 - activation markers for Treg; CD25++GARP - 
activation markers for Treg cells.  
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CHAPTER 5 DISCUSSION AND CONCLUSION 
The hypothesis of this study was that chronic HIV-1 infection induces changes in monocytes, CD8, CD4 and 
Treg cells that are associated with risk factors for the development of atherosclerosis. Here markers for 
immune activation and coagulation, monocyte subsets and Treg cells expressing classical phenotypic 
(FOXP3+) and novel activation markers (SATB-1, GARP) were investigated in a South African cohort. 
These parameters were then correlated with classic CVD markers (CRP, lipid profile), markers of disease 
progression (CD4, VL) and FMD. The most original findings of this study are: a) the identification of a 
unique coagulation marker (CD142) expressed on CD8 and CD4 T cells and its relatively early expression in 
HIV-infected individuals (naïve). More importantly, it is co-expressed with immune activation and strongly 
correlates with disease progression markers; b) changes in lipid subclasses that significantly correlated to 
HIV immunological markers despite a decrease in terms of the traditional lipid profile expected. Such 
subclass changes may also be a driver for CVD onset, although further research is needed to pursue this 
interesting notion; and c) upregulation of both anti-inflammatory GARP and pro-inflammatory SATB-1 in 
Treg cells in HIV-treated individuals (with immune dysregulation) may alter the balance of Treg cell 
function and also potentially contribute to CVD onset (refer Figure 5.1).   
 
 
Figure 5-1: Novel findings generated by this study and integration into master model. Our data reveal 
enhanced immune activation and inflammation (in persons with decreased CD4 counts) together with 
increased coagulation marker presentation. In addition, there is an upregulation of Treg cell markers and 
inflammatory monocyte subsets with altered lipid profile. We propose that such effects, together with 



























(FOXP3,  SATB1 & 
GARP)
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5.1  INCREASED CD8 T CELL-ASSOCIATED IMMUNE ACTIVATION MARKER 
EXPRESSION 
This study confirmed the phenomenon of decreased CD4 counts and higher levels of immune activation 
(measured by CD38/8 expression) which occur relatively early-on during infection. The results demonstrated 
significant immune activation in the HIV-positive group with a relatively low CD4 count (< 200). Such 
correlations are supported by previous studies (Sousa et al., 2002; Bandrea et al., 2010; Paiardini and Muller-
trutwin. 2013). In addition, immune activation is highly significant between controls and the HIV-positive 
group with a CD4 count > 500 (most of the patients in this group are cART naïve). Thus even with viral 
suppression by cART, high levels of immune activation persist – these findings are in agreement with others 
(Lederman et al., 2013; Paiardini and Muller-trutwin. 2013). Thus our findings link the persistence of 
immune activation to CD4 depletion (activation-induced cell death) in HIV-infected individuals.  In support, 
Lederman et al. (2013) recently described a syndrome characterized by increased T cell activation together 
with high inflammation and coagulation in HIV-treated patients that is referred to as the residual immune 
dysregulation syndrome (RIDS).  RIDS is more common in persons who fail to increase circulating CD4+ T 
cells to normal levels and is linked to individuals with relatively low CD4 counts.  Our results are consistent 
with the latter notion, i.e. increased inflammation/immune activation in HIV-positive patients that is linked 
with immune dysregulation and the subsequent activation of coagulation pathways (Baker et al., 2013).  
5.2 THE ORGINAL EXPRESSION OF COAGULATION MARKERS (CD142) ON 
CYTOTOXIC T LYMPHOCYTES (CD8) AND T-HELPER CELLS (CD4) 
The current study showed – for the first time as far as we are aware - significant expression of TF (CD142) 
on CD8 and CD4 T cells during HIV infection. Moreover, this was co-expressed with the immune activation 
marker CD38+. Such expression in both HIV-naïve and HIV-treated groups demonstrates the role of HIV per 
se in inducing coagulation and inflammation early-on and increasing the risk for both subsets investigated. 
The current study also revealed that co-expression of immune activation and coagulation markers correlates 
positively with VL and negatively with CD4 counts, respectively. Furthermore, co-expression of immune 
activation and coagulation markers correlated positively with intermediate and non-classical monocyte 
subsets. By contrast, a negative correlation with classical monocytes was found. These data support the 
concept that the monocyte shift is related to higher immune activation and coagulation during HIV infection. 
Furthermore, correlations showed a positive relationship between activated Treg cells and increased 
inflammation and coagulation during HIV infection. TF was also positively correlated to CRP, further 
supporting a relationship between inflammation and coagulation in HIV-positive persons. 
HIV-infected patients display a two- to tenfold higher risk of developing thromboembolic events and a two-
fold higher risk of an acute myocardial infarction (Cerrato et al., 2015; Triant et al., 2012). The link between 
inflammation and coagulation during HIV infection is supported by previous work, e.g. the SMART Study 
highlighted the role of inflammation and coagulation (IL-6 and D-dimer) in the prediction of all-cause 
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mortality and CVD events (Kuller et al., 2008). Levi et al. (2003 and 2004) also reported that TF is usually 
expressed on mononuclear cells. However, the disturbance of vascular integrity and a relatively high levels 
of pro-inflammatory cytokines (IL-6) activate TF on mononuclear cells in circulation, which in turn can 
activate coagulation pathways (Funderburg and Lederman. 2014) (Figure 5.2). The current thesis is in 
agreement with such notions and demonstrates a link between inflammation and coagulation by the co-
expression of CD38 and CD142 on CD8 and CD4 T lymphocytes during HIV infection. There is also a 
significant correlation between coagulation markers and atherogenic inflammatory monocyte subsets 
(CD14+CD16+ and CD14+CD16++), with the latter thought to play a role in coagulation pathways during HIV 
infection. 
 
Figure 5-2: The link between inflammation and coagulation. Here the 
increase of the extrinsic coagulation pathway (TF activation) is highly linked 
to greater LPS and IL-6 levels that  are in turn affected by increased immune 
activation during chronic HIV infection (reproduced from Levi et al., 2004). 
 
 
5.3 UPREGULATION OF INTERMEDIATE AND NON-CLASSICAL MONOCYTE 
SUBSETS IN HIV-POSITIVE GROUPS WITH A RELATIVELY LOW CD4 COUNT 
Our data showed an upregulation of both intermediate monocyte and non-classical monocyte subsets during 
HIV infection. In parallel, there was a decrease in the classical monocyte subset in the HIV-positive group, 
particularly for treated patients. These data are in agreement with others that also detected such an expansion 
of monocyte subsets with HIV infection (Funderburg et al., 2012). 
Our monocyte subset profile also shows a positive correlation with Treg cell activation markers (SATB-1 
and GARP). This relationship may help explain pro- and anti-inflammatory roles for SATB-1 and GARP, 
respectively, and may indicate an imbalance in cytokine regulation during HIV infection. 
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The proportion of non-classical monocytes correlated positively with immune activation and coagulation 
markers, indicating a link with inflammation and coagulation with HIV infection. Earlier in the thesis 
(Chapter 2) it was highlighted that non-classical monocytes express relatively high levels of the fractalkine 
receptor (CX3CL1). The latter is usually expressed on activated endothelial cells as a transmembrane-
anchored adhesion receptor, thus attracting and arresting monocytes from the circulation into the 
atherosclerotic plaque (Ghattas et al., 2013). In addition, Funderburg et al. (2010) reported that non-classical 
monocytes express higher TF levels during HIV infection, further supporting the important role of non-
classical monocytes in terms of promoting coagulation pathways in HIV-treated patients.  
Our findings also show that intermediate monocytes correlated positively with coagulation markers, 
suggesting a link with intravascular coagulation. It also correlated positively with activated Treg cell markers 
such as SATB-1. This may reflect a relationship between intermediate monocytes and pro-inflammatory 
cytokines, where higher SATB-1 levels are linked to an increased pro-inflammatory role of T helper cells. In 
support, Rogacev et al. (2012) reported that intermediate monocytes may be an independent predictor of 
CVD events and that this could be linked to its ability to secrete inflammatory cytokines. Although there is 
disagreement in the literature regarding the exact role of each monocyte subset, it is beginning to emerge that 
both intermediate and non-classical monocytes may be highly atherogenic. In support, others found that such 
subsets are linked to inflammation and coagulation markers in persons saddled with chronic HIV infection 
(and receiving cART) (Stansfield et al., 2015; Rogacev et al., 2012; Yang et al., 2014).     
5.4 INCREASED FOXP3 EXPRESSION IN TREG CELLS TOGETHER WITH 
UPREGULATION OF PRO-INFLAMMATORY (SATB-1) AND ANTI-
INFLAMMATORY MARKERS (GARP) 
5.4.1 Upregulation of CD4+FOXP3+ in HIV-infected Individuals  
The present research study showed an expansion of FOXP3+ Treg cells as a percentage of the total CD4+ T 
cells with chronic HIV infection. This correlated negatively with CD4 count and positively with immune 
activation. The enhanced Treg frequency may be an indication of higher immune activation due to increased 
Treg activity and function (Chevalier and Weiss. 2013). However, there are conflicting findings regarding 
Treg cells in this context due to the lack of a clear surface-identifying marker and additional studies are 
required to identify more specific markers. Most studies link Treg expansion to increased FOXP3 induction 
under antigenic persistence, while HIV infection has direct effects on Treg expansion from CD4+CD25- cells 
(T helper) in the presence of TGF-β (Amarnath et al., 2007). Moreover, Suchard et al. (2010) concluded that 
enhanced FOXP3 frequency in CD4+ T cells can help explain elevated FOXP3 expression with greater 
lifespan of these cells or increased cell death of FOXP3- CD4+ cells (AICD). The other suggestion made is 
that the progression from HIV to AIDS leads to an increase in the number of circulating CD4+CD25+ Tregs 
as a proportion of CD4 T cells, with a corresponding decrease in function (Février et al., 2011).Our study 
showed  increased FOXP3 expression on CD8+ T cells in the HIV-positive group with immune deficiency 
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(CD4 < 200), meaning that a small population of CD8+CD25+FOXP3+ T cells are emerging as an important 
subset Treg cells with clinical significance (Churlaud et al., 2015). Mayer et al. (2011) demonstrated that 
CD8+FOXP3+ T cells share developmental and phenotypic features with classical CD4+FOXP3+ regulatory T 
cells but lack potent suppressive activity. 
5.4.2 Upregulation of GARP in HIV-infected Groups and Correlation with Disease Progression 
The current study showed increased GARP expression on CD25++ CD4+ cells in HIV-infected individuals 
with a relatively low CD4 count. This expansion correlated negatively with CD4 counts, and positively with 
immune activation markers and VL. The correlation between greater GARP activation and markers of 
disease progression may be explained by increased suppressive activity (viral-induced activation of the 
suppressor population). This would result in the inhibition of CD4+CD25- cells (T helper) leading to the 
inhibition of the HIV-specific T cell response and the development of a chronic model of HIV infection 
(Paiardini and Muller-Trutwin. 2013; Keynan et al., 2008). Thus GARP activation together with the 
persistence of HIV is associated with increased immune activation and inflammation, with downstream 
effects including upregulation of monocyte subsets and coagulation pathways. 
5.4.3 Upregulation of GARP on both CD4+CD25++ and CD4+CD25- Cells  
Findings from the current study revealed an upregulation of GARP on CD4+CD25++ and CD4+CD25– cells 
during chronic HIV infection for the low CD4 count group. Such an increase is linked to disease progression 
markers e.g. VL, CD4 counts and immune activation. Moreover, GARP upregulation during HIV chronic 
infection correlated positively with an increase of both intermediate and non-classical monocyte subsets. 
This increase in GARP expression with chronic infection is further supported by Miller et al. (2013 and 
2014) who demonstrated that FIV directly activated CD4+CD25+ regulatory T cells in vitro together with 
higher GARP expression on the surface of activated Treg cells. Such activation of Treg cells plays a role in 
converting CD4+CD25- T helper cells into phenotypic and functional regulatory T cells. Furthermore, Miller 
et al. (2014) explains the role of the activated GARP–TGF-β complex in converting CD4+CD25- T helper 
cells into Treg cells. This helps to explain the depletion of CD4+ T cells during the chronic stages. For the 
current study, there was a positive correlation between GARP expression and VL and this underscores 
GARP’s involvement under chronic conditions where it inhibited T effector cell function against the HIV 
infection. 
The transcriptional factor, FOXP3 (suppressor function) interacts with target genes that promote suppression 
activity, e.g. GARP to be expressed on CD4+CD25++ Treg cells (Probst-Kepper and Buer. 2010). GARP is 
linked to naturally occurring activated Treg cells (CD4+CD25++) and is not expressed on induced Tregs in the 
presence of TGF-β (Wang et al., 2009). During the late stages of HIV infection FOXP3 expansion from the 
total CD4+ cell population manifests together with increased GARP expression on CD25++ and ectopic 
expression on CD4+CD25- cells. This may explain the role of GARP in the induction of FOXP3 during 
chronic HIV infection. 
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What is the reason for GARP not being expressed on Tregs? Wang et al. (2009) demonstrated that GARP 
expression on activated Tregs correlated with their suppressive capacity. However, GARP was not induced 
on T cells activated in the presence of TGF-β. Here the T cells expressed relatively high FOXP3 levels and 
lacked suppressive function. This may indicate that increased FOXP3 induced in the presence of TGF-β 
during HIV infection may not be involved in suppression pathways (Wang et al., 2009) as such cells do not 
express GARP on their surface. By contrast, activated natural Treg cells (CD4+CD25++FOXP3-) and ectopic 
Treg cells (CD4+CD25-FOXP3-) express GARP during HIV infection (Elkord et al., 2015). This especially 
occurs during the chronic stages when such cells are involved in suppression pathways.  Further studies are 
required to assess whether GARP upregulation during HIV infection is directly involved in CD4 depletion 
and if it contributes to immune deficiency during the latter stages of infection (Miller et al., 2014).  
5.4.4 Increased SATB-1 Expression on CD25++ T Cells with low CD4 Counts and Correlation to 
Disease Progression 
The upregulation of SATB-1 correlated negatively with the CD4 counts and positively with immune 
activation and coagulation markers. Our data revealed a significant increase of SATB-1 on CD4+CD25++ T 
cells in the HIV-treated group and also those with a relatively low CD4 count. This indicates a shift towards 
T effector cells together with the inhibition of Treg cell function. Relatively low levels of SATB-1 were 
observed in the control and the HIV-positive groups (CD4 count > 500 cells/µL) that indicate the normal 
suppressive function of Treg cells in this instance. By contrast, there is an upregulation of SATB-1 in Treg 
cells (CD25++FOXP3+) in the relatively low CD4 count group afflicted by chronic HIV infection; this 
correlated positively with immune activation markers and coagulation markers. High SATB-1 levels in Treg 
cells also correlated with intermediate and non-classical monocyte subsets. Moreover, increased SATB-1 
levels in Treg cells is associated with the upregulation of T effector cytokines that may indicate the inability 
of Treg cells to suppress the activation of effector T cells. This may also show that there is skewing of the 
regulatory function towards the effector program and increasing pro-inflammatory pathways (Beyer et al., 
2011; Thabet et al., 2012). The latter may help explain the correlation between SATB-1 and the relatively 
high levels of intermediate and non-classical monocyte subsets during chronic infection. It may also shed 
light on the positive correlation of SATB-1 with immune activation and coagulation markers expressed on 
CD8 T cells. There is also substantial upregulation of SATB-1 on CD25- CD4+ T helper cells in the HIV-
positive groups together with significant increases in the naïve group. Such an increase may indicate the pro-
inflammatory role of T helper cells in early HIV infection (naïve).  
There is some controversy regarding the increase of GARP and SATB-1 expression on Treg cells during 
chronic HIV infection and upregulation of the former in Tregs involved in the induction of adaptive 
regulatory T cells (Hahn et al., 2013). Such upregulation can act as a form of immunomodulation by 
inhibition of effector function in naive T cells and by FOXP3 induction. Conversely, the upregulation of 
SATB-1 in Treg cells can indicate a weakened suppressive function and an increase of pro-inflammatory 
properties.  Whether the plasticity of Treg cells plays a role in this case and if there is an imbalance between 
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Treg and T helper cells due to the immunodeficiency state is not known at present. However, this may reflect 
an imbalance between anti- and pro-inflammatory cytokines during chronic HIV-infection. Further studies 
are required to gain additional insights into such intriguing questions. 
5.5 INCREASING CRP IN CHRONIC HIV PATIENTS  
CRP is an important marker for inflammation assessment and is linked to CVD in chronic HIV infection 
(Baker and Duprez. 2010). The results of the present study showed a significant increase in CRP levels in 
chronic HIV-positive patients, with the highest levels found in the HIV-positive group with a relatively low 
CD4 count. These findings are in agreement with other studies where increased CRP levels were associated 
with HIV disease progression, independently of CD4 lymphocyte counts and HIV RNA levels. This in turn 
may have consequences for CVD in HIV-infected persons (Lau et al., 2006). CRP elevation is an indicator of 
an inflammatory condition (as a consequence of infection) and increased levels are linked to pro-
inflammatory cytokines such as IL-1 and IL-6.  Here even relatively small changes in CRP concentrations 
can lead to increased CVD risk and hence lower levels in HIV-positive persons would predict a longer 
survival chance (Osman et al., 2006; Lau et al., 2006). 
5.6 HIV INFECTION-ASSOCIATED DECREASE IN LIPID PROFILES  
 
Figure 5-3: Lipid metabolism in HIV infection and the role of cART and inflammation.  (1) HIV infection 
and cART may alter the lipid profile and eventually result in the onset of the metabolic syndrome. (2) The 
decreased lipid profile in cART naïve patients can contribute to damaging downstream effects; (3) 
Inflammation-induced oxidative stress can result in detrimental effects in circulation and the eventual 
onset of the metabolic syndrome. (4) Higher oxidative stress and altered lipid profile contribute to 
increased OX-LDL formation. (5) OX-LDL may contribute to the monocyte subset shift and increase pro-
inflammatory cytokine production. 
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This study revealed a decrease in lipid blood metabolite levels in early HIV-infected (naïve) individuals, 
particularly triglyceride and total cholesterol levels (Souza et al., 2013)(Riddler et al., 2003). In addition, 
there was a significant decrease in circulating LDL levels in the HIV-positive group treated with second line 
therapy. Such alterations may be linked to HIV itself and/or increased inflammation and immune activation. 
After cART initiation the lipid profile undergoes further changes in accordance with the particular treatment 
regimen applied. For example, after treatment initiation there was an increase in HDL-cholesterol levels - 
this was particularly linked to the NNRTi group. These findings match other published studies (Souza et al., 
2013; Riddler et al., 2003) where they showed that lipid profile values were substantially decreased in naïve 
persons and then slightly increased following cART (first line treatment) with such changes dependent on the 
type of treatment applied. cART can also lead to the metabolic syndrome during HIV infection and is 
associated with several risk factors, including insulin resistance, low HDL-cholesterol levels, 
hypertriglyceridemia and postprandial hyperlipidemia (Wijk and Cabezas. 2012) 
The early inflammation and immune activation associated with HIV infection may enhance lipid 
peroxidation which is associated with decreased antioxidant capacity and a lower CD4 count in untreated 
asymptomatic HIV-infected individuals (Wanjiku et al., 2013). A persistent inflammatory environment 
during HIV infection together with relatively high levels of inflammatory cytokines (maintained by 
activation of oxidases released from macrophages and neutrophils) may promote pro-inflammatory 
alterations of the lipid profile (Gori et al., 2016; Lederman et al., 2013). This in turn can lead to increased 
formation of OX-LDL which further contributes to monocyte activation (Zidar et al., 2015) (Figure 5.3). 
Decreased LDL levels during early HIV infection is accompanied by increased OX-LDL which alters the 
inflammatory profiles of blood monocytes and increases TF expression on monocytes (Zidar et al., 2015). 
Studies have revealed that HIV-infected patients display an oxidative imbalance early-on during the disease 
(Wanjiku et al., 2013). Here serum and tissue anti-oxidant levels were relatively low and peroxidation 
products elevated. Such dysregulation may be the source of immune activation during HIV infection. 
However, after the initiation of cART the lipid profile changes depending on specific treatment regimens. 
For example, PIs can affect the lipid profile by interference with intracellular regulation of lipid metabolism, 
increased VLDL production, and impaired catabolism of free fatty acids and increased liver triglyceride 
synthesis.  Genetic background can also affect lipid abnormalities associated with cART (Estrada and 
Portilla. 2011)  
The evaluation of lipid subclasses during HIV infection is important in order to identify pro-inflammatory 
and atherogenic molecules.  The findings of this thesis revealed a significant increase in the non-atherogenic 
type of intermediate density lipoprotein type 3 (IDL-C) in cART-naïve and in HIV-treated (second line) 
patients. This parameter correlated positively with immune activation in treated patients. For the HDL 
subclasses there was an increase in the large HDL species for all HIV-positive groups (cART-naïve and 
cART-treated). Souza et al. (2013) showed the presence of small and large HDL in HIV-infected individuals 
at high risk for CVD onset. However, in this study there is significant decrease in small HDL in HIV-treated 
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(first and second line treatments) persons. Small HDL is the most protective lipoprotein in terms of 
atheroprotective effects and anti-inflammatory activities through inhibition of OX-LDL uptake and anti-
thrombotic function. In support, some found that small HDL is inversely associated with IL-6 levels (Baker 
et al., 2010). Krychtiuk et al. (2014) demonstrated that small HDL levels correlated with circulating pro-
inflammatory non-classical monocytes and showed an inverse relationship to circulating classical 
monocytes, independently from other lipid parameters.  Thus lower small HDL availability would blunt its 
atheroprotective role.  This phenomenon together with increased inflammatory monocytes may contribute to 
future CVD onset. 
The analyses also revealed a positive correlation between atherogenic IDL-A and immune activation and 
immune activation + coagulation markers in the naïve group. This suggests an important role for immune 
activation and coagulation during early HIV-infection (naïve). The correlation in the naïve group also 
showed a positive relationship between non-atherogenic (I-HDL) and both immune activation and classic 
monocytes, while I-HDL correlated negatively with intermediate monocytes. Thus there is significant 
correlation between lipid subclasses and immune activation and coagulation markers in especially naïve 
individuals, suggesting a role for such metabolic modulators in this group. The atherogenic IDL-B also 
showed a positive correlation with Treg cells in HIV-treated patients.  What is the value of such subclass 
lipid profiles?   Atherogenic lipoprotein profiles are indeed  very useful  in the assessment of CVD risk and 
onset, especially as studies showed that 75% of patients with acute coronary syndrome or myocardial 
infarction displayed normal cholesterol, LDL-C and HDL-C plasma levels) (Haque et al., 2016). It can 
therefore be concluded that the traditional lipid profile in the current study’s cohort is not significant for 
CVD risk, but that instead the atherogenic lipoprotein subclasses offer greater value to assess CVD events in 
HIV-infected individuals.  
5.7 EVALUATION OF FMD WITH HIV INFECTION  
The findings of this thesis showed a relatively small (insignificant) improvement in FMD in HIV-positive 
groups (7.3 ± 4%) versus controls (4.7 ± 3%). Further comparisons of FMD demonstrated that a relatively 
high FMD percentage characterized the HIV-positive group with a higher CD4 count (> 500 cells/µL). By 
contrast, others showed a decrease with HIV infection (indicating endothelial dysfunction) that improved 
with cART (Torriani et al., 2008; Solage et al., 2006). Moreover, Stein et al (2006) linked FMD changes in 
HIV-infection to abnormal lipid metabolism and insulin resistance (effects of PI) and proposed that this 
would not occur in the presence of a normal lipid profile. Together this means increased CVD risk with HIV-
infection occurs together with greater inflammation and coagulation, and that this is usually accompanied by 
changes in endothelial function (decreased FMD percentage). However, this was not the case in our study 
and we propose that this may occur due to: a) limited samples sizes and b) the alternative lipid profile 
observed with HIV infection. Further studies with a greater number of subject recruits should help clarify 
such questions. 
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5.8  STUDY LIMITATIONS  
The current study has three limiting factors.  Firstly, a relatively small sample size was investigated that 
impacted on statistical significance in some instances.  Although the sample size was relatively small, a 
considerable amount of time and resources were spent to launch the study. We also found that subject 
recruitment was difficult at times as patients did not always attend the clinic due to work commitments, lack 
of transport and/or inclement weather conditions in the Worcester area.  As this is an ongoing study, samples 
from additional subject recruits can be further investigated and this should further strengthen existing 
findings. Secondly, the current research project was a cross-sectional one and a longitudinal study would be 
essential to confirm the interesting data thus far generated. Finally, further research would also be required to 
delineate mechanisms underlying immune activation, coagulation, monocyte subclass shifts and altered lipid 
profile changes observed and how exactly these are contributing to CVD onset in HIV-infected individuals. 
5.9 CONCLUDING REMARKS  
This study has demonstrated greater immune activation in cytotoxic T cells with relatively lower CD4 counts 
in HIV-infected persons from the Worcester region in South Africa. In parallel, there was evidence for 
increased coagulation in such cells. These findings therefore support the link between inflammation and 
coagulation markers during HIV infection and emphasize its importance in persons with immune 
dysregulation. The current study also identified a unique coagulation marker expressed on CD4 and CD8 T 
cells that is expressed relatively early on in HIV-infected individuals. In addition, there is activation of Treg 
cell markers together with upregulation of particular monocyte subsets that are linked to immune activation 
and coagulation. Together such perturbations increase the risk for atherosclerosis and CVD onset, especially 
in HIV-positive individuals with some degree of immune dysregulation. This therefore alerts to the nature of 
future clinical management of HIV-positive patients and makes a case for earlier therapeutic interventions to 
decrease chronic inflammation and immune activation. Longer-term benefits of such a strategy would be 
decreased coagulation and lowered CVD risk in HIV-infected individuals treated with cART.  In addition, 
another group of HIV-infected patients, i.e. with poor immune recovery (failure to boost CD4 counts despite 
treatment) is also at high risk for inflammation and coagulation. Thus, it is recommended that clinicians 
should: 
 a) Be mindful of immune activation and coagulation with HIV infection, even at relatively early stages of 
disease progression;  
b) request additional evaluations to be completed on blood samples collected from such individuals, e.g. 
immune activation and coagulation markers, and detailed lipid profiles; and 
 c) Actively manage such identified high-risk patients with appropriate pharmacotherapy and lifestyle 
modifications, e.g. changing smoking habits and improving dietary habits.  
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ADDENDUM – A: FLOW CYTOMETRY RESULT AND OPTIMIZATION 
 
 
Figure 1: Diagrams Show CD8 T cell co- expression of CD38 and CD142 : a) APC-H7 mouse 
anti-human (CD3)versus BV412 mouse anti-human CD8; b) Co-expression of APC anti- 




Figure 2: The monocytes subsets and the expression of CD38 and CD 142 on each subset : a) Gate for CD14+ 
and CD3- (SSC) versus CD3 APC-CY7 to exclude any CD3 positive from monocyte subsets; b) CD16 PE-CY7 
versus SSC to differentiate monocyte subsets (classical, intermediate and non-classical monocyte); c) Non-
classical monocyte and co-expression of CD142 and CD38; d) Intermediate monocyte and co-expression of 









Figure 3: Treg (CD25++FOXP3+) and expression of SATB-1 and GARP. (a) CD4 FITC versus FSC (b) 
CD25 PE-CY7 versus FOXP3 and 3 different subsets(CD25++FOXP3+,CD25+FOXP3+ and CD25-
FOXP3+) (c) Co-expression of SATB-1 and GARP in CD25++FOXP3+ (d) Co-expression of SATB-1 and 













Optimization data Fluorescence minus one (FMO) 
 




Figure 5: Fluorescence minus CD4 
 





Figure 6: Fluorescence minus FOXP3 
 
 
Figure 7: Fluorescence minus CD25 
 





Figure 8: Fluorescence minus GARP 
 
 
Figure 9: Fluorescence minus SATB-1 
 






Figure 10: Fluorescence minus CD14 
 
 
Figure 11 Fluorescence minus CD16 
 





Figure 12: Fluorescence minus CD142 (coagulation factor expression on monocytes) 
 
 
Figure 13: Fluorescence minus CD8 T cell 
 





Figure 14: Fluorescence minus CD142 (coagulation factor expressed on T cells) 
Antibody titration  
 
Figure 15: Titration of CD25 with different antibody concentration: The titration 
shows a bright result (intense signal) with a relatively low antibody concentration. 
(2.5µL) 




 ADDENDUM – B: Data for FMD 
Table 5-1: Data for FMD (baseline diameter, maximum diameter and percentage of FMD) 
 
Baseline diameter (mm) Maximum diameter (mm) FMD% 
CWH2H008 3.82 3.91 2.52 
CWH2H0012 4.72 4.85 2.86 
CWH2H0013 4.26 4.37 2.79 
CWH2H0016 3.57 3.87 8.38 
CWH2H0020 3.21 3.51 9.47 
CWH2H0022 3.28 3.63 10.61 
CWH2H0023 3.17 3.41 7.74 
CWH2H0030 3.27 3.85 17.89 
CWH2H0031 3.59 3.85 7.37 
CWH2H0033 3.33 3.68 10.61 
CWH2H0039 3.59 3.69 2.61 
CWH2H0040 3.32 3.66 10.19 
CWH2H0041 3.11 3.17 2.01 
CWH2H0043 5.25 5.27 0.55 
CWH2H0046 3.25 3.45 6.16 
CWH2H0047 3.82 3.98 4.11 
CWH2H0051 5.36 5.47 2.09 
CWH2H0053 3.31 3.59 8.32 
CWH2H0054 3.27 3.54 8.30 
CWH2H0055 2.98 3.29 10.34 
CWH2H0056 2.39 2.58 8.19 
CWH2H0057 3.58 3.73 4.07 
CWH2H0058 3.22 3.28 1.97 
CWH2H0059 3.27 3.49 6.91 
CWH2H0065 2.25 2.54 12.65 
CWH2H0071 4.17 4.43 6.25 
CWH2H0075 3.05 3.35 9.59 
CWH2H0076 3.06 3.33 8.81 
CWH2H0077 3.53 3.89 10.10 
CWH2H0078 2.74 2.92 6.60 
CWH2H0079 4.52 4.73 4.53 
CWH2H0080 4.51 4.56 1.27 
CWH2H0081 4.06 4.12 1.56 
CWH2H0083 3.69 3.93 6.54 
CWH2H0085 3.90 4.07 4.20 
CWH2H0086 3.15 3.37 6.78 
CWH2H0088 3.15 3.35 6.54 
CWH2H0092 3.64 4.03 10.69 
CWH2H0093 2.03 2.25 10.61 
CWH2H0095 3.58 3.78 5.59 
CWH2H0096 3.96 4.12 3.92 
CWH2H0097 2.86 3.36 17.42 
CWH2H0098 4.13 4.32 4.55 
CWH2H0099 3.08 3.45 12.08 
CWH2H0100 4.89 5.02 1.72 
CWH2H0101 4.58 4.88 6.68 
CWH2H0102 2.20 2.41 9.52 
CWH2H0103 3.47 3.77 8.70 
CWH2H0104 3.68 3.61 -2.03 
CWH2H0105 4.42 4.64 4.96 
CWH2H0106 3.46 3.52 1.65 
CWH2H0107 4.00 4.40 10.12 
CWH2H0109 3.19 3.54 11.17 
CWH2H0111 3.54 3.83 8.20 
CWH2H0113 3.99 4.39 10.19 
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 ADDENDUM – E: Consent form 
 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
WINELANDS HAART to HEART STUDY 
 
REFERENCE NUMBER: N12/12/086 
 
PRINCIPAL INVESTIGATOR: Prof MF Essop 
 
ADDRESS: 
Department of Physiological Sciences 
Mike de Vries Building 
Room 2005a  
Stellenbosch University 
 
CONTACT NUMBER: 021 8083146 
 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand. It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved. Also, your participation is entirely 
voluntary and you are free to decline to participate. If you say no, this will not affect you 
negatively in any way whatsoever. You are also free to withdraw from the study at any 
point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 






What is this research study all about? 
 This study will only be done in the Stellenbosch district and surrounding areas. We 
will need approximately 300 Patients. We are trying to gather information on 
laboratory tests, body composition and patient questionnaires profiles of chronic 
HIV patients on ARV treatment (1st and 2nd line). By getting this information we 
would be able to assess the attenuation of metabolic function and contractail 
dysfunction caused by ARV treatment.  
 As Africa adopts a more westernised lifestyle there is a higher incidence of HIV 
infection, diabetes and heart diseases.  
Your blood will be taken by a registered medical nurse. It will then be sent away to 
Pathcare (Stellenbosch) where metabolic-associated parameters will be measured. Other 
biochemical tests that will be done by Pathcare include C-reactive protein measurements. 
The remainder of your blood samples will be used to obtain genetic material (RNA). 
The blood presser assessment, evaluation of cardiac function (ECG, echocardiography 
and carotid intima media thickness), full anthropometric evaluation and life style 
questionnaire will be done at the clinic 
Why have you been invited to participate? 
 We are trying to gather information on laboratory tests, body composition and 
patient questionnaires profiles of chronic HIV patients on ARV treatment (1st and 
2nd line). By donating blood to our study you will be helping us to determine these 
profiles and how we can relate them to the current diagnostic tests to investigate 
cardio-metabolic effects of ARV treatment. By getting this information we would be 
able to assess the attenuation of metabolic function and contractail dysfunction 
caused by ARV treatment. With your help we hope to identify the suitable 
therapeutic interventions that will blunt metabolic dysfunction, oxidative stress and 
enhance mitochondrial function under conditions where PIs are chronically 
administered. 
 
What will your responsibilities be? 
 As we need to examine the selected patients and then take the blood for laboratory 
tests and lifestyle questionnaire regarding your line of ARV treatment. A registered 
anthropometrist, Dr Theo Nel, will also perform anthropometric measurements 
that include waist circumference, waist: hip ratio, height and mass. 
 
Will you benefit from taking part in this research? 




 Although there may not be any direct benefits to me/the participant by 
participating at this stage, future generations may benefit if the researchers 
succeed in finding out more about how ARV treatment can lead to metabolic 
dysfunction and cardiac disease. If you choose to know the results of your blood 
tests we will make these available. However, you would have to discuss this 
information with your personal doctor, at your own cost, in order to assess your 
medical status with ARV treatment (metabolic and cardiac status).  
 
Are there in risks involved in your taking part in this research? 
There are no more than minimal medical or physiological risks associated with this study. 
 
 I/the participant may feel some pain associated with having blood drawn from a 
vein and may experience some discomfort, bruising and/or slight bleeding at the 
site. 
 
If you do not agree to take part, what alternatives do you have? 
 It is your decision to participate or not and nothing will be done from the 
researchers’ part to in any way to persuade you to take part.  
 
Who will have access to your medical records? 
 Only the principal researcher (Prof Faadiel Essop and the following Doctoral 
student: Dr. Eman Teer) will have access to your data and records. All information 
will be treated with respect and utmost confidentiality. Under no circumstances 
will your name or any form of identification be used in any publication, poster, 
lecture or thesis that results from this study. Professor Faadiel Essop and Dr. 
Eman Teer will be the only authorised personnel who will have access to your 
results. 
What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
 Not applicable here. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
 No, you will not be paid to take part in the study. There will be no costs involved 
for you, if you do take part. Travelling costs in order to get to the Department of 
Physiological Sciences will not be covered by this study and you will need to cover 
this cost yourself. 
 




Would you like to know the results of your blood tests? 
 Please indicate by marking the correct box with an X 
    YES 
    NO 
Is there anything else that you should know or do? 
 You can contact Professor MF Essop on 021 808 3146 if you have any further 
queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by your 
study doctor. 
 You will receive a copy of this information and consent form for your own 
records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (Investigation of cardio-metabolic effects of ARV treatment in 
the winelands region). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
Signed at (place) ......................…………….. On (date) …………....………... 
 ......................................................................  .................................................................... 
Signature of participant Signature of witness 




Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use a interpreter. (If a interpreter is used then the interpreter must 
sign the declaration below. 
 
Signed at (place) ..............…........…………….. on (date) …………....………... 
 
 ......................................................................  .................................................................... 
Signature of investigator Signature of witness 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..………….. Using the language medium of Tswana/English. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…......……….. on (date) ……….……………….. 
 
 
 ......................................................................  .................................................................... 
Signature of interpreter Signature of witnes




 ADDENDUM – F: Data Sheet 
________________________________________________________________ 
Project title: Cape Winelands HAART 2 HEART 
Ethics approval nr: N12/12/086  
IDENTIFICATION CODE: CWH2H________ 
Date of interview:  
Interviewer:  
Health District Site: 
 
Worcester TC Newman Mbekweni Stellenbosch 
Age: 
 
Blood pressure (Sys/Dia): 
 




Negative Naive 1st line 2nd line 
WHO stage: 
 
1 2 3 4 
Time since HIV diagnosis (months):  
HAART start date:  
Time on HAART:  
Current HAART regimen:  
Time on current HAART:  




Viral load:  
Previous co-infections:  
Current co-infections:  
Drug history:  
Family history CVD:  
Smoking/snuff:  
Quantity per day:  
Frequency per week:  




 ADDENDUM – G: Demographic questioner 
____________________________________________________________ 
Project title: Cape Winelands HAART to HEART study 
Ethics approval nr: N12/12/086 
IDENTIFICATION CODE: CWH2H_______ 
Date of interview:  
Interviewer:  
Health District Site: 
 
Worcester TC Newman Mbekweni Stellenbosch 
Household (Brick 
house, shack other 
dwelling) 
 
Total in household Male Female 
Children 0-6 yrs   
Children 7-12 yrs   
Children 13-18 yrs   
Adults 18-30   
Adults 31-45   
Adults 46-60   
Adults 61+   
LANGUAGE AND ACCULTURATION 
Home language of respondent Afrikaans Xhosa Zulu English Sotho Other  
Household head speaks Home language only Home language + 
Afr/Eng 
English/Afrikaans only 
Can you read and understand a 
newspaper in your home 
language easily, difficult or not 
at all? 
Easily 1  
With difficulty 2 
Not at all 3 
Can you read and understand a 
newspaper in the English 
language easily, difficult or not 
at all? 
Easily 1  
With difficulty 2 
Not at all 3 
NEAREST CLINIC/HOSPITAL 
Name of clinic/hospital Walk (minutes) Mode of transport 
Walk=1; Taxi=2; Own 
car=3; bicycle=4 
   
 
 





 ADDENDUM – H: Normal range of lipid profile 
 
 
PARAMETER REFERENCE RANGE UNIT 
TC 
Desirable < 5.2 
Borderline 5.2–6.2 




High > 2.2 
mmol/L 
HDL 
Desirable > 1.2 
Low < 1 
mmol/L 
LDL 
Desirable < 2.6 
Borderline 2.6–3.3 
High > 3.3 
mmol/L 
CRP Normal < 10 mg/L 
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